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ABSTRACT 
 
The discovery of the antitumor properties of cisplatin revolutionized the field of 
medicinal inorganic chemistry and fostered the development of metal-based anticancer 
drugs, a topic that continues to play a prominent role in chemotherapy. Ruthenium (Ru) 
compounds are a promising class of anticancer compounds that display improved 
therapeutic activities, different mechanisms of action, and reduced side-effects as 
compared to cisplatin. Two ruthenium compounds are being tested in clinical trials for 
the treatment of cancer malignancies for which platinum drugs are inactive and several 
other transition metal complexes are in preclinical studies.  
In an effort to expand the current state-of-the art in cancer metallotherapeutics, 
two new classes of ruthenium compounds were synthesized and fully characterized. The 
first class of complexes is based on Ru(II) coordination compounds of general formula 
[Ru(N^N)2(N^O–)][PF6], where N^N is a bidentate polypyridyl ligand (bpy = 2,2’-
bipyridine; phen = 1,10-phenanthroline) and N^O– is a bidentate nitrogen/oxygen-donor 
anionic ligand (dphol = dibenzo[a,c]phenazin-10-olate; hbtz = 2-(benzo[d]thiazol-2-
yl)phenolate). These molecules exhibit cytotoxic properties that are comparable or more 
effective than cisplatin against lung cancer cells and were found to induce cellular death 
through the intrinsic pathway of apoptosis. 
The second class of molecules consist of organometallic Ru(II) compounds of 
formula [Ru(phpy)(N^N1)(N^N2)][PF6], where phpy is cyclometallated 2-phenylpyridine 
and N^N are bidentate polypyridyl ligands. The compounds [Ru(phpy)(bpy)(dppn)][PF6] 
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and [Ru(phpy)(pap)(dppn)][PF6] (dppn = benzo[i]dipyrido[3,2-a:2′,3′-c]phenazine; pap 
= 2-(phenylazo)pyridine) are the most potent members of the series against cervical and 
ovarian cancer cells and are also active in the multidrug resistant NCI/ADR-RES ovarian 
cancer cell line. In addition, the compound [Ru(phpy)(biq)2][PF6] (biq = 2,2’-
biquinoline) was shown to exhibit an enhancement of its cytotoxicity when irradiated 
with red light, results that poise Ru(II) cyclometallated compounds as promising 
candidates for further development in cancer chemotherapy and photochemotherapy. 
Finally, an unprecedented fluorophore-labeled metal-metal bonded dirhodium 
compound was synthesized and characterized, and its cellular distribution and 
subcellular localization were studied in living cancer cells by using confocal 
fluorescence microscopy. This fluorescent compound traverses the cellular membrane of 
lung cancer cells and localizes in lysosomes and mitochondria. In contrast to previous 
reports of dirhodium anticancer compounds, it does not target the cell nucleus, 
supporting the contention that other cellular targets can be reached by tuning the ligand 
environment around the dirhodium core, opening new avenues for drug design. 
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CHAPTER I  
INTRODUCTION 
 
Motivation: Worldwide and United States Cancer Statistics 
 
Cancer is a complex family of more than one hundred diseases characterized by 
the uncontrolled growth of cells produced by multiple alterations at the genomic level.1,2 
It is caused by both internal factors (inherited DNA mutations, hormones, immune 
system defects) and external factors (tobacco consumption, passive smoking, infectious 
organisms, environmental chemicals and radiation).3,4 The abnormal gene expression 
that occurs in cancer causes an imbalance between cell proliferation and cell death and 
evolves into a population of cells (tumor or neoplasm) that can invade other tissues by 
spreading through the blood and lymph systems often interrupting vital functions, 
causing significant disease and, if untreated, death of the host.1,2 In contrast, benign 
tumors grow by expansion, are encapsulated and do not invade surrounding tissue, but 
they may become life threatening if they press on nerves or blood vessels.1 
According to the World Health Organization and the American Cancer Society, 
cancer is the leading cause of death worldwide in developed countries and the second 
leading cause of death in developing countries following heart disease.5 In 2008, 12.7 
million new cancer cases were diagnosed, from which 5.6 million and 7.1 million cases 
occurred in economically developed and economically developing countries, 
respectively, and 7.6 million deaths were estimated the same year (2.8 million and 4.8 
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million deaths in economically developed and economically developing countries, 
respectively).5 Lung and bronchial cancer (~0.95 million deaths) and breast cancer 
(~0.46 million deaths) were the most common cancer types in men and women 
worldwide, respectively, in 2008.5 The World Cancer Research Fund has estimated that 
overweight or obesity, physical inactivity, and/or poor nutrition cause up to one third of 
the cancer cases in developed countries.3 
Cancer is the second leading cause of death in the Unites States after heart 
disease.6,7 Lung cancer remains the most common cancer that leads to death in men since 
the 1950s.3 Although the mortality rates of this type of cancer in men have decreased 
gradually since 1990,1,3 data indicate that it still has one of the lowest 5-year percent 
survival rates (16.8% for both sexes the 2004–2010 period).8 Breast cancer has been the 
leading cause of death among cancer types in women since the 1950s and was later 
overtaken by lung cancer since the 1985–1990 period.3 
In the year 2014, it the American Cancer Society has estimated that ~1.67 million 
new cancer cases will be diagnosed and ~0.58 million deaths will occur (~1 600 deaths 
per day!).3 The cancer types with the highest mortality (both sexes) continue to be lung 
and bronchial, colorectal, breast and prostate cancers (Figure 1.1) and account for almost 
half (~0.28 million) of the estimated deaths in the present year.3 The prevalence of lung 
cancer as the first cause of death in the United States has been attributed to cigarette 
smoking, pollution, diet and lifestyle changes, and the American Cancer Society has 
estimated that almost 176,000 of the estimated deaths in 2014 could have been prevented 
by stopping cigarette smoking and the heavy use of alcohol.3 Although there has been a 
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steady rise in cancer death rates during the past >75 years (in part because more people 
live long enough to acquire this disease), a greater amount of people are cured from 
cancer today. For example, only 25% of people diagnosed with cancer lived at least 5 
years after treatment in the 1940s and that figure rose to 40% in the 1990s.1 
The aforementioned cancer statistics underscores the fact that cancer is a 
worldwide problem and a major health issue in the United States. Such statistics 
continue to prompt enormous global research efforts across several disciplines to gain a 
better understanding of cancer biology with the aims of providing faster and more 
accurate cancer diagnosis, improved treatments and better health care for cancer patients. 
Chemistry is the scientific discipline that is at the forefront of cancer drug research and 
continuously provides solutions for the treatment of cancer through the development of 
more effective and safer chemotherapy drugs.  
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Figure 1. 1 Estimated number of cancer deaths in the United States for 2014. Data 
obtained from the National Cancer Institute, reference 3. 
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Platinum Compounds in Cancer Drug Research 
 
Cisplatin, The Landmark Story of an Inorganic Compound 
 
Bioinorganic chemistry is a research area that focuses on the role of metal ions in 
biological processes including the transport, storage and function of metal ions in living 
systems, the structure and activity of metalloproteins, the impact of metals in natural 
environments and the application of metals in medicine.9,10 The latter field is known as 
medicinal inorganic chemistry, where the unique properties of metal ions are exploited 
in the rational design of metallodrugs for the diagnosis and therapy of diseases and 
metabolic disorders.11,12,13,14 The great variety of coordination numbers and molecular 
geometries of transition metal complexes, which are not readily available to organic-
based drugs, the possibility to access different redox states and fine-tune ligand 
substitution kinetics, as well as the intrinsic properties of the metal ion and the ligand 
environment, constitute a rich platform to tailor the medicinal properties of a drug.14,15,16 
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A revolution on this field occurred in the 1960’s, when Barnet Rosenberg, 
Loretta VanCamp and Thomas Krigas at Michigan State University serendipitously 
discovered the antiproliferative properties of platinum (Pt) compounds while studying 
the effects of an electric field on the cell growth of Escherichia coli bacteria. In their 
seminal paper published in 1965,17 the authors reported filamentous bacterial growth and 
inhibition of cell division a few hours after turning on the electric field. The observed 
antiproliferative activity was not due to the generated electric current, but by a Pt 
compound that was formed by oxidation of the Pt mesh electrodes that were included in 
the growth chamber that also contained ammonium chloride (NH4Cl) buffer. Further 
studies suggested that an octahedral Pt(IV) species such as [NH4]2[PtCl6] or cis-
Pt(NH3)2Cl4 was responsible of bacterial growth inhibition.17  
In 1969, Rosenberg and coworkers reported that two Pt(IV) compounds cis-
Pt(NH3)2Cl4 and Pt(NH2CH2CH2NH2)Cl4 (Figure 1.2a), and two Pt(II) compounds, cis-
Pt(NH3)2Cl2 and Pt(NH2CH2CH2NH2)Cl2 (Figure 1.2b), decreased the tumor size and 
increased the survival time of mice bearing sarcoma 180 and leukemia L1210 tumors. 
The Pt(II) compound cis-Pt(NH3)2Cl2 (cisplatin) was the most active and led to the 
realization “that inorganic platinum metal compounds form a new class of antitumor 
agents”.18 Such a discovery represents a milestone in Inorganic Chemistry and has 
profoundly influenced the design of anticancer drugs and cancer research. Later, 
cisplatin (Platinol®, Bristol Myers Squibb) was approved by the Food and Drug 
administration (FDA, 1978) to treat metastatic ovarian and testicular cancers. In 1993, its 
approval to treat cell bladder cancer was quickly granted.9,19 Other cancers that are 
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treated with cisplatin include cervical, head and neck, esophageal, non-small cell lung 
cancer (NSCLC) and small-cell lung cancer (SCLC).20,21 Since the discovery of tis 
antitumor properties, cisplatin has become a benchmark in the field, a front-line 
anticancer agent and one of the most effective chemotherapeutic agents in clinical use, 
achieving impressive cure rates of 90% for testicular cancer.22,23  
 
 
 
 
 
Figure 1. 2 Molecular structures of (a) Pt(IV) and (b) Pt(II) antitumor compounds 
reported by Rosenberg in 1969 and (c) carboplatin. 
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The clinical use of cisplatin is, unfortunately, accompanied by detrimental dose-
limiting side effects such as neurotoxicity (nervous system damage), hepatotoxicity 
(liver damage), ototoxicity (hearing loss), nephrotoxicity (kidney damage), 
gastrointestinal tract toxicity, nausea and vomiting, because of its indiscriminate uptake 
by normal healthy cells as well as rapidly dividing tumor cells.19,21 These side effects are 
due to cisplatin binding to proteins present in the bloodstream, particularly those 
containing thiol groups such as human serum albumin: it has been reported that one day 
after cisplatin administration, ~90% of the platinum in blood plasma is protein 
bound.24,25 Inherent resistance (observed in patients with colorectal, prostate, breast and 
NSCLC) or acquired resistance (as occurs in patients with ovarian cancer) during cycles 
of therapy is the second major problem associated with Pt drugs.19,26,27  
Carboplatin (Paraplatin®, Bristol Myers Squibb, Figure 1.2c), a second 
generation Pt(II) compound, was developed to lower the systemic toxicity of cisplatin 
and it was approved by the FDA in 1989 to treat ovarian cancer.9,19 This drug has similar 
efficacy profile to cisplatin, but with the advantage that it does not exhibit nephrotoxicity 
and provokes lower neurotoxicity and gastrointestinal toxicity than cisplatin. However, 
myelosuppression (decreased bone marrow activity that leads to low levels of red blood 
cells, white blood cells and platelets) is dose-limiting for this drug.19 Carboplatin is 
currently undergoing clinical trials for the treatment of salivary gland cancer and 
advanced mullerian cancer (a type of ovarian cancer).21 
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Mechanism of Action 
 
Upon administration via intravenous injection, the high chloride (Cl–) 
concentration in the bloodstream (~100 mM) prevents hydrolysis of the Pt–Cl 
bonds.19,20,22 Cisplatin then traverses the cellular membrane of cancer and healthy cells 
via passive diffusion;28,29,30,31 facilitated diffusion through the copper transporter-1 
protein (CTR1), a transmembrane plasma protein that mediates copper homeostasis, has 
also been reported to play an important role in the cellular uptake of this 
drug.19,31,32,33,34,35,36 Cisplatin is then thermally activated intracellularly by hydrolysis 
(aquation) of one of the Pt–Cl bonds (PtII–Cl + H2O → PtII–OH2 + Cl–, Figure 1.3) 
forming the reactive cationic monoaqua species cis-[Pt(NH3)2(H2O)Cl]+,37,38,39 which is 
able to react more readily with cellular targets. The lower cytoplasmic chloride 
concentration (~4 mM) facilitates the hydrolysis reaction.19,22,31 Cisplatin can be 
therefore regarded as a prodrug since it needs to be activated by hydrolysis before it 
binds to DNA.40 
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Figure 1. 3 Cellular uptake and mechanism of action of cisplatin. 
 
 
 
Although many cellular components (RNA, proteins, membrane phospholipids, 
and microfilaments that make up the cytoskeleton) react with cis-[Pt(NH3)2(H2O)Cl]+, it 
is well-accepted that the antitumor activity of cisplatin derives from its ability to from 
bifunctional DNA crosslinks.20 Different types of DNA adducts can be formed, with 1,2-
intrastrand cis-[Pt(NH3)2(dGpG)] (cis-GG) and cis-[Pt(NH3)2(dApG)] (cis-AG) cross-
links being the major adducts (65% and 25%, respectively), in which the Pt center is 
bound to the N7 positions of the two adjacent purine bases.20,41,42 Figure 1.4 depicts the 
2.6 Å resolution X-ray crystal structure of a DNA dodecamer containing a 1,2-
intrastrand cis-[Pt(NH3)2(dGpG)] reported by Stephen J. Lippard in 1995, in which  the 
helix unwinds and bends by ~50° toward the major groove.20,42 
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Figure 1. 4 X-ray structure of duplex DNA containing a cisplatin 1,2-d(GpG) intrastrand 
cross-links (left) and space filling model of the same structure (right). The platinum ion 
is depicted in gray color. Adapted with permission from reference 31. Copyright 2007 
American Chemical Society. 
 
 
 
Cisplatin binding to DNA is kinetically controlled and the rate limiting step for 
DNA binding is the aquation reaction mentioned above, with a half-life (t1/2) of ~2 h that 
is in the same order of magnitude as cellular division processes,20,22,43 explaining the 
success of this type of Pt(II) compound as an anticancer drug since rapid ligand 
substitution kinetics would prevent it from reaching its biological target. The DNA 
distortions caused by cisplatin impede replication and transcription and eventually lead 
to apoptotic cell death or cell cycle arrest.19,20,31  
Carboplatin forms the same type of DNA adducts like cisplatin, but hydrolysis 
and Pt-DNA adduct formation rates are slower for carboplatin because the 
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cyclobutanediendicarboxylato ligand is a not a good leaving group compared to the 
chloride ligands of cisplatin. For example, the rate constants for the aquation of cisplatin 
and carboplatin at 37°C in free Cl– phosphate buffer (pH = 7) are 8 × 10-5 s-1 (t1/2 = 2.4 h) 
and 7.2 × 10-7  s-1 (t1/2 = 267 h), respectively.44 In addition, higher doses of carboplatin 
(20–40-fold) with respect to that of cisplatin are needed to produce the same amount of 
bound Pt-DNA lesions in vivo due to the much faster rate of aquation of cisplatin.44 The 
slower ligand substitution kinetics of carboplatin also explains the reduced side effects in 
cancer patients with respect to cisplatin.  
 
Tumor Resistance 
 
Cisplatin and carboplatin resistance can occur from (i) reduced platinum 
accumulation by decreased influx or increased efflux of the Pt drugs, (ii) increased 
production of intracellular thiol-containing molecules, (iii) increased ability to repair Pt-
DNA lesions and (iv) increased ability to tolerate Pt-DNA lesion thereby failing to 
induce cell death.19,20,27,45,46  
Down-regulation of CTR-1 and overexpression of proteins that are involved in 
copper intracellular transport and efflux (copper export pump proteins ATP7A ATP7B) 
have been implicated in cisplatin and carboplatin resistance.34,35,47 High intracellular 
levels of thiol-containing species such as glutathione (GSH) and metallothioneins (a 
detoxification protein rich in cysteine and methionine amino acids) have been also found 
in Pt-resistant cancer cells, which are able to deactivate and facilitate the efflux of Pt 
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drugs.19,45 For example, the cisplatin-GSH conjugate is readily exported from cells by 
the ATP-dependent glutathione S-conjugate export pump (GS-X pump, also known as 
MRP2 or ABCC2), decreasing the intracellular accumulation of cisplatin.48,49  
Increased DNA-repair capacity has been observed in Pt-resistant cancer cells, in 
which nucleotide excision repair (NER) is one of the major pathways for the removal of 
DNA lesions.19,31,45 In contrast, low NER capacity in testicular tumors explains the high 
cure rates observed for this cancer type.19 The mismatch repair (MMR) system also 
plays an important role in cisplatin resistance.45,50 When this pathway is active, MMR 
proteins are unable to repair DNA lesions at the platination site and trigger an apoptotic 
signal to destroy the cell; this death signal, however, is reduced by MMR deficiency in 
cisplatin- and carboplatin-resistant cancer cells.50 Increased ability of DNA polymerases 
(such as Pol β and Pol η) to bypass cisplatin-DNA lesions during DNA replication (a 
process called translation synthesis)51,52 and decreased expression of apoptotic signaling 
pathways (e.g. mutations on the tumor suppression protein p53, down-regulation of Bax, 
overexpression of Bcl-2)45 have also been involved in cell  resistance to cisplatin and 
carboplatin.  
The development of Pt compounds that circumvent cancer cell resistance 
continued during the 1900’s and several drugs entered clinical trials. Armed with a better 
understanding of the mechanism of action of Pt drugs, a third Pt(II) drug which is called 
oxaliplatin (Eloxatin®, Sanofi-Aventis, Figure 1.5) was discovered and received 
accelerated FDA approval in 2002 for the treatment of metastatic colorectal cancer in 
combination with 5-fluorouracil and leukovorum, for which both cisplatin and 
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carboplatin are clinically inactive due to cell resistance to these two drugs.9,19,53 Studies 
have revealed that up-regulation of organic cation transporters (OCTs) in cancer cells 
increase the cellular uptake of oxaliplatin; the propensity of colorectal cancer cells to 
overexpress OCTs in the plasma membrane may explain the efficacy of oxaliplatin for 
the treatment of metastatic colorectal cancer.54 It has been also hypothesized that the 
ability of oxaliplatin to overcome resistance relies on the bulkiness of the cyclohexane 
moiety around the Pt-DNA lesion that prevents the recognition and binding of DNA 
repairing proteins, inducing cell death more efficiently.21,32,53 Neuropathy (nerve 
toxicity) is one of the side effects reported for oxaliplatin.9,19,53 
The design and development of new antitumor Pt compounds (Figure 1.5), such 
as nedaplatin (approved in Japan in 1995 for the treatment of NSCLC and SCLC, head, 
neck and esophageal cancers), lobaplatin (approved in China for the treatment of chronic 
myelogenous leukemia, inoperable metastatic breast cancer and SCLC), heptaplatin 
(approved in South Korea for the treatment of gastric cancer), satraplatin (phase III 
clinical trials; orally active; treatment of hormone-refractory prostate cancer), picoplatin 
(phase III clinical trials; treatment of SCLC, colorectal and ovarian cancer, hormone-
refractory prostate cancer) and phenanthriplatin (developed by Stephen J. Lippard, MIT; 
preclinical trials), among others, as well as the strategies that are currently being 
followed to improve the delivery of Pt drugs to tumors (ProlindacTM and LipoplatinTM) 
and overcome cell resistance will not be further addressed since thorough reviews have 
been published in the literature.14,19,21,55,56,57,58 
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Figure 1. 5 Molecular structures of oxaliplatin and other Pt drugs.  
 
 
 
The development of cisplatin as an antitumor drug is considered the most 
successful example of an inorganic compound in medicinal chemistry and it is often 
referred as the “gold standard” or “prototype” inorganic drug, because it gave birth to 
modern medicinal inorganic chemistry and started a new area of anticancer research 
based on metallopharmaceuticals. Numerous studies to understand the activation, 
mechanism of action, toxicity, cell resistance and cellular processing of cisplatin both in 
vitro and in vivo have been fundamental for the successful development of new 
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generations of Pt-based antitumor drugs (carboplatin and oxaliplatin) which are widely 
used in cancer treatment today worldwide. Considering that approximately half of all 
cancer patients are currently treated with a platinum drug,57 and that the worldwide 
annual sales of platinum anticancer drugs in 2011 were $2.062 billion in the United 
States59 with Eloxatin® alone occupying the fifth place among the leading cancer drugs 
(~$1.3 billion in revenue),60 reflects the importance of metal based-drugs on the 
treatment of the second cause of death in the United States. 
Several strategies are currently under investigation to improve the activity, 
reduce systemic toxicity, overcome cellular resistance and develop vehicles for targeted 
chemotherapy of Pt compounds with the ultimate goal of improving cancer patient care. 
The success of Pt compounds in the clinic has also stimulated the exploration of the 
antitumor properties of several other transition metals including ruthenium, osmium, 
rhodium, iridium, gold and titanium, among which ruthenium has emerged as a 
particularly attractive alternative to platinum in cancer therapeutics. This topic will be 
discussed after providing an overview of one of the main mechanisms of cell death that 
is relevant to metal-based cancer drugs, namely apoptosis. 
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Intrinsic Pathway of Apoptosis  
 
Apoptosis, also known as programmed cell death, is a tightly regulated and 
ordered process wherein cells that are no longer needed, or that are a threat to the 
integrity of an organism, are induced to commit “suicide”.61,62,63 Since most 
chemotherapeutic drugs act through induction of apoptosis,64 the topic will be briefly 
described. 
 The intrinsic pathway is one of the two most characterized (the other one being 
the extrinsic pathway) and prominent mechanisms that leads to apoptosis; most 
apoptosis in mammals occurs through this mechanism.61,64,65 The intrinsic pathway is 
also known as mitochondrial pathway since mitochondria, the powerhouse of the cell, 
play a crucial role in this route to cell death. The outer mitochondrial membrane contains 
anti-apoptotic (also called pro-survival) proteins of the Bcl-2 family such as Bcl-2 and 
Bcl-xL that maintain the integrity of the outer mitochondrial membrane and promote cell 
survival by preventing the release of cytochrome c and other pro-apoptotic proteins from 
the mitochondria to the cytosol and the nucleus.61,64,65  
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When internal cell stress occurs, such as DNA damage, mitochondria damage, 
endoplasmic reticulum stress, formation of reactive oxygen species (ROS), pro-apoptotic 
proteins from the Bcl-2 family such as Bax and Bak migrate to the outer mitochondrial 
membrane and oligomerize which inhibits Bcl-2 proteins and creates supramolecular 
openings (pores) on the surface of the mitochondrion. As a consequence, outer 
mitochondrial membrane permeabilization (MMP) takes place and proteins located in 
the intermembrane space (e.g. cytochrome c) are able to diffuse into the cytosol.61,64,65,66 
Cytochrome c translocates to the endoplasmic reticulum where it binds the inositol 
(1,4,5) trisphosphate receptor (InsP3R), triggering Ca2+ release and an increase in the 
concentration of this cation in the cytosol.67   
MPP is accompanied by the long-lasting opening of the mitochondrial 
permeability transition pore (MPTP, which is a protein complex that forms a channel 
and allows the exchange of metabolites between the cytosol and the mitochondrial 
matrix), allowing the entrance of Ca2+ into the mitochondrial matrix and causing 
permanent dissipation of the inner mitochondrial transmembrane potential (ΔΨm), 
permeabilization of the inner mitochondrial membrane and decreased ATP 
production.61,67 As a consequence, an augmented release of cytochrome c is produced.67 
In addition, swelling of the mitochondria is observed due to the massive entry of solutes 
and water. 
After these initial events, cytosolic cytochrome c is recruited by the apoptotic 
protease activating factor-1 (Apaf-1), along with the cofactors dATP/ATP 
(deoxyadenosine triphosphate/adenosine triphosphate), and forms a wheel-shaped 
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multiprotein complex known as apoptosome. The apoptosome binds and activates 
caspase-9 (caspase = cysteine-dependent aspartate specific proteinase). This initiator 
caspase then activates the executioner (effector) caspases -3, -6 and -7, which digest 
structural proteins in the cytoplasm and degrades chromosomal DNA during the 
demolition phase of apoptosis.68 Other morphology changes that are observed during 
apoptosis are: cell shrinkage, plasma membrane blebbing, chromatin condensation, 
nuclear fragmentation, chromosomal DNA degradation and phosphatidylserine exposure 
on the surface of the plasma membrane.61,62,63 The downstream cascade of proteolytic 
activity dismantles the cell; the cell breaks apart and forms membrane-bound vesicles 
called apoptotic bodies that are phagocytized and digested by macrophages or 
neighboring cells without activating immune response.62,63,65,68  
 Necrosis is a different mechanism of cancer cell death that is characterized by 
gain of cell volume that leads to rupture of the plasma membrane, along with an 
unorganized dismantling of organelles.62,63 Necrosis is considered to be harmful because 
necrotic cells burst, damage neighboring healthy cells and promote a local inflammation 
response that may support tumor growth.61,62,63 For this reason, harmless removal of 
tumor cells through apoptosis is a desirable feature for cancer chemotherapy.  
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The Emergence of Ruthenium Anticancer Drugs 
 
Ruthenium(III) Drugs in Clinical Trials for Cancer Chemotherapy 
 
Ruthenium (Ru) is a second row transition metal that belongs to the so-called 
platinum group elements. The investigation of Ru complexes as metallopharmaceuticals 
for the treatment of cancer disease has been fuelled by the success of Pt drugs in the 
clinic and is now a fruitful and mature field that has successfully led to the investigation 
of two drugs in clinical trials.16,69,70 
The Ru compounds that are in phase II clinical trials are [H2im][trans-RuCl4(S-
dmso)(Him)] (NAMI-A; Him = imidazole, dmso = dimethylsulfoxide, Figure 1.6) and 
[H2ind][trans-RuCl4(Hind)2] (KP1019; Hind = indazole, Figure 1.6).70,71 Although the 
structures of these drugs are quite similar, they exhibit contrasting anticancer properties. 
NAMI-A was developed by Enzo Alessio, Gianni Sava and coworkers in Italy, it is does 
not exhibit appreciable cytotoxicity in cancer cell cultures, but it has an impressive 
efficacy for stopping solid tumor metastases, such as lung metastases. The drug entered 
clinical trials in 1999.71 This Ru compound induces caspase activation, inhibits matrix 
metalloproteinases (Zn-containing proteolytic enzymes that degrade the extracellular 
matrix that surrounds tumors and facilitate tumor migration), promotes tumor adhesion 
and decreases angiogenic activity, preventing tumor invasion to healthy tissue.69,71,72,73,74 
The drug KP1019 was developed by Bernhard K. Keppler and coworkers in Germany 
and is superbly active against platinum-resistant colorectal tumors and kills tumors cells 
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via the intrinsic pathway of apoptosis (induces depolarization of inner mitochondrial 
membrane, activation of caspase-3 and down-regulation of Bcl-2);70 this drug entered 
clinical trials in 2003.75,76,77 Both Ru drugs display low general toxicity toward healthy 
tissues because the Ru(III) ion is capable of mimicking iron (Fe(III)) in binding to 
important carrier proteins, such as transferrin.74,78 In fact, X-ray crystallographic studies 
have demonstrated that KP1019 binds to apo-lactoferrin via a histidine residue and the 
indazole ligands remain bound to the Ru center.75,78,79 Since cancer cells overexpress 
transferrin receptors to satisfy their increased demand for iron,71,76,80 NAMI-A and 
KP1019 may be delivered more efficiently and selectively to cancer cells, explaining 
their lower systemic toxicity.71 
 
 
 
 
 
Figure 1. 6 Molecular structures of Ru drugs in clinical trials.  
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KP1019 and NAMI-A contain a Ru(III) center and it has been hypothesized by 
Clarke and coworkers that these two drugs are activated by intracellular reduction 
(promoted by glutathione) of the metal center to Ru(II), followed by hydrolysis and 
binding to biological targets.74 This type of activation may confer selectivity towards 
solid tumors because they are more hypoxic due to insufficient vascularization and 
provide a more reducing environment than normal tissues facilitating the metal-based 
reduction.71,81 The ligand exchange kinetics of coordination compounds of Pt(II) and 
Ru(II) with chloride and N-donor ligands is similar, and within the timescale of cellular 
division processes, which could explain in part the applicability of Ru(II) compounds as 
chemotherapy drugs.22,43,82 However, this “activation by reduction” mechanism still 
remains only a hypothesis.69 Although numerous in vitro and in vivo investigations have 
been performed, the mechanism of action of NAMI-A and KP1019 is still poorly 
understood, biological targets in vivo have not been conclusively determined and their 
identification remains a challenging task that requires the collective knowledge from 
many different fields, including chemistry, pharmacology, molecular biology, 
physiology and medicine, requiring an interdisciplinary approach.40,69,75  
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Ruthenium(II) Organometallic Compounds as Anticancer Agents 
 
The impressive antitumor properties of NAMI-A and KP1019 and their 
evaluation in human clinical trials sparked interest in the exploration of the biological 
activities of Ru compounds across different research areas leading to the development of 
novel classes of Ru(II) antitumor compounds, among which organometallic complexes 
reported by Peter J. Sadler (United Kingdom) and Paul J. Dyson (Switzerland) hold great 
potential and are currently in preclinical trials.70,82,83,84,85,86 These organometallic 
anticancer drugs belong to an emerging and exciting field known as bioorganometallic 
chemistry, which will be further discussed in Chapter II. 
Organometallic Ru(II)-arene compounds of the type [(η6-arene)RuCl(en)]+ (en = 
ethylendiamine, Figure 1.7a), developed by Sadler and coworkers, were reported to 
exhibit cytotoxic properties against a variety of cancer cell lines.87,88,89 In these 
complexes, the arene ligand stabilizes the Ru(II) oxidation state and occupies three 
coordination sites of the pseudo-octahedral geometry.40 The bidentate en ligand provides 
relatively good water solubility and recognition sites since its NH groups can engage in 
hydrogen-bonding interactions, and the chloride ligand endows these complexes with a 
reactive site.40 In particular, [(η6-biph)RuCl(en)][X] (RM175; biph = biphenyl, X = Cl– 
or PF6–, Figure 1.7b) and [(η6-THA)RuCl(en)][X] (HC11; THA = 5,8,9,10-
tetrahydroanthracene, X = Cl– or PF6–, Figure 1.7b) are two of the most active 
compounds and exhibit high anticancer activity in A2780 human ovarian cancer 
xenografts, with activities comparable to cisplatin and carboplatin.87,88,89 
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Figure 1. 7 Molecular structures of (a) Ru(II) organometallic anticancer compounds 
from Sadler’s laboratories, (b) RM175 and HC11. 
 
 
 
The main reaction that is important for these compounds is aquation of the Ru–Cl 
bond to afford the more reactive aqua complex [(η6-arene)Ru(OH2)(en)]+.40,90 The rate of 
hydrolysis is faster (~5 × 10-3 s-1  at 37°C in 0.1 M NaClO4 (aq)) as compared to cisplatin, 
with t1/2 values (~ 2.5 min) that are ~50-times shorter than that of the Pt drug.91 Although 
it has not yet been established unequivocally, the primary cellular target for these 
compounds is thought to be nuclear DNA.40,90 It has been shown that after hydrolysis, 
[(η6-arene)Ru(OH2)(en)]2+ is able to form monofunctional Ru-DNA adducts by 
substitution of the aqua ligand with the N7 atom of guanine preferentially,92 a process 
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that is enhanced by hydrogen-bonding between the NH group of the en ligand and the 
O6 atom of guanine.92,93,94 Interestingly, it was shown that [(η6-biph)Ru(OH2)(en)]+ 
binds covalently to the 14-mer DNA duplex d(5’-ATACATGGTACATA-3’)/(3’-
TATGTACCATGTAT-5’) and that it also intercalates its biphenyl moiety between 
DNA bases and engages in π-π stacking interactions, thereby increasing DNA affinity. 
Such a dual DNA binding mode represents a new structural feature in metal-DNA 
adducts.92,93,94,95 The coordinated water molecules of [(η6-biph)Ru(OH2)(en)]2+ and [(η6-
THA)Ru(OH2)(en)]2+ have pKa values of 7.71 and 8.01, respectively, in water at 37°C, 
indicating a low acidity for the water ligand which means that only small amounts of the 
hydroxo species [(η6-arene)Ru(OH)(en)]+ will be present in physiological media.91 This 
is an important factor for this class of anticancer compounds because the hydroxo 
species is less susceptible to DNA binding.40,92 
 Paul J. Dyson and coworkers developed a closely related series of neutral Ru(II)-
arene compounds of formula Ru(η6-arene)(pta)Cl2, where pta is the amphiphilic 
phosphine 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane.84 This family of compounds 
are known in the literature as RAPTA compounds. For example, Ru(η6-toluene)(pta)Cl2 
(RAPTA-T; Figure 1.8a) and Ru(η6-p-cymene)(pta)Cl2 (RAPTA-C; Figure 1.8b) are not 
cytotoxic in vitro, but display selective activity for metastatic tumors in vivo, similar to 
NAMI-A.96,97 The RAPTA compounds have a strong preference for protein binding over 
DNA,98 and are devoid of toxicity to healthy cells even with prolonged exposure at 
millimolar concentrations.70 Part of their mode of action involves the inhibition of 
detachment of tumor cells from the primary tumor, inhibition of re-adhesion to a new 
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growth substrate and down-regulation of matrix metalloproteinases.84,97 Although the 
RAPTA compounds are still under development,84 it is remarkable that a second type of 
metal-based drugs that prevents tumor invasion and formation of metastases has been 
discovered.  
 
 
 
 
 
Figure 1. 8 Molecular structure of (a) RAPTA-T and RAPTA-C, (b) Ru(η6-
phenylethacrynate)(pta)Cl2 and (c) a Ru-based kinase inhibitor. 
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 The design of hybrid compounds containing an organometallic Ru(II)-arene 
moiety and an enzyme inhibitor has been a successful approach for targeted therapies in 
this field.82,83,84,85 For example, Ru(η6-phenylethacrynate)(pta)Cl2 (Figure 1.8b) is a 
potent inhibitor of glutathione-S-transferase (GST), which is a detoxification enzyme 
that catalyzes nucleophilic attack of GSH with electrophilic molecules (such as 
anticancer drugs) and facilitates expulsion of the molecule-GSH conjugates through the 
glutathione S-conjugate efflux pump.99 The GST enzyme is overexpressed in primary 
and metastatic tumors99 and inhibition of GST will play an important role in overcoming 
cancer cell resistance. The compound Ru(η6-phenylethacrynate)(pta)Cl2 inhibits GSTP1-
1 by accommodation of the ethacrinic acid moiety in a hydrophobic pocket within the 
enzyme active site (H-site) and by covalent binding of a cysteine residue (Cys101) to the 
Ru center by displacement of the chloride ligands at the G-site (which is the binding 
motif for GSH). Therefore, the inhibitory ability of ethacrinic acid is enhanced by 
providing an additional binding mode at the active site.100 Kinetically inert Ru(II) 
organometallic compounds that act as highly selective enzyme inhibitors (e.g. 
cycplopentadienyl Ru(II) compounds as protein kinase inhibitors) have been reported by 
Eric Meggers (Germany) and have been found to be highly toxic toward human 
melanoma cells. Although such work will not be discussed herein, the interested reader 
is encouraged to read the articles published in this vibrant area.101,102,103,104,105,106 
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Ruthenium(II) Polypyridyl Anticancer Compounds 
 
Coordinatively saturated and kinetically inert Ru coordination compounds have 
also been studied in cancer drug research. The structure of this class of molecules 
departs from the paradigm of using the inherent reactivity of the transition metal to exert 
a therapeutic effect by DNA binding, because there are no labile positions at the metal 
center in these compounds. Numerous examples of Ru(II) polypyridyl complexes that 
display promising anticancer properties have been reported. More interestingly, new 
cellular targets, such as mitochondria and endoplasmic reticulum, have been recognized. 
Due to the relevance of this field to my research work, this topic will be discussed more 
in detail to continuation. 
 
Early Reports of Biological Activity 
 
The first report of the biological activity of Ru(II) polypyridyl complexes 
appeared in 1952.102,107 Dwyer and coworkers determined that the LD50 (dose required to 
kill half a cell population after a specified test duration) of the dicationic compounds 
[Ru(phen)3]2+ (phen = 1,10-phenanthroline, Figure 1.9) and [Ru(bpy)3]2+ (bpy = 2,2’-
bipyridine, Figure 1.9) are ~10–15  mg/kg when administered to mice via intraperitoneal 
(IP) injection.107 For comparison sake, the oral and intravenous LD50 values of cisplatin 
in mice are 32.7 and 11 kg/mg, respectively.108 Exposure of mice with a dose equal to 
the LD50 of the Ru compounds resulted in paralysis and respiratory failure due to direct 
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inhibition of acetylcholinesterase.107,109 The two Ru compounds were reported to be 
chemically highly stable as they are not attacked by concentrated acids or bases and 
dissociation of the complexes is considered extremely minimal in biological systems.107 
In fact, it was shown that [Ru(phen)3]2+ is not metabolized and is excreted essentially in 
an unaltered state in the urine after IP injection in mice.110  
In 1965, the same year when the antiproliferative properties of cisplatin were 
discovered, the antitumor properties of [Ru(tmphen)3]2+ (tmphem = 3,4,7,8-tetramethyl-
1,10-phenanthroline, Figure 1.9) and [Ru(tmphen)2(acac)]+ (acac = acetylacetone, Figure 
1.9) were studied in mice bearing Landschütz ascites tumors (a transplantable highly 
virulent tumor that can be grown in any strain of mice).111 Significant inhibition of tumor 
growth without substantial weight loss of the animals was observed after administration 
of the compounds, with the monocationic compound exhibiting more pronounced tumor 
growth inhibition. Such a finding represents an early example of the effectiveness of 
reducing the positive charge of Ru(II) polypyridyl complexes from 2+ to 1+ by 
coordination of a monoanionic chelating ligand (such as acac) for increasing the cellular 
accumulation of the metal compound. It was also reported that [Ru(tmphen)2(acac)]+ 
localizes in the mitochondria of Landschütz ascites tumor cells.110  
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Figure 1. 9 Molecular structures of the cationic complexes [Ru(phen)3]2+, [Ru(bpy)3]2+, 
[Ru(tmphen)3]2+ and [Ru(tmphen)2(acac)]+. 
 
 
 
Cellular Uptake  
 
The mechanisms by which this class of molecules traverse the plasma membrane 
of cells has been thoroughly studied by Barton and coworkers.112,113,114,115 The cellular 
uptake of the lipophilic cationic compound [Ru(DIP)2(dppz)]2+ (DIP = 4,7-diphenyl-
1,10-phenanthroline, dppz = dipyrido[3,2-a:2',3'-c]phenazine,  Figure 1.10) was studied 
in human cervical (HeLa) cancer cells using confocal fluorescence microscopy, 
inductively coupled plasma mass spectrometry  (ICP-MS) and flow cytometry. 
Confocal imaging revealed that emission from [Ru(DIP)2(dppz)]2+ is observed 
throughout the cytosol and very weak emission is observed in the nucleus (Figure 1.10), 
indicating that [Ru(DIP)2(dppz)]2+ does not target specific cellular compartments in this 
cancer cell line. There is substantial cellular uptake of the complex after 1 h of 
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incubation (37°C) which reaches a concentration of 16 µM and 398 µM inside the cells 
when incubated in serum and serum-free medium, respectively, as determined by ICP-
MS. No uptake preference was observed when the Δ- and Λ-isomers of 
[Ru(DIP)2(dppz)]2+ were incubated with the cells separately.112  
Cellular uptake of small molecules occurs through energy-dependent 
(endocytosis, active protein transport) and energy independent (facilitated diffusion, 
passive diffusion) processes. In order to deplete the cells of energy, HeLa cells were 
incubated with [Ru(DIP)2(dppz)]2+ at low temperature (4°C) or in the presence of 
metabolic inhibitors, such as deoxyglucose (a glucose analogue that inhibits glycolysis) 
and oligomycin (an inhibitor of oxidative phosphorylation). Energy depletion did not 
decrease the uptake of [Ru(DIP)2(dppz)]2+, ruling out the energy-dependent pathways 
endocytosis and active protein transport as mechanisms of cellular uptake.112 Organic 
cation transporters (OCTs) are polyspecific transporters that facilitate the cellular 
uptake/efflux of organic cations.116 Incubation of HeLa cells with [Ru(DIP)2(dppz)]2+ in 
the presence of OCTs inhibitors (e.g. procainamide, tetraalkylammonium salts) also did 
not have a negative impact on the uptake of the metal complex either. In contrast, 
decreasing the potential of the plasma membrane to close to zero (membrane potential of 
cells is –50 to –70 mV; inside of the cell is negative with respect to the outside)112,117 by 
incubation in buffer with K+ concentration similar to that found in the cytosol of HeLa 
cells (~170 mM)118 produced a 66% decrease of uptake of [Ru(DIP)2(dppz)]2+, 
indicating that the potential difference across the cellular membrane drives the cellular 
internalization of this Ru complex and that [Ru(DIP)2(dppz)]2+ enters HeLa cancer cells 
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by passive diffusion.112 This study is very important for the field of anticancer Ru(II) 
polypyridyl drugs because it paved the road for the design of other lipophilic Ru 
compounds. Moreover, since passive diffusion is a mechanism of cellular uptake that 
does not rely on specific transporters, lipophilic Ru compounds could potentially exhibit 
cytotoxicity against a broad panel of cancer cells, even against those that are cisplatin-
resistant. 
 
 
 
         
 
Figure 1. 10 Molecular structure of [Ru(DIP)2(dppz)]2+ and confocal image of HeLa 
cells incubated with 5 μM [Ru(DIP)2(dppz)]2+ for 4 h. Scale bar is 10 μm. Adapted with 
permission from reference 112. Copyright 2008 American Chemical Society. 
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Cytotoxicity and Mechanism of Cancer Cell Death 
 
Lipophilicity and cellular uptake play a crucial role on the cytotoxicity of Ru(II) 
polypyridyl complexes. Several studies in this vein, as well as the elucidation of the 
mechanism of cancer cell death induced by this type of complexes, have been published 
over past few years and several reviews have appeared on the topic.114,115,119 Selected 
examples are discussed below. 
Schatzschneider and coworkers studied the cellular uptake of polypyridyl 
complexes of the type [Ru(bpy)2(L)]2+, where L = bpy, phen, dpq, dppz, dppn (Figure 
1.11).120 The cellular uptake (measured by atomic absorption spectrometry (AAS)) of 
these compounds in human colon (HT-29) and breast (MCF-7) cancer cells was related 
to the lipophilicity (or size) of the L ligand, suggesting that more lipophilic Ru 
compounds are able to traverse the plasma membrane more easily than less lipophilic 
compounds. Moreover, their cytotoxicity increases with cellular uptake, indicating that 
ligands with extended aromatic systems may improve the cellular accumulation of Ru 
polypyridyl compounds inside the cells leading to higher cytotoxicities. The most potent 
compound was found to be [Ru(bpy)2(dppn)]2+ (dppn = benzo[i]dipyrido[3,2-a:2',3'-
c]phenazine) and is as cytotoxic as cisplatin against both cancer cell lines (96 h of 
treatment).120 Analogous results have been reported for other Ru(II) and Ir(III) 
compounds with a similar series of L ligands including dppn.121 
 
 
 34 
 
 
 
Figure 1. 11 Molecular structures of [Ru(bpy)2(L)]2+ complexes. 
 
 
 
Liu, Wong and coworkers studied the anticancer activity of several compounds 
of general type [Ru(N^N)2(L)]2+, where N^N is a bpy-type ligand and L is a 
phenylimidazo-phenanthroline ligand (Figure 1.12a).122,123 It was found that RuPOP 
(Figure 1.12b) is the most cytotoxic of the series in melanoma (A375), hepatocellular 
carcinoma (HepG2) and  colorectal adenocarcinoma (SW620) cancer cells (48 h of 
treatment), and that RuPOP is ~2-fold more cytotoxic than cisplatin. RuPOP exhibits 
lower cytotoxicities towards normal cells (fibroblast (Hs68) and kidney cells (HK-2)), a 
highly desirable feature for cancer drug design. In contrast, cisplatin did not show any 
selectivity towards either normal or cancer cells under the same experimental conditions. 
RuPOP induces apoptosis, in which DNA fragmentation, nuclear condensation and 
cytoplasmic shrinkage were observed. This compound also induces mitochondrial 
fragmentation and loss of ΔΨm, confirming cell death via the intrinsic pathway of 
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apoptosis. Further biological analyses revealed that RuPOP suppresses the expression of 
the Bcl-2 anti-apoptotic protein, upregulates the expression of the pro-apoptotic protein 
Bad and activates caspase-9, concluding that RuPOP induces mitochondria-mediated 
and caspase-depended apoptosis in human cancer cells.122 
 
 
 
 
 
Figure 1. 12 (a) Molecular structures of Ru polypyridyl complexes with phenylimidazo- 
phenanthroline ligands and (b) molecular structure of RuPOP. 
 
 
 
Xu and coworkers conducted biological studies on three polypyridyl complexes 
of the type [Ru(N^N)2(bpy-norharman)]2+ (Figure 1.13a), where N^N = bpy, phen and 
DIP; bpy-norharman is a chelating ligand derived from the norharman β-carboline 
alkaloid.124 The three complexes exhibit greater cytotoxicities than [Ru(bpy)2(dppz)]2+ 
(which is practically inactive) against three types of tumor cells (HeLa, HepG2, MCF-7; 
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48 h of treatment). As expected, their cytotoxicities increased with their lipophilicity and 
cellular uptake: [Ru(bpy)2(bpy-norharman)]2+ < [Ru(phen)2(bpy-norharman)]2+ < 
[Ru(DIP)2(bpy-norharman)]2+. Increasing the lipophilicity enhances the rate of cellular 
uptake and, consequently, the cytotoxic activity increases, as observed in previous 
studies. The bpy-norharman ligand alone was inactive against all the cells tested. The 
most active compound, [Ru(DIP)2(bpy-norharman)]2+, was found to be ~6-fold more 
cytotoxic than cisplatin in the three cell lines tested and the three complexes were found 
to traverse the cellular membrane by an energy-independent process (passive diffusion) 
as proposed for [Ru(DIP)2(dppz)]2+.112,124  
The three compounds induced apoptosis via the intrinsic pathway: increased 
percentage of sub-G1 phase cells, cell shrinkage, membrane blebbing, chromatin 
condensation, nuclear fragmentation, depletion of ΔΨm and promotion of caspase-3/7 
activity were observed. Autophagy, a self-digestion process in which parts of the cytosol 
are sequestered within acidic vesicular organelles and are degraded by lysosomal 
hydrolytic enzymes,61,125 was observed simultaneously with apoptosis in HeLa cells and 
both processes seemed to be triggered by production of ROS. Suppression of autophagy 
using autophagy inhibitors enhanced apoptotic cell death, suggesting that autophagy had 
a protective role.124 This family of complexes represents the first example of dual 
apoptosis- and autophagy-inducing Ru compounds.  
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Figure 1. 13 Molecular structures Ru polypyridyl (a) bpy-norharman and (b) norharman 
complexes.  
 
 
 
Confocal microscopy studies revealed that red emission from [Ru(N^N)2(bpy-
norharman)]2+ (N^N = phen, DIP) is observed in the cytosol and increases gradually 
inside the nucleus of HeLa cells over time. In contrast, [Ru(bpy)2(dppz)]2+ and 
[Ru(DIP)2(dppz)]2+ localizes mainly in the cytosol,112,113,124 indicating that bpy-
norharman influences the cellular localization of these Ru complexes. The in vitro DNA 
binding ability of the three Ru bpy-norharman complexes increases in the following 
order: [Ru(bpy)2(bpy-norharman)]2+ < [Ru(phen)2(bpy-norharman)]2+ < [Ru(DIP)2(bpy-
norharman)]2+, which when correlated with their cytotoxicities suggests that DNA 
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intercalation may be triggering the apoptotic response.124 The same authors reported that 
Ru complexes of formula [Ru(N^N)2(norharman)]2+ (N^N = bpy, phen and DIP), 
featuring norharman as a monodentate ligand (Figure 1.13b), induce cancer cell death 
via the intrinsic pathway.126 Similar to the previous series of compounds, the most 
cytotoxic molecule is [Ru(DIP)2(norharman)]2+, and it is ~20-fold more cytotoxic than 
cisplatin (Hela, HepG2, MCF-7 cancer cells; 48 h of treatment) and targets the nucleus 
of HeLa cells.126 
Gasser and coworkers documented the biological effects of a photoluminescent 
Ru(II) compound, [Ru(dppz)2(CppH)]2+ (CppH = 2-(2′-pyridyl)pyrimidine-4-carboxylic 
acid, Figure 1.14a).127 This compound exhibits cytotoxic properties (48 h treatment) 
comparable to cisplatin in HeLa, MCF-7, human ovarian carcinoma (A2780) and 
osteosarcoma (U2OS) cancer cells, and is three times more cytotoxic than cisplatin in 
the cisplatin-resistant A2780-CP70 cell line. It binds DNA by intercalation in vitro but 
does not target DNA in cellulo. Confocal microscopy studies indicate that the primary 
target of [Ru(dppz)2(CppH)]2+ is mitochondria: Figures 1.14b-e shows that the orange 
emission of [Ru(dppz)2(CppH)]2+ colocalizes with the green emission of Mitotracker 
green (a mitochondria-specific fluorescent dye), indicating that the Ru complex localizes 
in mitochondria. Quantification of the ruthenium content by using AAS in mitochondria 
of HeLa cells exposed to this compound supported the microscopy results and it was 
found that 68% of the total uptake of [Ru(dppz)2(CppH)]2+ localizes in mitochondria. 
These findings underscores the contention that if a Ru complex binds DNA through 
intercalation in vitro, it does not necessary imply that nuclear DNA will be the target in 
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cellulo (or in vivo). The mechanism of cell death was investigated in HeLa cells and it 
was shown that [Ru(dppz)2(CppH)]2+ impairs the ΔΨm and induces apoptosis via the 
intrinsic pathway. In addition, Ru(dppz)2(CppH)]2+ enters HeLa cells through an energy-
dependent mechanism.127 
 
 
 
         
 
Figure 1. 14 (a) Molecular structure of [Ru(dppz)2(CppH)]2+. Fluorescence confocal 
microscopy images of HeLa cells incubated with [Ru(dppz)2(CppH)]2+ (20 μM) for 2 h: 
(a) nuclear staining, (b) cellular staining of [Ru(dppz)2(CppH)]2+, (c) mitochondrial 
staining, and (d) the overlay image. Adapted with permission from reference 127. 
Copyright 2012 American Chemical Society. 
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More recently, Ji, Chao and coworkers showed that polypyridyl complexes of the 
type [Ru(N^N)2(PAIH)]2+ (N^N = bpy, phen, dmphen, DIP), where PAIH is an 
anthracenyl chelating ligand (2-Pyridyl-1H-anthra[1,2-d]imidazole-6,11-dione, Figure 
1.15), are cytotoxic against various cancer cell lines, such as HeLa, HepG2, human 
hepatocellular carcinoma (BEL-7402) and lung carcinoma (A549).128 The compound 
with the greatest lipophilicity, [Ru(DIP)2(PAIH)]2+, is the most cytotoxic and its IC50 
values (48 h treatment) are comparable to those of cisplatin in all the cell lines tested but 
less cytotoxic than cisplatin against normal cells (hepatic cells (LO2)). The PAIH ligand 
alone is inactive. As documented in previous studies, the cellular uptake (measured by 
ICP-MS) and cytotoxicities of the compounds correlates with the lipophilicity of the 
complex. HeLa cells incubated with [Ru(DIP)2(PAIH)]2+ showed nuclear fragmentation, 
chromatin condensation, externalization of phosphatidylserine, and an increased number 
of cells in the subG1 phase, suggesting apoptosis as the mechanism of cancer cell death. 
Additionally this Ru compound accumulates preferentially in mitochondria, induces 
production of ROS in a dose-dependent fashion, disrupts the ΔΨm, suppresses the 
expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL, increases the expression 
level of the pro-apoptotic protein Bax, induces the release of cytochrome-c and promotes 
the activation of the initiator caspase-9 and the downstream effectors caspase-3 and 
caspase-7. These collective findings indicate that the intrinsic pathway is operating 
during cancer cell death.128 
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Figure 1. 15 Molecular structure of Ru polypyridyl complexes containing the 
anthracenyl chelating ligand PAIH 
  
 
 
Thomas and coworkers studied the antitumor properties of two Ru complexes 
containing the lipophilic thppz ligand (tetrapyrido[3,2-a:2',3'-c:3'',2''-h:2''',3'''-
j]phenazine): [Ru(bpy)2(tpphz)]2+ (Figure 1.16a) and [Ru(phen)2(tpphz)]2+ (Figure 
1.16b).129 Both compounds show strong DNA binding through intercalation in vitro, 
exhibit comparable cytotoxicity to cisplatin against MCF-7 and A2780 cancer cells and 
are active in the A2780-CP70 cisplatin-resistant cell line. Confocal fluorescence studies 
revealed that these photoluminescent compounds target the nucleus of MCF-7 cancer 
cells and are remarkable DNA stains, and that both compounds traverse the cellular 
membrane by an active transport mechanism.129  
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Figure 1. 16 Molecular structures of (a) [Ru(bpy)2(thppz)]2+, (b) [Ru(phen)2(thppz)]2+ 
and (c) [(Ru(DIP)2)2(µ-tpphz)]4+. 
 
 
 
The Thomas group later studied the cytotoxic properties and subcellular 
localization of the homodinuclear polypyridyl compound [(Ru(DIP)2)2(µ-tpphz)]4+.130 In 
contrast to their previous studies on mononuclear complexes,129 this photoluminescent 
compound was found to localize in the endoplasmic reticulum of MCF-7 cancer cells, 
which was attributed to its great lipophilicity and affinity for hydrophobic membranes. 
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In fact, this is the first example of a Ru compound that targets this cellular organelle, 
extending the scope of biological activities exhibited by Ru polypyridyl complexes.130 
The dinuclear complex is three times more cytotoxic than cisplatin in HeLa and MCF-7 
cells (24 h treatment) and cell swelling, cellular debris and evidence of intracellular 
vacuolization were apparent in these two cell lines, suggesting that the cells died by 
necrosis. Its cellular uptake in MCF-7 cells is temperature-dependent, indicating that 
[(Ru(DIP)2)2(µ-tpphz)]4+ traverses the cellular membrane by an active transport 
mechanism. The analogous compound [(Ru(phen)2)2(µ-tpphz)]4+ is inactive against the 
cancer cells tested and was found to targets nuclear DNA.130,131 
In summary, the biological studies discussed herein reveal that the lipophilicity 
of the ancillary ligands of Ru polypyridyl compounds with a [RuIIN6]2+ coordination 
environment plays an important role on their cellular accumulation and cytotoxicity. The 
Ru polypyridyl compounds are now considered as promising new candidates in cancer 
drug research, exhibiting antitumor properties comparable or superior to the benchmark 
drug cisplatin. Moreover, their photoluminescent properties facilitate the study of their 
subcellular localization, allowing for straightforward identification of cellular targets by 
using confocal fluorescence microscopy. Since this class of complexes is coordinatively 
saturated and kinetically inert, they do not bind covalently to nuclear DNA as in the case 
of cisplatin; in fact, they exhibit very different mechanisms of action and are able to 
target other organelles such as mitochondria and endoplasmic reticulum, which is a 
desirable feature for overcoming tumor resistance in cancer chemotherapy. 
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Dissertation Objectives and Outline 
 
The research conducted to date in the field of medicinal inorganic chemistry has 
led to the conclusion that Ru-based anticancer drugs are a very promising generation of 
metallopharmaceuticals for cancer chemotherapy. Two Ru compounds are currently in 
human clinical trials and several more are being evaluated in preclinical studies. The 
structural diversity, reactivities, and rich redox and photophysical properties of Ru 
complexes lead to a wide array of possibilities for the rational design of anticancer 
drugs.  
The research on Ru-based metallopharmaceuticals, however, has focused mainly 
on Ru(II) polypyridyl compounds with a [RuIIN6]+ pseudo-octahedral coordination 
environment and organometallic Ru(II)-arene piano-stool complexes, with almost no 
attention focused on the other scaffolds that are accessible in Ru(II) chemistry. The 
primary objective of this work, therefore, was to design, synthesize and characterize two 
novel Ru(II) architectures that have not been well-developed in the field and to evaluate 
their potential use in cancer drug research by studying their cytotoxic properties in 
cancer cell lines. In the case of those found to be anticancer active the goal is to 
determine the mechanism(s) of cancer cell death. In addition, albeit not discussed in this 
introductory chapter due to a need for brevity, a fluorescent metal-metal bonded 
dirhodium compound, the first of its kind, has been used as a model compound to gain a 
better understanding of the cellular distribution of metal-metal bonded compounds in 
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cancer cells and to discover new cellular targets in order to guide the research of this 
class metal compounds in cancer therapeutics.  
 Chapter II is a thorough investigation of the mechanism of cell death in human 
lung adenocarcinoma (A549) cells induced by Ru(II) polypyridyl compounds that 
possess a [RuIIN5O]+ pseudo-octahedral coordination environment. This study expands 
the diversity of Ru(II) polypyridyl drugs and demonstrates that compounds of this type 
are capable of inducing apoptosis. A discussion of the cytotoxicity of an iridium analog 
is also included. 
In Chapter III, the cytotoxic properties of a group of coordinatively saturated 
organometallic Ru(II) compounds whose structure, redox and optical properties are 
similar to those of Ru cyclometallated dyes used in dye-sensitized solar cells, are 
explored in human cervical (HeLa) and ovarian (OVCAR-8 and NCI/ADR-RES) cancer 
cells and a commentary on the suitability of Ru organometallic dyes as anticancer agents 
is provided. 
Chapter IV describes a study aimed at determining new cellular targets for 
anticancer metal-metal bonded dirhodium compounds. A literature review of the 
anticancer properties of dirhodium drugs is provided and the synthesis, characterization, 
subcellular distribution and localization of a fluorophore-labeled dirhodium compound 
in human lung adenocarcinoma (A549) cells are discussed. 
Overall conclusions and future research work are found in Chapter V.  
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CHAPTER II 
CYTOTOXICITY STUDIES OF RUTHENIUM COMPOUNDS AND AN  
IRIDIUM ANALOG WITH N^O– ANCILLARY LIGANDS  
 
Introduction 
 
Cisplatin (cis-Pt(NH3)2Cl2) is the most successful example of a metal-based drug 
in the history of cancer therapeutics.19 The compound was approved by the Food and 
Drug Administration (FDA) in 1978 to treat metastatic testicular and ovarian cancers, 
with high curing rates (80–90%) being standard for cisplatin-treated testicular cancer.23 
The early success of cisplatin notwithstanding, the severe side effects and cancer cell 
resistance observed during the treatment of cancer patients with this drug led to intense 
exploration of the antitumor properties of other platinum (Pt) compounds19,55 and 
complexes with different transition metal ions.15,16,85,132 The search for metal anticancer 
drugs with (i) greater antiproliferative activity, (ii) lower side effects experienced by 
patients and (iii) different mechanism of action to overcome cell resistance, continues to 
be an active and important research area within the field of medicinal chemistry for 
providing safe and effective drugs for the treatment and cure of cancers, the second 
cause of death in the United States. 
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Figure 2. 1 Location of the platinum group metals in the Periodic Table. Ru = 
ruthenium, Os = osmium, Rh = rhodium, Ir = iridium, Pd = palladium, Pt = platinum. 
 
 
 
As has been discussed in Chapter I, ruthenium (Ru) pharmaceuticals are the 
second most explored metal compounds in cancer therapeutics among the platinum 
group elements (Figure 2.1).70,83,133 Although there is great interest in developing Ru 
complexes as an alternative to Pt drugs in cancer chemotherapy, it is surprising that most 
of the reports on the biological activity of octahedral Ru(II) polypyridyl molecules have 
focused mainly on substitutionally inert complexes that possess an “all nitrogen” 
coordination environment115,119,127 ([RuIIN6]2+, Figure 2.2a), with no attention paid to 
donor atoms such as oxygen (O), sulfur (S) and phosphorus (P). The rich photophysical 
properties of octahedral [RuIIN6]2+ polypyridyl compounds may be one of the reasons for 
this tendency, since their intrinsic relatively intense phosphorescence facilitates 
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tremendously the study of the cellular distribution, subcellular localization and cellular 
uptake using confocal fluorescence microscopy, as described in Chapter I.119,134 
There is one main study on the cytotoxicity of Ru complexes on a [RuIIN5O]+ 
coordination environment (Figure 2.2b). In this report, Meggers and coworkers used a 
combinatorial, high throughput screening approach that led to the discovery of the first 
examples of cytotoxic octahedral Ru(II) polypyridyl compounds with N^O– bidentate 
ligands (Figure 2.2c).135 
 
 
 
 
 
Figure 2. 2 (a) Schematic representation Ru polypyridyl complexes on (a) [RuIIN6]2+ 
and (b) [RuIIN5O]+ coordination environments. (c) Molecular structures of phox and quo 
ligands. 
 
 
 
The most active drugs in this series of compounds, Ruphox3 and Ruquo 
(Figures 2.3a and 2.3b, respectively), exhibit low micromolar IC50 values (which is the 
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concentration of compound required to inhibit 50% of cell survival) in HeLa cervical 
cancer cells and Ruphox3 was found to decrease the mitochondrial membrane potential 
of Burkitt-like lymphoma (BJAB) cells, suggesting the involvement of the intrinsic 
pathway of apoptosis.135 Interestingly a decrease in the lipophilicity of the Ruphox-type 
compounds (Ruphox3 > Ruphox2 > Ruphox1, Figure 2.3a) is correlated with a 
decrease in the cytotoxicity of these compounds, stressing the importance of including 
hydrophobic moieties to improve the cellular uptake and activity of metal compounds. 
The lipophilicity of these compounds is due to the incorporation of tert-butyl groups on 
the 4,4’-positions of the bipyridine ligands (highlighted in blue color for Ruquo in 
Figure 2.3b). The authors also investigated the cytotoxicity of the 2+ charged analogs, 
Rubpy and RutBu2bpy (Figure 2.3c), and found that they were less active than the 
monocationic compounds. For example, RutBu2bpy is ~15 times less cytotoxic than 
Ruphox3.135 It is worth noting that the increase in positive charge from Ruphox3 (or 
Ruquo) to Rubpy decreases the activity of these structurally related molecules, hinting 
that a decrease in lipophilicity (or increase in hydrophilic character) leads to a reduced 
ability to traverse the cellular membrane for Rubpy.135 Confocal fluorescence studies 
using the compounds with N^O– bidentate ligands were not possible to be performed 
because Ru complexes with a [RuIIN5O]+ coordination environment are either non-
emissive or display very weak phosphorescence at room temperature.136,137 
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Figure 2. 3 Molecular structures of (a,b) monocationic Ru compounds incorporating 
N^O–-ligands and (c) dicationic Ru polypyridyl compounds related to those shown in 
(a,b). IC50 values (µM) are shown in parenthesis. 
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A platinum group element that has gained momentum in cancer drug research in 
the past five years is iridium (Ir), a third-row (5d) transition metal element. The current 
state-of-the-art of Ir compounds as anticancer agents has been recently reviewed by 
Peter J. Sadler, a main contributor to this field,138 and quite a few compounds have been 
shown to exhibit promising antitumor activity. Some examples and structure-activity 
relationship studies are highlighted in the passages below.  
 Three piano-stool Ir(III) compounds (Figure 2.4a) of the type [Cp*Ir(N^N)Cl]+ 
(Cp* = pentamethylcyclopentadienyl, N^N = 1,10-phenanthroline (phen)) are shown in 
Figure 2.4b. It was found that their cytotoxicity against human ovarian carcinoma 
(A2780) cells increases by addition of phenyl substituents on the Cp* ring (highlighted 
in green color in Figure 2.4b).139 The trend in the anticancer activity of these compounds 
correlates with an increase of their lipophilicity (quantified by the log(P) value; P = 
partition coefficient in n-octanol/water) and cellular uptake, indicating that the 
hydrophobicity of the Cp* ring facilitates the passage of these compounds through the 
cellular membrane. The most active compound, Irphenbiph, is two-fold more cytotoxic 
than cisplatin in A2780 cells. In addition, it was found that the three complexes undergo 
hydrolysis of the Ir–Cl bond forming Ir–OH2 species (Figure 2.4c) that can bind 
covalently to DNA bases (guanine). These compounds are also able to modify DNA by 
intercalation of their Cp*-arene moieties. In fact, this series of drugs were found to 
access the nucleus of A2780 cells, suggesting that DNA binding is one of their 
mechanisms of action.139 
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Figure 2. 4 (a) Schematic representation of Ir(III) cyclopentadienyl complexes. (b) 
Monocationic Cp*Ir(III) compounds. IC50 values (µM) are shown in parenthesis. (c) 
Dual DNA binding mode of Irphenbiph.  
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A closely related series of compounds is illustrated in Figure 2.5a. First, 
substitution of a N atom donor by isoelectronic C– (indicated in purple color in Figure 
2.5a) decreases the overall charge of the compound, thereby increasing the 
hydrophobicity, cellular uptake and cytotoxicity against A2780 cells (compare Irbpy vs 
Irphpy).140 Increasing the hydrophobicity of the Cp* moiety in Irphpybiph (highlighted 
in green in Figure 2.5a) further improves the cellular uptake and anticancer activity (2-
fold more cytotoxic than cisplatin).139,140,141  
Increasing the hydrophobicity of the ancillary bidentate ligands is also a strategy 
that has been used to design anticancer active Ir(III) compounds in an octahedral 
geometry.142,143 For example, the cytotoxicity of compounds of the type 
[Ir(phpy)2(N^N)]+ increases when expanding the π-system of the chelating polypyridyl 
N^N ligand (Figure 2.5b).142 The compound [Ir(phpy)2(DIP)]+ exhibits the highest 
cellular uptake and was the most active of the series. This monocationic compound is 6-
fold, 20-fold and 10-fold more cytotoxic than cisplatin against cervical (HeLa), lung 
(A549) and breast (MCF-7) cancer cells, respectively.142 [Ir(phpy)2(DIP)]+ was shown 
to localize in the endoplasmic reticulum (ER), induce ER stress and release of ER stored 
Ca2+ into the cytoplasm. The authors found that rapid accumulation of Ca2+ in the matrix 
of mitochondria led to swelling and fragmentation of these organelles. Moreover, 
increase of cytoplasmic cytochrome c levels and induction of the activity of caspase 3, 
along with chromatin condensation and blebbing of the plasma membrane, was observed 
when HeLa cells were treated with [Ir(phpy)2(DIP)]+. These series of events clearly 
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demonstrate that the intrinsic pathway of apoptosis was the mechanism of cancer cell 
death.142  
 
 
 
 
 
Figure 2. 5 (a) Cyclometallated piano-stool Ir cytotoxic compounds. IC50 values (µM) 
are shown in parenthesis. (b) Octahedral Ir(III) molecules wit anticancer activity.  
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To further explore the cytotoxic properties of Ru polypyridyl complexes in an 
[RuIIN5O]+ pseudo-octahedral coordination environment and taking into account the 
direct relation between hydrophobicity, cellular uptake and  cytotoxic activity, the 
synthesis of Ru(II) monocationic compounds with N^O–-donor ligands possessing π-
extended systems was pursued. It was hypothesized that introducing lipophilic N^O– 
bidentate ligands will provide a new family of cytotoxic Ru complexes. Four new Ru 
complexes (Figure 2.6a), [Ru(bpy)2(dphol)][PF6] (1; bpy = 2,2’-bipyridine, dphol = 
dibenzo[a,c]phenazin-10-olate), [Ru(phen)2(dphol)][PF6] (2; phen = 1,10-
phenanthroline), [Ru(bpy)2(hbtz)][PF6] (3; hbtz = 2-(benzo[d]thiazol-2-yl)phenolate) and 
[Ru(phen)2(hbtz)][PF6]  (4) and the known compound [Ru(bpy)2(quo)][PF6] (5; quo = 
quinolin-8-olate), were synthesized and characterized and their cytotoxicity against 
human lung adenocarcinoma (A549) cells was tested. The mechanism of cancer cell 
death was also investigated using two different biological assays. Additionally, due to 
the current interest on the antitumor properties of Ir compounds, preliminary results on 
the anticancer properties of an octahedral Ir(III) complex with the hbtz ligand,  
Ir(phpy)2(hbtz) (6; Figure 2.6b) will be discussed.  
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Figure 2. 6 Molecular structures of (a) Ru(II) and (b) Ir(III) compounds containing 
N^O–-bidentate ligands in this study. 
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Experimental Section 
 
General Methods 
 
Standard Schlenk-line techniques (N2 atmosphere) were used to maintain 
anaerobic conditions during the preparation of the compounds. The solvents used were 
of reagent grade quality. Ethanol (KORTEP, 200 proof), acetone (EMD Chemicals), 
dichloromethane (EMD Chemicals), diethyl ether (EMD Chemicals) and glacial acetic 
acid (EMD Chemicals) were used as received without further purification. RuCl3•xH2O 
(Pressure Chemicals Co.), IrCl3•xH2O (Pressure Chemicals Co.), 2,2′-bipyridine (bpy, 
Alfa Aesar), 1,10-phenanthroline (phen, Alfa Aesar), 8-hydroxyquinoline (quoH, Acros 
Organics), 2-(2-hydroxyphenyl)benzothiazole (hbtzH, Sigma Aldrich), 2,3-
diaminophenol (Sigma Aldrich), 9,10-phenanthrenequinone (Sigma Aldrich), NH4PF6 
(Sigma Aldrich), NaHCO3 (Mallinckrodt) and K2CO3 (Spectrum) were purchased and 
used as received. The compounds cis-RuCl2(N^N)2•2H2O (N^N  = bpy, phen),144 
[Ir(pphpyhpy)2Cl]2145,146 and Ir(phpy)2(hbtz) (6)147 were prepared following reported 
procedures.  
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Instrumentation 
 
The 1H NMR spectra were recorded on an Inova 500 MHz spectrometer. 
Chemical shifts are reported in δ (ppm) and coupling constants (J) in hertz (Hz). The 
residual solvent peak was used as an internal reference (δ 1.94 for CD3CN, 2.05 for 
(CD3)2CO2). Electrospray ionization (ESI) mass spectra were acquired on an Applied 
Biosystems PE SCIEX QSTAR mass spectrometer (MDS Sciex). Elemental analyses 
were performed by Atlantic Microlab, Inc. (Norcross, GA). Absorption spectra were 
recorded on a Shimadzu UVPC-3001 spectrophotometer. Electrochemical measurements 
were performed under anaerobic conditions (N2 atmosphere) with a HCH 
Electrochemical Analyzer model CH 1620A using a BAS Pt disk working electrode, Pt 
wire auxiliary electrode, Ag/AgCl (3M KCl(aq)) reference electrode and 0.1 M tetra-n-
butylammonium hexafluorophosphate ([nBu4N][PF6]) in dry acetonitrile as a supporting 
electrolyte and 0.1 V/s scan rate. The concentration of the Ru complexes for the 
electrochemical experiments was ~1 mM. Ferrocene was used as an internal standard 
and exhibited a E1/2 = 0.44 V vs Ag/AgCl for the Fc+/Fc couple under the same 
experimental conditions. The E1/2 of the Ru complexes were referenced vs NHE using 
the following expression: E1/2 vs NHE = [(E1/2 vs Ag/AgCl of Ru complex) + (0.64 – 
0.44)] V, where 0.64 V = E1/2 [Fc+/Fc] vs NHE and 0.44 V = E1/2 [Fc+/Fc] vs Ag/AgCl.  
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Synthetic Details 
 
Dibenzo[a,c]phenazin-10-ol (dpholH). A mixture of 2,3-diaminophenol (210 mg, 1.69 
mmol) and 9,10-phenanthrenequinone (336 mg, 1.61 mmol) in 20 mL of ethanol/acetic 
acid (1:1) was heated to reflux for 2 h. The yellow precipitate was collected by filtration, 
dissolved in hot dichloromethane (100 mL) and filtered through a short plug of SiO2. A 
yellow band was eluted with dichloromethane and the combined fractions were reduced 
to ca. 25 mL. After keeping the yellow solution in an ice bath for 30 min, the light 
yellow precipitated was collected and washed with cold dichloromethane. Yield: 208 mg 
(44%). 1H NMR (500 MHz, CDCl3): δ 9.39 (dd, 1H, 3J = 8.0, 4J = 1.5), 9.29 (dd, 1H, 3J 
= 8.0, 4J = 1.0), 8.57 (m, 2H), 8.15 (s, 1H), 7.87 (dd, 1H, 3J = 8.5, 4J = 1.0), 7.84-7.72 
(m, 5H), 7.31 (dd, 1H, 3J = 7.5, 4J = 1.5). HRMS (ESI+): Calcd. for [C20H13N2O]+ ([M + 
H]+), 297.1028. Found: 297.1026.  
 
[Ru(bpy)2(dphol)][PF6] (1). cis-RuCl2(bpy)2•2H2O (150 mg, 0.29 mmol), dpholH (95 
mg, 0.32 mmol) and NaHCO3 (74 mg, 0.88 mmol) were suspended in ethanol (70 mL) 
and were heated to reflux for 8 h. The resulting dark red solution was cooled to room 
temperature and filtered. NH4PF6(aq) (5 eq dissolved in 2 mL of water) was added to the 
filtrate and a dark red solid precipitated. The solid was dissolved in dichloromethane (50 
mL) and washed with water (3 x 30 mL). The organic layer was dried with MgSO4 and 
reduced to dryness. The residue was dissolved in acetone (10 mL), diethyl ether was 
added slowly until solid started precipitating and the mixture was kept at 0°C overnight. 
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A dark red microcrystalline solid was collected by filtration and was washed with diethyl 
ether (25 mL). Yield: 195 mg (79%). 1H NMR (500 MHz, (CD3)2CO): δ 9.01 (m, 2H), 
8.94 (d, 1H, 3J = 5.0), 8.86 (d, 1H, 3J = 8.5), 8.75 (d, 1H, 3J = 8.5), 8.51 (d, 1H, 3J = 5.5), 
8.47 (d, 1H, 3J = 8.0), 8.33 (m, 3H), 8.25 (ddd, 1H, 3J = 8.0, 3J = 8.0, 4J = 1.5), 8.16 (d, 
1H, 3J = 8.0), 8.03 (ddd, 1H, 3J = 8.0, 3J = 8.0, 4J = 1.5), 7.87 (ddd, 1H, 3J = 8.0, 3J = 
8.0, 4J = 1.5), 7.77 (ddd, 1H, 3J = 8.5, 3J = 7.0, 4J = 1.5), 7.70 (ddd, 1H, 3J = 8.0, 3J = 
7.0, 4J = 1.0), 7.66 (m, 2H), 7.61 (ddd, 1H, 3J = 7.5, 3J = 5.5, 4J = 1.5), 7.59 (d, 1H, 3J = 
5.5), 7.41-7.35 (m, 2H), 7.29 (ddd, 1H, 3J = 7.5, 3J = 5.5, 4J = 1.5), 7.24 (dd, 1H, 3J = 
8.0, 4J = 1.0), 7.18 (ddd, 1H, 3J = 7.5, 3J = 5.5, 4J = 1.5), 7.13 (ddd, 1H, 3J = 8.5, 3J = 
7.5, 4J = 1.0), 6.94 (dd, 1H, 3J = 8.0, 4J = 1.5). HRMS (ESI+): Calcd. for 
[C40H27N6ORu]+ ([M - PF6]+), 709.1290. Found: 709.1287. Anal. Calcd. for 
C40H27N6OF6PRu·1.05(CH3)2CO: C, 56.66; H, 3.67; N, 9.19. Found: C, 56.84; H, 3.82; 
N, 9.36. 
 
[Ru(phen)2(dphol)][PF6] (2). The compound was prepared in a similar fashion to that 
described for 1 using cis-RuCl2(phen)2•2H2O (151 mg, 0.27 mmol), dpholH (87 mg, 
0.19 mmol), NaHCO3 (69 mg, 0.82 mmol) and ethanol (70 mL) as solvent. A dark red 
microcrystalline solid was obtained. Yield: 185 mg (77%). 1H NMR (500 MHz, 
(CD3)2CO): δ 9.18 (dd, 1H, 3J = 5.5, 4J = 1.0), 9.05 (dd, 1H, 3J = 8.0, 4J = 1.0), 8.75 (m, 
2H), 8.70 (dd, 1H, 3J = 8.0, 4J = 1.0), 8.66 (d, 1H, 3J = 8.0),  8.49 (dd, 1H, 3J = 8.0, 4J = 
1.0), 8.41 (dd, 1H, 3J = 5.5, 4J = 1.0), 8.36 (d, 2H, 3J = 8.0), 8.28-8.19 (m, 3H), 8.18 (d, 
1H, 3J = 8.0), 8.11 (d, 1H, 3J = 9.0), 8.01 (dd, 1H, 3J = 8.0, 3J = 5.5), 7.88 (dd, 1H, 3J = 
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8.0, 3J = 5.5), 7.75-7.66 (m, 2H), 7.63 (t, 1H, 3J = 8.0), 7.56 (dd, 1H, 3J = 5.5, 4J = 1.0), 
7.46 (dd, 1H, 3J = 8.0, 3J = 8.0), 7.29-7.22 (m, 2H), 7.21 (ddd, 1H, 3J = 8.0, 3J = 7.0, 4J = 
1.0), 6.87 (dd, 1H, 3J = 8.0, 4J = 1.0), 6.44 (t, 1H, 3J = 7.5). HRMS (ESI+): Calcd. for 
[C44H27N6ORu]+ ([M - PF6]+), 757.1290. Found: 757.1284. Anal. Calcd. for 
C44H27N6OF6PRu: C, 58.61; H, 3.02; N, 9.32. Found: C, 58.60; H, 3.06; N, 9.30.  
 
[Ru(bpy)2(hbtz)][PF6] (3). The compound was prepared in a similar fashion to that 
described for 1 using RuCl2(bpy)2•2H2O (158 mg, 0.30 mmol), hbtzH (77 mg, 0.34 
mmol), K2CO3 (88 mg, 0.64 mmol) and ethanol/water 1:1 (30 mL) as solvent. A dark red 
microcrystalline solid was obtained. Yield: 175 mg (73%). 1H NMR (500 MHz, 
CD3CN): δ 8.94 (d, 1H, 3J = 5.5), 8.61 (d, 1H, 3J = 5.5), 8.43 (d, 1H, 3J = 8.0), 8.40 (d, 
1H, 3J = 8.0), 8.34 (m, 2H), 8.06 (d, 1H, 3J = 5.5), 8.01-7.94 (m, 2H), 7.85 (ddd, 1H, 3J = 
8.0, 3J = 7.5, 4J = 1.5), 7.82 (d, 1H, 3J = 8.0), 7.76 (ddd, 1H, 3J = 8.0, 3J = 7.5, 4J = 1.5), 
7.57 (dd, 1H, 3J = 8.0, 4J = 1.5), 7.47 (ddd, 1H, 3J = 7.5, 3J = 5.5, 4J = 1.5), 7.40 (d, 1H, 
3J = 5.5), 7.34 (ddd, 1H, 3J = 7.5, 3J = 5.5, 4J = 1.5), 7.20-7.11 (m, 3H), 7.02 (ddd, 1H, 3J 
= 8.5, 3J = 7.0, 4J = 1.5), 6.90 (ddd, 1H, 3J = 8.5, 3J = 7.0, 4J = 1.5), 6.45 (ddd, 1H, 3J = 
8.5, 3J = 7.0, 4J = 1.5), 6.40 (d, 1H, 3J = 8.5), 6.37 (dd, 1H, 3J = 8.5, 4J = 1.0). HRMS 
(ESI+): Calcd. for [C33H24N5OSRu]+ ([M - PF6]+), 640.0748. Found: 640.0752. Anal. 
Calcd. for C33H24N5OF6PSRu·0.95(CH3)2CO: C, 51.27; H, 3.56; N, 8.34. Found: C, 
51.36; H, 3.55; N, 8.42. 
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[Ru(phen)2(hbtz)][PF6] (4). The compound was prepared in a similar fashion to that 
described for 1 using RuCl2(phen)2•2H2O (177 mg, 0.31 mmol), hbtzH (81 mg, 0.36 
mmol), K2CO3 (86 mg, 0.62 mmol) and ethanol/water 1:1 (30 mL) as solvent. A dark 
red-green microcrystalline solid was obtained. Yield: 156 mg (60%). 1H NMR (500 
MHz, CD3CN): δ 9.27 (dd, 1H, 3J = 5.0, 4J = 1.0), 9.03 (dd, 1H, 3J = 5.0, 4J = 1.0), 8.56 
(m, 2H), 8.32 (dd, 1H, 3J = 8.0, 4J = 1.0), 8.25-8.18 (m, 3H), 8.15 (d, 1H, 3J = 9.0), 8.11 
(d, 1H, 3J = 9.0), 8.06 (d, 1H, 3J = 8.5), 7.88 (dd, 1H, 3J = 8.5, 3J = 5.0), 7.78-7.73 (m, 
2H), 7.62 (dd, 1H, 3J = 8.0, 4J = 1.5), 7.46 (dd, 1H, 3J = 5.5, 3J = 1.5), 7.34-7.28 (m, 2H), 
7.08 (ddd, 1H, 3J = 8.0, 3J = 7.0, 4J = 1.0), 7.00 (ddd, 1H, 3J = 8.5, 3J = 7.0, 4J = 1.5), 
6.72 (ddd, 1H, 3J = 8.5, 3J = 7.5, 4J = 1.5), 6.50-6.42 (m, 2H), 6.28 (dd, 1H, 3J = 8.5, 4J = 
1.0). HRMS (ESI+): Calcd. for [C37H24N5OSRu]+ ([M - PF6]+), 688.0745. Found: 
688.0714. Calcd. for C37H24N5OF6PSRu·(CH3)2CO: C, 53.30; H, 3.44; N, 7.97. Found: 
C, 53.51; H, 3.58; N, 7.89. 
 
[Ru(bpy)2(quo)][PF6] (5). The compound was prepared in a similar fashion to that 
described for 1 using cis-RuCl2(bpy)2•2H2O (121 mg, 0.23 mmol), quoH (41 mg, 0.28 
mmol), K2CO3 (65 mg, 0.47 mmol) in ethanol/water (1:1, 30 mL). A dark green-red 
microcrystalline solid was collected by filtration and was washed with diethyl ether (25 
mL). Yield: 138 mg (85%). 1H NMR (500 MHz, (CD3)2CO): δ 8.89 (d, 1H, 3J = 5.5), 
8.74-8.65 (m, 4H), 8.17 (d, 1H, 3J = 6.0), 8.13-8.04 (m, 4H), 8.00 (m, 2H), 7.89 (d, 1H, 
3J = 5.0), 7.65 (ddd, 1H, 3J = 7.5, 3J = 6.0, 4J = 1.5), 7.55 (dd, 1H, 3J = 5.0, 4J = 1.0), 
7.46 (m, 1H), 7.40 (m, 2H), 7.32 (t, 1H, 3J = 8.0), 7.20 (dd, 1H, 3J = 8.5, 3J = 5.0), 6.87 
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(dd, 1H, 3J = 8.0, 4J = 1.0), 6.79 (dd, 1H, 3J = 8.0, 4J = 1.0). HRMS (ESI+): Calcd. for 
[C29H22N5ORu]+ ([M - PF6]+), 558.0868. Found: 558.0866. Calcd. for 
C29H22N5OF6PRu·0.5(CH3CH2)2O: C, 50.34; H, 3.68; N, 9.47. Found: C, 50.29; H, 3.79; 
N, 9.23. 
 
X-Ray Crystallography 
 
Single crystals of compounds 1, 3 and 4 were obtained by slow diffusion of 
diethyl ether into acetone solutions of the compounds at room temperature. Single 
crystals of compound 6 were grown from slow evaporation of an ethyl acetate solution 
of the compound at room temperature. X-ray data were collected at 110 K on a Bruker 
APEX II CCD X-ray diffractometer equipped with a graphite monochromated MoKα 
radiation source (λ = 0.71073 Å). The data sets were integrated with the Bruker SAINT 
software package.148 The absorption correction (SADABS)149 was based on fitting a 
function to the empirical transmission surface as sampled by multiple equivalent 
measurements. Solution and refinement of the crystal structures was carried out using 
the SHELX150 (2013) suite of programs and the graphical interface ShelXle151 was used 
during the refinement. The structures were solved by Patterson methods, all non-
hydrogen atoms were refined with anisotropic displacement parameters using a full-
matrix least-squares technique on F2. Hydrogen atoms were fixed to parent atoms and 
refined using the riding model. PLATON/SQUEEZE was employed in the case of 4 after 
attempts to model a disordered diethyl ether solvent molecule failed. The solvent 
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molecules in the unit cell (one solvent molecule per asymmetric unit, Z = 4) were 
determined to occupy 642.9 Å3. The number of electron counts in voids per unit cell was 
159, which is close to that expected for four diethyl ether molecules (168 electrons). 
 
Cell Culture Experiments 
 
The human lung adenocarcinoma A549 cell line, derived from type II 
pneumocytes (CCL 185), was obtained from American Type Culture Collection 
(Manassas, VA). Cells were cultured in DMEM-F12 medium (Dulbecco's Modified 
Eagle Medium: Nutrient Mixture F-12) with 10% FBS. Cell cultures were incubated in a 
humidified atmosphere containing 5% CO2 at 37°C and were approximately 80% 
confluent at the time of analysis. 
 
In vitro Cytotoxicity  
 
A549 cells were plated in a 96 well plate and were pre-incubated in a humidified 
atmosphere containing 5% CO2 at 37°C for 24 h. Solutions of the metal complexes in 
DMEM/F12 medium were added at different concentration (final concentrations of 
compounds: 0–50 µM range, 0.1 % DMSO) and the cells were incubated for another 48 
h. Cells were then washed twice with PBS and fixed with methanol for 30 min. 
Following fixation, Janus green B (1 mg/mL, Alfa Aesar) was added to each well and 
incubated at room temperature for 5 min. Cells were again washed twice with PBS and 
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100 μL of methanol was added to each well to extract the dye. Janus Green B signal was 
then measured using a BioTek Synergy 4 plate reader set to an absorbance of 630 nm. 
 
JC-1 Assay 
 
Live cell imaging studies were performed using a Zeiss 510 META NLO 
multiphoton system consisting of an Axiovert 200 MOT inverted laser scanning confocal 
microscope (Carl Zeiss Microimaging, Thornwood, NY). A Zeiss Plan-Neofluar 
40x/NA=1.3 oil immersion objective was used to acquire the images. 
Cells were plated in coverglass chamber slides for 24 h prior to treatment with 
compounds 1–4 and cisplatin for 48 h. Cells were then washed with PBS and labeled 
with JC-1 at a final concentration of 5 µg/mL for 30 min at 37°C. Excitation of JC-1 
(Invitrogen) was performed using an Ar–ion laser at 488 nm and emission data were 
collected using a dichroic 545 nm SP in combination with 2 filters 500–550  BP and 
565–615 BP. At least eight areas per well were scanned. Two wells were analyzed per 
treatment. Two experiments were conducted on different days. 
 
Calcein AM Assay 
 
Cells were plated in coverglass chamber slides for 24 h prior to treatment with 
compound 4 and cisplatin for 48 h. Cells were then washed with PBS and incubated with 
1 µg/ml Hoeschst 33258 (Invitrogen) and 10 µM acetoxymethyl ester of Calcein dye 
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(calcein AM, Invitrogen) for 30min, and with 50 nM Mitotracker Deep Red FM 
(Invitrogen) for 15 min. Following loading, cells were washed and 1 mM cobalt (II) 
chloride hexahydrate was added to the cells and images were acquired. To collect 
Hoechst 33258 (Invitrogen) fluorescence, cells were irradiated with the Chameleon 
tunable Ti:Sapphire laser (Coherent Inc., Santa Clara, CA) at an excitation wavelength 
of 740 nm (which is roughly equivalent to 370 nm in single photon excitation with a 
continuous wavelength laser system) and emission was collected at 430–480 nm. 
Calcein was excited with an Ar–ion laser at 458 nm and emission was monitored using a 
band pass 500–530 filter. Mitotracker Deep Red FM (Invitrogen) was excited with a He–
Ne laser at 633 nm and emission was collected using a BP 650–710 filter. Image 
acquisition was performed sequentially to reduce the possibility of bleedthrough 
between channels. At least eight areas per well were scanned. Two wells were analyzed 
per treatment. Two experiments were conducted on different days. 
 
Caspase Glo Assay 
 
Cells were cultured for 24 h prior to addition of compound 4 or cisplatin for 48 h. 
Cells were then washed twice with PBS and 100 µL of the Caspase-Glo® 3/7 reagent 
solution (Promega) was added to each well. Wells were then scanned every 10 min for 
30 min and luminescence readings were recorded with Biotek Synergy plate reader. Four 
wells per concentration were recorded.  
 
 67 
 
Results and Discussion 
 
Synthesis and Characterization 
 
The precursor for the syntheses of 1–5 is cis-RuCl2(N^N)2 (N^N = bpy, phen) 
that was prepared by reacting RuCl3 with 2 eq of N^N in refluxing DMF and in the 
presence of LiCl (Figure 2.7).144 The crude products [Ru(N^N)2(N^O–)][PF6] were 
obtained by reacting cis-RuCl2(N^N)2 with 1.1 eq of N^OH (dpholH, hbtzH and quoH) 
in refluxing ethanol (or aqueous ethanol) and in the presence of a base (NaHCO3 or 
K2CO3) to deprotonate the phenol moiety of N^OH, followed by precipitation with 
NH4PF6(aq). The five complexes were obtained as dark red microcrystalline solids after 
recrystallization from acetone/diethyl ether. Although hbtzH is a commercially available, 
there are no reports of Ru complexes with this ligand. Due to the C1 symmetry of 1–5, 
there are no magnetic equivalent protons in their 1H NMR spectra (Figures 2.8 and 2.9); 
the integration of the signals match the expected number of protons for each complex (1, 
27 H; 2, 27 H; 3, 24 H; 4, 24 H; 5, 22H). The identity and purity of the compounds were 
confirmed by elemental analyses and ESI-MS, where a single peak corresponding to the 
[M - PF6]+ cations was observed for all of the complexes (1, m/z = 709.1287; 2, m/z = 
757.1284; 3, 640.0752; 4, m/z = 688.0714; 5, 558.0866).  
The Ir compound Ir(phpy)2(hbtz) (6), which can be considered an analog of 
[Ru(bpy)2(hbtz)]+ (3) and [Ru(phen)2(hbtz)]+ (4), was obtained as a yellow solid by 
reacting the µ-chloro Ir(III) dimer [Ir(phpy)Cl]2 with 2 eq of hbtzH in the presence of a 
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base ([nBu4N][OH] or [Me4N][OH]) in dichloromethane, as reported in the 
literature.147,152 Compound 6 also possesses C1 symmetry and 24 H resonances were 
observed in its 1H NMR spectrum (Figure 2.9c). 147,152  
 
 
 
 
 
Figure 2. 7 Reaction scheme for the syntheses of 1–5. 
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Figure 2. 8 1H NMR spectra ((CD3)2CO, 500 MHz) of compounds (a) 1, (b) 2 and (c) 5. 
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Figure 2. 9 1H NMR spectra (500 MHz) of compounds (a) 3 (CD3CN), (b) 4 (CD3CN) 
and (c) 6 (CDCl3).  
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X-ray Structures of Compounds 1, 3, 4 and 6 
 
Single crystals of 1, 3 and 4 were obtained by slow diffusion of diethyl ether into 
acetone solutions of the compounds at room temperature. Their X-ray structures are 
shown in Figures 2.10 and 2.11 and the crystallographic data are compiled in Tables 
2.1–2.6. Compounds 1 and 3 crystallize in the triclinic space group P–1, whereas 4 
crystallizes in the monoclinic space group P2/n. There is an interstitial acetone molecule 
in the asymmetric unit of 1 and 3.  
The coordination sphere of the metal center in the structures of the three 
ruthenium molecules consists of five N atoms and one O atom in a distorted octahedral 
environment. The Ru–O bond distances are ~2.060 Å in the three compounds and are 
similar to that reported for [Ru(bpy)2(quo)][PF6] (5; 2.063(6) Å).153 Their Ru–N bond 
distances to bpy and phen fall in the 2.019–2.079 Å range and are also in agreement with 
the respective distances in [Ru(bpy)2(quo)][PF6] and Ru(II) polypyridyl compounds in a 
[RuN6] coordination environment. In contrast, the Ru–N bond distances to dphol in 1 
(Ru–N1, 2.152(3) Å) and to hbtz in 3 (Ru–N5, 2.110(2) Å) and 4 (Ru–N5, 2.110(3) Å) 
are longer. The elongation of such Ru–N bonds is likely to be caused by steric repulsions 
between the bulky phenanthrene moiety of dphol and adjacent bpy ligand in the case of 
1, and between the benzothiazolyl moiety of hbtz and adjacent bpy and phen ligands in 
the case of 3 and 4, respectively. The dphol ligand in 1 is twisted as depicted in Figure 
2.10, displaying dihedral angles of –30.7(5) for Ru1–N1–C19–C18 and –19.3(6) for N1–
C19–C18–C17. The hbtz ligands in 3 and 4 are twisted around the C–C bond that 
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connects the phenoxido and benzothiazolyl moieties, exhibiting dihedral angles of 
8.5(3)° (N5–C27–C26–C21) and –16.3(5)° ( N5–C31–C30–C25), respectively  
 
 
 
 
 
Figure 2. 10 (Top) Thermal ellipsoid plots at the 50% probability level of the X-ray 
structure of [Ru(bpy)2(dphol)][PF6] (1). The [PF6]– anion and H atoms have been 
omitted for the sake of clarity. (Bottom) Distortion of the dphol ligand in compound 1. 
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Figure 2. 11 Thermal ellipsoid plots at the 50% probability level of the X-ray structures 
of [Ru(bpy)2(hbtz)][PF6] (3), [Ru(phen)2(hbtz)][PF6] (4) and Ir(phpy)2(hbtz) (6). The 
[PF6]– anion (in the case of 3 and 4) and H atoms have been omitted for the sake of 
clarity. 
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Table 2. 1 Crystal Structural Data and Refinement Parameters for the compounds 
[Ru(bpy)2(dphol)][PF6]·(CH3)2CO (1) and [Ru(bpy)2(hbtz)][PF6]·(CH3)2CO  (3). 
 
Compound 1 3 
CCDC number 997833 997834 
Empirical Formula C43H33F6N6O2PRu C36H30F6N5O2PRuS 
Formula weight 911.79 842.75 
Temperature, K 110(2) 110(2) 
Crystal system Triclinic Triclinic 
Space group P–1 P–1 
Unit cell dimensions a = 9.894(2), α = 107.82(3) 
b = 11.556(2), β = 91.60(3) 
c = 17.230(3), γ = 96.54(3) 
a = 9.3106(19), α = 66.68(3) 
b = 13.975(3), β = 78.29(3) 
c = 14.581(3), γ = 88.96(3) 
Volume, Å3 1859.2(6) 1701.8(7) 
Z 2 2 
Density, g/cm3 1.629 1.645 
Absorption coefficient, mm-1 0.544 0.645 
F(000) 924 852 
Crystal color, morphology purple, block purple, block 
Crystal size, mm3 0.28 × 0.18 × 0.10 0.29 × 0.26 × 0.21 
Reflections collected 15696 18194 
Independent reflections 5493 [Rint = 0.0349] 7156 [Rint = 0.0178] 
Data/restraints/parameters 5493 / 0 / 534 7156 / 0 / 471 
Goodness-of-fit on F2 1.055 1.180 
R indices [I>2sigma(I)] R1 = 0.0377 
wR2 = 0.0979 
R1 = 0.0247 
wR2 = 0.0696 
R indices (all data) R1 = 0.0450 
wR2 = 0.1025 
R1 = 0.0278 
wR2 = 0.0805 
Largest diff. peak, hole, e/Å3 0.911 / –0.441 0.803 / –0.704 
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Table 2. 2 Crystal Structural Data and Refinement Parameters for the compounds 
[Ru(phen)2(hbtz)][PF6] (4) and Ir(phpy)2(hbtz) (6). 
 
Compound 4 6 
CCDC number 997835 997836 
Empirical Formula C37H24F6N5OPRuS C35H24IrN3OS 
Formula weight 832.71 726.83 
Temperature, K 110(2) 110(2) 
Crystal system Monoclinic Triclinic 
Space group P2/n P–1 
Unit cell dimensions a = 14.373(3), α = 90 
b = 12.824(3), β = 92.73(3) 
c = 20.057(4), γ = 90 
a = 10.912(2), α = 75.61(3) 
b = 11.655(2), β = 68.71(3) 
c = 12.099(2), γ = 71.55(3) 
Volume, Å3 3692.6(13) 1344.4(6) 
Z 4 2 
Density, g/cm3 1.498 1.795 
Absorption coefficient, mm-1 0.592 5.079 
F(000) 1672 712 
Crystal color, morphology purple, block orange, plate 
Crystal size, mm3 0.24 × 0.17 × 0.11 0.12 × 0.09 × 0.04 
Reflections collected 38831 15489 
Independent reflections 7583 [Rint = 0.0483] 5871 [Rint = 0.0296] 
Data/restraints/parameters 7583 / 0 / 470 5871 / 0 / 370 
Goodness-of-fit on F2 1.049 1.049 
R indices [I>2sigma(I)] R1 = 0.0419 
wR2 = 0.0942 
R1 = 0.0206 
wR2 = 0.0453 
R indices (all data) R1 = 0.0528 
wR2 = 0.0991 
R1 = 0.0232 
wR2 = 0.0464 
Largest diff. peak/hole, e/Å3 2.640 / –0.847 1.026 / –0.748  
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Table 2. 3 Selected bond distances and angles for [Ru(bpy)2(dphol)][PF6]·(CH3)2CO (1).  
 
Bond lengths (Å) Bond angles (°) 
Ru1–O1 
Ru1–N1 
Ru1–N2 
Ru1–N3 
Ru1–N4 
Ru1–N5 
2.061(3) 
2.152(3) 
2.065(4) 
2.052(3) 
2.035(3) 
2.060(4) 
N1–Ru1–O1 
N2–Ru1–N3 
N4–Ru1–N5 
O1–Ru1–N4 
N1–Ru1–N3 
N3–Ru1–N4 
80.5(1) 
78.4(1) 
78.7(1) 
89.9(1) 
105.6(1) 
84.1(1) 
Dihedral angles (°) 
N1–Ru1–O1–C1 
Ru1–N1–C19–C18 
N1–C19–C18–C17 
N6–C6–C7–C8 
3.7(2) 
–30.7(5) 
–19.3(6) 
–10.8(5) 
 
 
 
Table 2. 4 Selected bond distances and angles for [Ru(bpy)2(hbtz)][PF6]·(CH3)2CO (3).  
 
Bond lengths (Å) Bond angles (°) 
Ru1–O1 
Ru1–N1 
Ru1–N2 
Ru1–N3 
Ru1–N4 
Ru1–N5 
2.059(2) 
2.047(2) 
2.041(2) 
2.019(2) 
2.045(2) 
2.110(2) 
O1–Ru1–N5 
N1–Ru1–N2 
N3–Ru1–N4 
O1–Ru1–N2 
N5–Ru1–N3 
N2–Ru1–N3 
87.93(6) 
78.75(7) 
78.41(7) 
90.27(6) 
94.41(7) 
87.78(7) 
Dihedral angles (°) 
N3–Ru1–N4–C16 
N4–Ru1–N3–C15 
N5–Ru1–O1–C21 
O1–Ru1–N5–C27  
N5–C27–C26–C21 
C25–C26–C27–S1 
–16.4(1) 
17.1(1) 
27.6(2) 
–28.6(2) 
8.5(3) 
5.0(3) 
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Table 2. 5 Selected bond distances and angles for [Ru(phen)2(hbtz)][PF6] (4).  
 
Bond lengths (Å) Bond angles (°) 
Ru1–O1 
Ru1–N1 
Ru1–N2 
Ru1–N3 
Ru1–N4 
Ru1–N5 
2.060(2) 
2.053(3) 
2.035(3) 
2.028(3) 
2.079(3) 
2.110(3) 
O1–Ru1–N5 
N1–Ru1–N2 
N3–Ru1–N4 
O1–Ru1–N2 
N5–Ru1–N3 
N2–Ru1–N3 
87.18(9) 
80.4(1) 
80.0(1) 
84.54(9) 
100.0(1) 
88.3(1) 
Dihedral angles (°) 
N5–Ru1–O1–C25  
O1–Ru1–N5–C31  
N5–C31–C30–C25 
C29–C30–C31–S1 
–35.3(2) 
27.8(2) 
–16.3(5) 
–17.3(4) 
 
 
 
Table 2. 6 Selected bond distances and angles for Ir(phpy)2(hbtz) (6). 
 
Bond lengths (Å) Bond angles (°) 
Ir1–O1 
Ir1–N1 
Ir1–N2 
Ir1–N3 
Ir1–C1 
Ir1–C12 
2.141(3) 
2.049(2) 
2.048(2) 
2.205(2) 
1.999(3) 
1.995(4) 
O1–Ir1–N3 
N1–Ir1–C1 
N2–Ir1–C12 
O1–Ir1–C12 
N3–Ir1–C1 
C1–Ru1–C12 
82.35(8) 
79.9(1) 
80.9(1) 
90.5(1) 
98.2(1) 
89.0(1) 
Dihedral angles (°) 
O1–Ir1–N3–C29 
N3–Ir1–O1–C23  
C23–C28–C29–N3 
C27–C28–C29–S1 
–36.2(2) 
43.3(2) 
18.7(5) 
17.3(4) 
 
 
 
 78 
 
Although the synthesis, characterization and optical properties of the Ir 
compound 6 have been previously documented,152 its X-ray structure was not previously 
reported. Single crystals of 6 were grown from slow evaporation of an ethyl acetate 
solution of the compound at room temperature. Compound 6 crystallizes in the triclinic 
space group P–1. The Ir center exhibits a distorted octahedral environment (Figure 2.11), 
the C– donors of each phpy ligand are cis to each other, whereas the N atom donors of 
both phpy ligands are trans to each other. Such an arrangement of phpy ligands is well-
stablished in Ir(III) complexes possesing the “Ir(phpy)2” fragment. The reason for this  
disposition of C– and N donor atoms is the strong trans influence of the cyclometallating 
C– donor of phpy, avoiding the positioning the both C– strong donors in trans 
disposition.154,155 The elongation of the Ir–N3 bond (2.205(2) Å) with respect to Ir1–N1 
and  Ir1–N2 bond distances (2.048(2) and 2.048(2) Å, respectively)  is due to the strong 
donating properties (trans influence) of the C12 atom donor that is in trans position, as 
also observed in the Ru cyclometallated compounds that will be described in Chapter III. 
The Ir1–O1 bond (2.141(3) Å) is longer than the Ru–O bond in 3 and 4 (~2.06 Å) 
because of the trans influence of the C1 atom that is located in trasn position to the Ir1–
O1 bond in 6. The bond distances and angles in compound 6 are also similar to those 
reported for the related compounds of formula Ir(phpy)2(quoR), where quoR = 
derivatives of 8-hydroxyquinolinolate.156 The hbtz ligand is twisted around the C–C 
bond that connects the phenoxido and benzothiazolyl (C23–C28–C29–N3, 18.7(5)°), as 
observed in the Ru compounds 3 and 4.  
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Intermolecular π-π stacking interactions involving dphol ligands of different 
[Ru(bpy)2(dphol)]+ cations are observed in the crystal packing of 1 (Figure 2.12), where 
the distance between the planes containing the phenanthrene moieties is 3.52 Å. The 
ancillary bpy ligands of 1 are also involved in intermolecular π-π stacking interactions 
(Figure 2.13). Likewise, stacking interactions between polypyridyl ligands (bpy, phen, 
phpy) are observed in the crystal packing of 3, 4 and 6 (Figures 2.14–2.16). A summary 
of centroid-centroid distances, interplanar distances and displacement angles is compiled 
in Tale 2.7 These three parameters in complexes 1, 3 and 4 and 6 are within the range 
observed for polypyridyl metal complexes reported in the literature.157,158 In addition, the 
hbtz ligands in 3, 4 and 6 exhibit stacking interactions in the crystal packing, with 
interplanar distances of 3.62, 3.92 and 3.43 Å, respectively (Figures 2.14–2.16).  
 
 
 
Table 2. 7 Distances and angles associated with the π-π stacking interaction of 
polypyridyl ligands in compounds 1, 3 and 4. 
 
Compound Ligands  
involved 
Centroid-centroid  
distance (Å) 
Interplanar  
Distance (Å) 
Displacement 
angle (°) 
1 bpy–bpy 3.63 3.28 28 
3 bpy–bpy 3.69 3.38 24 
4 phen–phen 4.09a 3.50 31 
6 phpy–phpy  4.66b 3.40 43 
aCentroid of the central benzene ring of phen ligands. bCentroid of pyridyl ring to centroid 
phenyl ring of phpy ligands. 
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Figure 2. 12 Space filling models highlighting intermolecular π-π stacking interactions 
between phenanthrene moieties of dphol ligands in the crystal packing of compound 1. 
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Figure 2. 13 Space filling models highlighting intermolecular π-π stacking interactions 
between bpy ligands in the crystal packing of compound 1.  
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Figure 2. 14 Intermolecular π-π stacking interactions in the crystal packing of compound 
3. Space filling models highlighting the interactions between (a) bpy ligands and (b) hbtz 
ligands. 
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Figure 2. 15 Intermolecular π-π stacking interactions in the crystal packing of compound 
4. Space filling models highlighting the interactions between (a) phen ligands and (b) 
hbtz ligands. 
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Figure 2. 16 Intermolecular π-π stacking interactions in the crystal packing of compound 
6. Space filling models highlighting the interactions between (a) phpy ligands and (b) 
hbtz ligands. 
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Electrochemical Properties 
 
The redox properties of complexes 1–6 were studied by cyclic voltammetry in 
acetonitrile. The half-wave potential values (E1/2) vs Ag/AgCl were obtained from the 
cyclic voltammograms of 1–6 and are provided in Figures 2.17–2.19. The E1/2 values 
have been referenced vs NHE for the discussion of the results (NHE = normal hydrogen 
electrode) as described in the Experimental Section and the values are presented in Table 
2.8. The redox events observed in the cyclic voltammogram of 1–6 are quasi-reversible 
(ipa/ipc ≈ 1), except for the metal-based oxidation process of 1, 2 and 6, which are 
irreversible.  
 
 
 
Table 2. 8 Half wave redox potentials (E1/2) of 1–6 recorded in acetonitrile. 
  
Compound E1/2 (V) vs NHE (ΔE = Epa-Epc in mV) 
E1/2 [M(n+1)+/n+]a E1/2,red1 E1/2,red2 E1/2,red3 
[Ru(bpy)2(dphol)][PF6] (1) 0.86b –0.94 (66) –1.35 (66) –1.61 (88) 
[Ru(phen)2(dphol)][PF6] (2) 0.85b –0.93 (64) –1.36 (85) –1.59 (80) 
[Ru(bpy)2(hbtz)][PF6] (3) 0.74 (80) –1.25 (60) –1.52 (78) - 
[Ru(phen)2(hbtz)][PF6] (4) 0.74 (90) –1.26 (65) –1.54 (86) - 
[Ru(bpy)2(quo)][PF6] (5) 0.76 (95) –1.28 (68) –1.53 (94) - 
Ir(phpy)2(hbtz) (6) 1.71b - - - 
aRu3+/2+ couple for 1–5; Ir4+/3+ couple for 6.  bIrreversible; the anodic peak potential (Ep,a) is 
reported.  
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Figure 2. 17 Cyclic voltammograms (vs Ag/AgCl) of compounds 1, 2 and 5 in 
acetonitrile (0.1 M [nBu4N][PF6], 100 mV/s scan rate). ic = cathodic current, ia = anodic 
current, ox. = oxidation, red. = reduction. The black arrows indicate the direction of the 
scan. 
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Figure 2. 18 Cyclic voltammograms (vs Ag/AgCl) of compounds 3–5 in acetonitrile (0.1 
M [nBu4N][PF6], 100 mV/s scan rate). ic = cathodic current, ia = anodic current, ox. = 
oxidation, red. = reduction. The black arrows indicate the direction of the scan. 
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The Ru3+/2+ redox couples of 1–5 (E1/2 [Ru3+/2+] = 0.86 to 0.74 V range) occur at 
less positive potentials with respect to [Ru(bpy)3]2+ (E1/2 [Ru]3+/2+ = 1.54 V159). The 
anionic character and π-donating ability of the O-atom donor of the N^O– ligands 
destabilizes the Ru(dπ) “t2g-type” orbitals (Figure 2.20) and facilitates metal oxidation. 
This destabilization effect was verified by DFT calculations reported for the known 
compound 5,160 where the HOMO has contributions from both the Ru(dπ) and O(pπ) 
orbitals and the HOMO-1 and HOMO-2 are mainly metal-based. In contrast, the Ir4+/3+ 
redox couple of 6 occurs at a more positive potential (E1/2 [Ru4+/3+] = 1.71 V). The 
stronger ligand field splitting for third-row (5d) transition metal ions with respect to 
second-row (4d) transition metal ions, as well as the more positive charge of the metal 
center in 6 (Ir3+ vs Ru2+), results in a greater stabilization of the occupied “t2g-type” 
Ir(5dπ) orbitals as schematically shown in Figure 2.21, 154,155 explaining why 6 is more 
difficult to oxidize than 1–5 and [Ru(bpy)3]2+. 
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Figure 2. 19 Cyclic voltammogram (vs Ag/AgCl) of compound 6 in acetonitrile (0.1 M 
[nBu4N][PF6], 100 mV/s scan rate). ic = cathodic current, ia = anodic current, ox. = 
oxidation, red. = reduction. The black arrows indicate the direction of the scan. 
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Figure 2. 20 Schematic representation of the destabilization of the occupied Ru(4dπ) 
orbitals in 1–5 with respect to [Ru(bpy)3]2+. EMLCT = energy of the MCLT transition. 
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Figure 2. 21 Schematic representation of the relative energies of Ru(4dπ) and Ir(5dπ) 
orbitals. EMLCT = energy of the metal-to-ligand charge transfer transition. 
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The redox events observed for 5 are in agreement with previous reports.160,161,162 
The metal-based redox couple at E1/2 = 0.76 V corresponds to the Ru3+/2+ oxidation 
couple, whereas those at  E1/2 = –1.28 and –1.53 V correspond to consecutive 1e– 
reductions of the bpy ligands. Reduction of quo is not observed in the 1.8 to –1.8 V 
range of potentials. The Ru3+/2+ redox events for 1 and 2 are irreversible and are shifted 
anodically by ~100 mV with respect to 5 (Figure 2.17), that is, compounds 1 and 2 are 
more difficult to oxidize than 5.  
The first reduction waves of 1 and 2 (E1/2,red1 ~ –0.94 V) occur at less negative 
potentials than that of 5 (E1/2,red1 = –1.28 V, bpy-based reduction) and are assigned as 
reduction of the dphol ligand: dphol + e– → dphol–. The dphol ligand is easier to reduce 
than bpy (or quo) due to its more delocalized π-system and it is likely that the electron is 
delocalized in the phenanthrene moiety of dphol. The other two ligand-based reduction 
waves at ~ –1.35 and ~ –1.60 V are assigned as consecutive 1e– reductions of bpy in the 
case of 1, and phen in the case of 2.  
Compounds 3 and 4 display metal-based and ligand-based redox processes at 
very similar E1/2 values to those of 5 (Figure 2.18). Therefore, it can concluded that the 
E1/2 [Ru3+/2+] of 3 and 4 occurs at E1/2 = 0.74 V and that the ligand-based redox events at 
E1/2 –1.25 and –1.52 V for 3, and E1/2 –1.26 and –1.54 V for 4, correspond to 
consecutive 1e– reductions of bpy and phen ligands, respectively. The reduction of the 
hbtz ligand is likely to occur at more negative potentials and is not observed in the 
potential window of the cyclic voltammogram experiments. Compound 6 does not 
exhibit any reversible event in the 0 to –1.8 V range of potentials (Figure 2.19). 
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Optical Properties 
 
The absorption maxima (λabs) and molar extinction coefficients (ε) for 1–6 in 
acetonitrile are listed in Table 2.9 and their electronic absorption spectra in acetonitrile 
are shown in Figures 2.22–2.24. The Ru compounds with phen as an ancillary ligand (2 
and 4) exhibits slightly higher molar absorptivity coefficients in the visible region than 
those with bpy ligands (1, 3 and 5). The absorption maxima at ~500 nm for 1, 3 and 5 
are assigned as singlet metal-to-ligand charge transfer (1MLCT) transitions 
(Ru(dπ)→bpy(π*)). Similarly, broad 1MLCT bands centered in the 480–500 nm interval 
are observed for 2 and 4, which arise from Ru(dπ)→phen(π*) transitions. Such 1MLCT 
bands for 1–5 are red-shifted with respect to the prototype Ru(II) complex [Ru(bpy)3]2+ 
(1MLCT at 450 nm159) due to the destabilization of the Ru-HOMOs (occupied “t2g-type” 
orbitals), which in turn decreases the HOMO-LUMO gap and the energy of the MLCT 
transition as illustrated in Figure 2.20. Compounds 1 and 2 exhibit additional absorption 
features in the 650–800 nm region that are assigned as Ru(dπ)→dphol(π*) 1MLCT 
transitions. These low energy transitions are in agreement with the less negative 
reduction potential of coordinated dphol with respect to quo or hbtz, indicating that the 
π* MOs of dphol are lower in energy.  
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Table 2. 9 Electronic absorption data for 1–6 recorded in acetonitrile. 
 
Compound λmax, nm (ε × 104 M–1 cm–1) 
[Ru(bpy)2(dphol)][PF6] (1) 710 (0.14), 500 (0.83), 363 (1.92), 292 (4.67), 246 (5.65)   
[Ru(phen)2(dphol)][PF6] (2) 710 (0.23), 525a (1.10), 485 (1.26), 380 (1.80), 355 (2.07), 263 
(9.30), 226 (8.26) 
[Ru(bpy)2(hbtz)][PF6] (3) 652 (0.16), 496 (0.81), 351 (1.35), 292 (4.29) 
[Ru(phen)2(hbtz)][PF6] (4) 650 (0.20), 480 (1.28), 351 (1.00), 267 (7.14), 225 (7.53) 
[Ru(bpy)2(quo)][PF6] (5) 506 (0.89), 460 (0.65), 394 (0.74) 368 (0.80), 295 (3.47), 252 (3.52) 
Ir(phpy)2(hbtz) (6) 450 (0.57), 404 (0.65), 382 (0.67), 345 (0.81), 260 (4.05) 
aShoulder.  
 
 
 
 
 
Figure 2. 22 Electronic absorption spectra of 1, 2 and 5 in acetonitrile. 
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Figure 2. 23 Electronic absorption spectra of 3–5 in acetonitrile. 
 
 
 
 
 
Figure 2. 24 Electronic absorption spectra of free ligands in acetonitrile. The 
concentrations of the compounds were adjusted to have comparable intensities. 
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The transitions in the 300–400 nm range arise from 1ππ* ligand-centered (LC) 
transitions of the N^O– ligands, since the free ligands dpholH (374 and 393 nm), hbtzH 
(332 nm) and quoH (312 nm) display absorption maxima in this region (Figure 2.24). 
The maxima at higher energies (λ < 300 nm) correspond to overlapping L(π)→L(π*) and 
bpy(π)→bpy(π*) LC transitions in the case of 1 (L = dphol), 3 (L = hbtz) and 5 (L = 
quo), and overlapping L(π)→L(π*) and phen(π)→phen(π*) LC transitions for 2 (L = 
dphol) and 4 (L = hbtz). 
The Ir compound 6 exhibits absorption maxima in the 340–500 nm range, which 
has been assigned on the basis of DFT calculations as overlapping 1,3MLCT 
(Ir(4dπ)→phpy(π*)) and 1,3LLCT (ligand-to-ligand charge transfer, hbtz(π)→phpy(π*)) 
transitions.152 The strong spin-orbit coupling induced by 5d transition metal ions mixes 
singlet and triplet states and allows direct excitation into the spin-forbidden triplet 
excited states.154,155 The MLCT transitions of 6 occur at higher energies than those of 1–
5 because of the greater stabilization of the Ir-5dπ orbitals with respect to Ru-4dπ metal 
orbitals, as described in the previous section. The greater energy of the MLCT transition 
of 6 with respect to 1–5 also explains the striking difference in colors for these 
compounds (1–5, dark red-purple; 6, yellow), as shown in Figure 2.25. The intense 
peaks observed at λ < 300 nm are due to spin-allowed 1ππ* LC transitions of phpy 
(phpy(π)→phpy(π*)) and hbtz (hbtz(π)→hbtz(π*)) ligands. Compound 6 displays 
orange phosphorescence at room temperature (Figure 2.26) when excited at 350 nm. 
Two emission maxima at 515 nm and 607 nm (CH2Cl2 solution) were observed in 
aerated solutions, in agreement with previous reports.152 These two emission peaks have 
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been previously assigned to arise from 3MLCT (Ir(4dπ)→phpy(π*)) and 3LLCT 
(hbtz(π)→phpy(π*)), respectively, on the basis of DFT calculations.152 
 
 
 
 
 
Figure 2. 25 Photograph showing the solid state colors of compounds 4 and 6.   
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Figure 2. 26 (a) Emission spectrum of an aerated solution of compound 6 in CH2Cl2 (λex 
= 350 nm). (b) Photographs showing phosphorescence from a solution of 6 (~10-5 M) in 
CH2Cl2 (λex = 254 nm from a hand-held UV lamp).  
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Cytotoxic Properties  
  
The cellular studies discussed in this part and the following section were 
performed in collaboration with Professor Rola Barhoumi (Veterinary Integrative 
Biomedical Sciences, Texas A&M University). To evaluate the cytotoxicity of 
compounds 1–6 against human lung adenocarcinoma (A549) cells, cell viability was 
determined using the Janus Green B dye (3-(Diethyamino)-7-((p-(dimethylamino) 
phenyl)azo)-5-phenylphenazinium chloride, Figure 2.27a). In this assay, A549 cells are 
incubated with increasing concentrations of 1–6 (0–50 µM) for 48 h. Subsequently, the 
cells are washed and fixed to the microplate well. Following fixation, living cells are 
stained with Janus Green B. After removing the excess dye from solution, the amount of 
dye trapped inside living cells is solubilized with methanol. The absorbance of Janus 
Green B (λabs = 630 nm) is measured using a microplate absorbance reader, whose value 
is directly proportional to the number of living cells.  
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Figure 2. 27 Molecular structures of (a) Janus Green B and (b) JC-1. 
 
 
 
Table 2. 10 Cytotoxicity data for Ru and Ir complexes against A549 cells. 
 
Compound IC50, µM (95% CIa) 
[Ru(bpy)2(dphol)][PF6] (1) 6.6 (3.2 to 13.9) 
[Ru(phen)2(dphol)][PF6] (2) 1.3 (0.8 to 2.1) 
[Ru(bpy)2(hbtz)][PF6] (3) 1.1 (0.7 to 1.9) 
[Ru(phen)2(hbtz)][PF6] (4) 0.8 (0.5 to 1.2) 
[Ru(bpy)2(quo)][PF6] (5) > 50 
Ir(phpy)2(hbtz) (6) 4.7 (2.7 to 8.2) 
cisplatin 6.2 (2.9 to 13.5) 
aIncubation time = 48 h. Values in parenthesis 
represent the 95% confidence interval. 
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The IC50 values (concentration of compound required to inhibit 50% of cell 
survival) were calculated under reduced light conditions and are listed in Table 2.10. 
Compounds 1–6 exhibit IC50 values in the low micromolar range. Cisplatin was used as 
a positive control (IC50 = 6.2 µM). Compound 1 exhibits comparable activity than 
cisplatin, whereas compounds 2–4 are more active than the platinum drug. Compound 4 
is the most cytotoxic Ru compound (IC50 = 0.8 µM) and is 8-fold more cytotoxic than 
cisplatin. In contrast, compound 5 is not active in the range of concentrations that were 
tested (0–50 µM). It is likely that the higher cytotoxicity of 1–4 with respect to 5 is due 
to the increased lipophilicities of 1–4 since they have extended aromatic systems on the 
ligands dphol (1 and 2) and hbtz (3 and 4), supporting our initial hypothesis. The higher 
hydrophobicity of dphol and hbtz with respect to quo may increase the cellular uptake of 
1–4, as also shown in the work of Meggers135 and in several studies on the anticancer 
properties of Ru120,121,124,126,128 complexes. The Ir compound 6 exhibits cytotoxic activity 
similar to that of cisplatin and will encourage the synthesis and exploration of the 
anticancer properties of analogs of this Ir compound in the future. 
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Investigation of the Mechanism of Cancer Cell Death 
 
Disruption and permanent dissipation of the inner mitochondrial transmembrane 
potential (ΔΨm) is an event that is associated with the intrinsic pathway of apoptosis, as 
described in Chapter I. To determine the effect of 1–4 on mitochondria, mitochondrial 
dysfunction was assessed by measuring the changes in ΔΨm using JC-1 (5′,6,6′-
tetrachloro-1,1′,3,3′-tetraethylbenzimidazolyl carbocyanine iodide, Figure 2.27b).127,128 
JC-1 is a lipophilic cationic dye that accumulates in mitochondria due to the negative 
potential of the inner membrane on these organelles (–120 to –160 mV61,117), and its 
fluorescence wavelength is potential-dependent: regions within the cell with high 
mitochondrial polarization (high ΔΨm) are indicated by red fluorescence (590 nm) due to 
the formation of dye aggregates (so called J-aggregates). In contrast, green fluorescence 
(527 nm) of dye monomers is observed when mitochondria is depolarized (low 
ΔΨm).61,163 Therefore, mitochondrial depolarization is indicated by a decrease in the 
red/green emission intensity ratio (R) of JC-1.163  
A549 cells were incubated with 1–4 at different concentrations for 48 h. After 
this period of time the cells were incubated with JC-1 and R was calculated. The results 
are shown in Figure 2.28. In general, an increase of the concentration of the compounds 
is accompanied by a progressive decrease of R, indicating that 1–4 induce mitochondria 
depolarization in a dose-depended fashion and suggesting that cell death occursvia the 
intrinsic pathway of apoptosis. To compare the changes of R among 1–4, the change of R 
(ΔR) with respect to a control (no complex added) was calculated at 5 µM concentration 
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of Ru complex (ΔR = [(R5µM – Rcontrol)/Rcontrol] × 100%). The observed trend is as follow: 
4 (–97%) > 2 (–66%) ≈ 3 (–63%) > 1 (–23%), where the values in parenthesis represent 
ΔR. Interestingly, ΔR was directly proportional to the cytotoxicity, where the most 
cytotoxic compound, 4, decreases R to the greatest extend. Moreover, 4 induces a greater 
ΔΨm depolarization as compared to cisplatin (Figure 2.29), with ΔR = –70% and –15% 
for 4 and cisplatin at 1.5 µM concentration, respectively.   
A typical mitochondrion possesses a fibrous structure as can be seen in Figure 
2.30, where A549 cells were incubated only with JC-1. Green (Figure 2.30a) and red 
(Figure 2.30b) fluorescence images are shown to highlight the dual emission of JC-1 in 
mitochondria. Dramatic morphological changes of mitochondria occur when A549 cells 
are incubated with 4 for 48 h at concentrations as low as 500 nM, as shown in Figure 
2.31: complex 4 induces swelling and fragmentation of mitochondria, producing small 
and rounded organelles.61,142 Such morphological changes strongly indicate cell death by 
the intrinsic pathway. A progressive decrease of the red fluorescence intensity from J-
aggregates can be also seen when the concentration of 4 increases from 0 to 1 µM 
(Figure 2.31a-c), indicating loss of ΔΨm as described previously.  
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Figure 2. 28 R values from JC-1 when A549 cells are exposed after 48 h of incubation 
to different concentrations of compounds (a) 1, (b) 2, (c) 3 and (d) 4. The graphs 
represent means with standard deviation. Control experiments (no metal complex) are 
depicted in gray color. 
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Figure 2. 29 R values from JC-1 when A549 cells are exposed after 48 h of incubation 
to different concentrations of cisplatin and compound 4. The graphs represent means 
with standard deviation. 
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Figure 2. 30 Confocal fluorescence images of JC-1 in A549 cells in the absence of compound 4. (a) Green and (b) red 
fluorescence from JC-1. (c) Overlay of (a,b) images. Field of view = 75 × 75 µm. Images were collected after 48 h of 
incubation. 
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Figure 2. 31 Confocal red fluorescence images of JC-1 in A549 cells incubated with (a) 0 µM 4, (b) 500 nM 4 and (c) 1 µM 4. 
Field of view = 75 × 75 µm. Images were collected after 48 h of incubation. 
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Induction of outer mitochondrial membrane permeabilization (MMP) is a crucial 
event during cell death via the intrinsic pathway of apoptosis and is often considered as 
the “point of no return”.61 Such an even is accompanied by a dissipation of ΔΨm and 
permeabilization of the inner mitochondrial membrane (IMM). To support that the 
intrinsic pathway of apoptosis is triggered by these series of compounds, a biological 
assay that uses the calcein AM dye (Figure 2.32) was carried out for compound 4. 
 
 
 
 
 
Figure 2. 32 Molecular structure of calcein AM. 
 
 
 
In this experiment A549 cells are loaded with calcein AM and CoCl2. Calcein 
AM undergoes removal of the ester groups by intracellular esterases and is trapped in 
cytosolic compartments including mitochondria.61 The Co2+ ions quench the 
fluorescence of calcein in all subcellular compartments except in mitochondria since the 
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IMM is impermeable to Co2+ ions and water. When the IMM barriers are functional, a 
distinct bright green fluorescence signal from calcein identifies mitochondria,61 as can be 
observed in Figure 2.33a. Dim green fluorescence from calcein is observed elsewhere 
because Co2+ quenches calcein fluorescence. The signal from calcein overlays very well 
with the red fluorescence from Mitotracker, a mitochondria-specific fluorescent dye, 
confirming the localization of calcein in mitochondria (Figure 2.33a-c). In contrast, 
incubation of A549 cells with 1 µM 4 for 48 h leads to calcein fluorescence quenching 
inside mitochondria and dim green fluorescence is observed throughout the cells (Figure 
2.34). These results indicate long-lasting opening of the mitochondrial permeability 
transition pore (MPTP) complex, which allows Co2+ ions to enter the mitochondrial 
matrix and quench calcein fluorescence, supporting the intrinsic pathway of apoptosis as 
the mechanism of cancer cell death.  
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Figure 2. 33 Confocal fluorescence images of A549 cells coincubated with Calcein AM and Mitotracker. in the absence of 
compound 4. (a) Green fluorescence from Calcein (+CoCl2), (b) red fluorescence from Mitotracker and (c) overlay of (a,b) 
images. Field of view = 75 × 75 µm. Images were collected after 48 h of incubation. 
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Figure 2. 34 Confocal fluorescence images of A549 cells coincubated with compound 4 (1 µM), Calcein AM and Mitotracker. 
(a) Green fluorescence from Calcein AM (+CoCl2), (b) red fluorescence from Mitotracker and (c) overlay of (a,b) images. 
Field of view = 75 × 75 µm. Images were collected after 48 h of incubation. 
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Caspases are cysteine proteases wich are involved in both the initiation and 
execution phases of apoptosis and, indeed, the activation of these proteolytic enzymes is 
often used as a hallmark of apoptosis.68,126 In particular, caspase-3/7, known as the 
executioner caspases, are activated after cytochrome c leaks out of mitochondria when a 
cell dies via the intrinsic pathway of apoptosis.61 The effect of a chemotherapy drug on 
the activity of caspase-3/7 can be examined using the Caspase-Glo assay kit, which 
includes (i) the caspase-3/7 substrate DEVD-NH-luciferin and (ii) the Luciferase 
enzyme. Cancer cells are incubated with the Caspase-Glo reagents after treatment with 
the drug. Caspase-3/7 that are activated during apoptosis cleave the amino acid sequence 
DEVD (Asp-Glu-Val-Asp) releasing 6-amino-luciferin (Figure 2.35). The latter 
undergoes oxidative decarboxylation catalyzed by the Luciferase enzyme producing 
oxyluciferin in an electronically excited state (oxyluciferin*), which emits light (hv) 
when it is deactivated and returns to the ground state (oxyluciferin* → oxyluciferin + 
hv).  The luminescence intensity is proportional to the amount of caspase-3/7 activity. 
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Figure 2. 35 Reaction pathway that leads to oxyluciferin fluorescence during the 
measurement of caspase-3/7 activity. ATP = adenosine triphosphate. AMP = Adenosine 
monophosphate. PPi = pyrophosphate. 
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A549 cells were treated with compound 4 at three different concentration (0.75, 
1.5 and 2.25 µM) for 48 h and caspase -3/7 activity was determined after this period of 
time. Compound 4 induced caspase-3/7 activity in a concentration-dependent fashion as 
depicted in Figure 2.36, in which an increase in the oxyluciferin luminescence intensity 
is observed upon increasing the concentration of 4, confirming that this Ru compound 
induces cell suicide via the intrinsic pathway. Figure 2.36 also shows that a lower 
concentration of 4 is needed to induce caspase-3/7 activity with respect to cisplatin, in 
which 2.25 µM 4 reaches comparable activity to 6.25 µM cisplatin, showing the higher 
apoptosis inducing ability of 4.  
 
 
 
 
Figure 2. 36 Caspase-3/7 activity measurements when A549 cells are exposed to 
compound 4 and cisplatin (48 h of incubation). The graphs represent means with 
standard deviation. 
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Conclusions 
 
 The lack of studies in the literature of the cytotoxic properties of Ru(II) 
polypyridyl complexes in a [RuIIN5O]+ coordination environment prompted us to 
explore the biological activities of a new series of Ru polypyridyl compounds with the 
N^O– bidentate ligands dphol and hbtz. Four new Ru complexes (1–4) were successfully 
synthesized and characterized by 1H NMR spectroscopy, mass spectrometry, elemental 
analysis and X-ray crystallography. The 1MLCT transitions for thee complexes are 
bathochromically shifted with respect to that of [Ru(bpy)3]2+ due to the π-donating 
ability of the O–-donor of N^O–, which destabilizes the Ru(4dπ) HOMOs and decreases 
the energy of the Ru(4dπ)→L(π*) transition. This effect is also reflected in the less 
positive oxidation potential for this series of compounds with respect to the prototype 
complex [Ru(bpy)3]2+.  
The four compounds are cytotoxic against human lung adenocarcinoma (A549) 
cells with IC50 values in the low micromolar range. Compound 4, the most active of the 
series, is ~8 times more cytotoxic than cisplatin. The dissipation of ΔΨm was evaluated 
using the JC-1 probe and it was found that the four Ru complexes induce loss of ΔΨm in 
a concentration-dependent fashion. In addition, the cytotoxicity of 1–4 is directly 
proportional to the loss of ΔΨm. The dissipation of ΔΨm suggests that 1–4 are inducing 
apoptosis via the intrinsic pathway in A549 cells. Moreover, compound 4 promotes the 
long-lasting opening of the MPTP complex and induces the activity of caspase-3/7, 
confirming that A549 cells die by the intrinsic pathway when incubated with this type of 
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Ru complex. Therefore, increasing the lipophilicity of the N^O– ligand is a successful 
strategy to access a new family of pro-apoptotic Ru complexes with a [RuIIN5O]+ 
coordination environment. This work complements the strategy followed by Meggers135 
to increase cellular uptake and anticancer activity and we believe these results will 
encourage the exploration of the anticancer activities of octahedral Ru polypyridyl 
complexes in coordination environments different than [RuIIN6]2+.  
Finally, although the cellular targets and the mechanism by which the Ir(III) 
compound 6 promotes cancer cell death have not been studied, the fact that its 
cytotoxicity is comparable to that of cisplatin makes this class of Ir compounds 
interesting candidates for further development.    
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CHAPTER III 
RUTHENIUM CYCLOMETALLATED DYES AS A NEW CLASS OF 
ORGANOMETALLIC ANTICANCER DRUGS* 
 
Introduction 
 
Bioorganometallic chemistry is an emerging and vibrant research field that 
focuses on the study of naturally occurring or synthetic organometallic compounds 
(those possessing metal-carbon bonds) with biological or medicinal applications.84,164 
The name of this research area was first coined by Gérard Jaouen in 1985 when he 
described the use of chromium, cobalt and manganese carbonyl compounds to label 
hormonal steroids.165  
 
 
 
 
*Reprinted with permission from Peña, B.; David, A.; Pavani, C.; Baptista, M. S.; 
Pellois, J.-P.; Turro, C.; Dunbar, K. R. “Cytotoxicity Studies of Cyclometallated Ruthenium(II) 
Compounds: New Applications for Ruthenium Dyes”. Organometallics 2014, 33 (5), 1100-1103. 
Copyright 2014 American Chemical Society. 
Reprinted with permission from Peña, B.; Leed, N. A.; Dunbar, K. R.; Turro, C. 
“Excited State Dynamics of Two New Ru(II) Cyclometallated Dyes: Relation to Cells for Solar 
Energy Conversion and Comparison to Conventional Systems”. J. Phys. Chem. C 2012, 116 
(42), 22186-22195. Copyright 2012 American Chemical Society.  
Reproduced from Albani, B. A.; Peña, B.; Dunbar, K. R.; Turro, C. “New 
cyclometallated Ru(II) complex for potential application in photochemotherapy?”. Photochem. 
Photobiol. Sci. 2014, 13 (2), 272-280, with permission from the European Society for 
Photobiology, the European Photochemistry Association, and The Royal Society of Chemistry. 
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The first synthetic organometallic compound with demonstrated therapeutic 
effects that was marketed can be traced back to 1909, when the systematical studies by 
Paul Ehrlich in Europe on organoarsenic compounds led to the discovery of Salvarsan 
(3-amino-4-hydroxyphenylarsenic(I), Arsphenamine or Ehrlich 606)166 which was used 
to treat syphilis. Ehrlich was awarded the Nobel Prize in Physiology or Medicine in 1908 
for his contribution to this area.164 The subsequent establishment of a theoretical 
framework for understanding the structure and bonding of organometallic compounds in 
the second part of the twentieth century, the ability to control the behavior of 
organometallic complexes in water, and the seminal discovery of the antitumor 
properties of cisplatin by Barnett Rosenberg in the 1960’s,17,18 led to the emergence and 
success of this field in our century.83,84,86,164,167 
 
 
 
 
 
Figure 3. 1 Schematic representations of the molecular structures of (a) (η6-arene)Ru 
and (b) Ru(phpy) scaffolds. 
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Over the past 10 years, the growth of bioorganometallic chemistry has led to the 
discovery of new families of ruthenium (Ru) compounds with carcinostatic activities, 
with complexes with the (η6-arene)Ru(II) scaffold (also known as piano-stool or half-
sandwich compounds, Figure 3.1a) being some of the most well studied as described in 
Chapter I.82,83,84,86,90,164 In 2005, the anticancer properties of structurally different 
organometallic Ru(II) compounds were reported by the group of Pfeffer and coworkers, 
in which the metal center is six-coordinate and contains the orthometallated 2-
phenylpyridine ligand (phpy, Figure 3.1b). From a synthetic point of view, this class of 
Ru organometallic compounds is more appealing than piano-stool complexes since 
greater structural complexity (and the possibility to modulate the cytotoxic properties) 
can be introduced by installation of mono-, bi- tri- and tetradentate ligands. In addition, 
the phpy ligand can be modified more easily than the η6-arene ring in the piano-stool 
complexes which allows for the introduction of a variety of functional groups. 
The Pfeffer group evaluated the antiproliferative activities of seven Ru 
cyclometallated compounds (also called cycloruthenated or ruthenium-derived 
compounds (RDC) in the literature) and found that [Ru(phpy)(NCCH3)3(PMe2Ph)][PF6] 
(RDC9; Figure 3.2a) and [Ru(phpy)(phen)(NCCH3)2][PF6] (RDC11;  phen = 1,10-
phenanthroline, Figure 3.2b) exhibit comparable or slightly greater activity than that of 
cisplatin against a variety of cancer cell lines derived from glioblastoma (A172 and 
HS683), neuroblastoma (N2A and SH5Y) and adenocarcinoma (HCT116), among 
others.168,169 RDC9 and RDC11 induce G1 cell cycle arrest, DNA condensation and 
fragmentation, externalization of phosphatidylserine and promote the activity of caspase 
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3 which are proteolytic enzymes associated with programmed cell death. In addition, the 
two compounds promote the activity of the tumor suppressor proteins p53 and p73 (that 
induce cell growth arrest), indicating that apoptosis is the mechanism of cancer cell 
death.168 Moreover, RDC9 induces apoptosis in a cell line (TK6) for which the p53 gene 
has been deleted and maintained its cytotoxicity in a cell line (2008 ATP7B) that 
overexpressed ATP7B (a membrane transporter that is able to expel cisplatin out of the 
cell which is associated with cisplatin resistance170,171), highlighting the promising 
anticancer properties of this class of organometallic compounds. 
In 2009, the same group reported that RDC11 was more efficient than cisplatin at 
inhibiting the growth of various tumors implanted in mice and did not cause side effects 
such as liver or kidney toxicity172 (commonly associated with cisplatin treatment), 
results that motivated the study of its mechanism of action. It was determined that 
RDC11 stimulates the expression of the p53 protein and genes of the endoplasmic 
reticulum (ER) stress pathway, along with CHOP (CCAAT-enhancer-binding protein 
homologous protein, a transcription factor that is a critical mediator of ER stress 
apoptosis), suggesting that its anticancer activity involves the p53 and the ER stress 
pathways.172 Two years later, the cytotoxic activity of nearly 15 derivatives of RDC11 of 
the type [Ru(phpyX)(phen)2]+ were studied, where X represents different electron-
withdrawing and electron-donating groups (-NR2, -Br, -NO2, -CONR). From this series 
of compounds, [Ru(phpy)(phen)2][X] (phen = 1,10-phenanthroline, X = PF6– or 
CF3CO2–,  Figure 3.2c) was found to be one of the most active, displaying a 5-fold 
higher cytotoxicity than RDC11 against human colon HCT-116 cancer cells.173 More 
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recently, organometallic Ru(II) compounds incorporating both η6-arene and 
orthometallated ligands (Figure 3.2d) have been reported to have cytotoxicities higher 
than those of cisplatin against epithelial ovarian carcinoma (A2780 and A2780cisR 
(acquired resistance to cisplatin)), breast (T47D) and colon (HT29) cancer cells and to 
induce apoptosis.174  
RDC11 and [Ru(phpy)(phen)2]+ have been shown to be more active than their 
dicationic counterparts, [Ru(phen)2(NCCH3)2]2+ and [Ru(phen)3]2+, respectively. It is 
interesting to note that change of the ligand donor atoms (from N to C–) increases the 
anticancer activity of these metal compounds. The higher cytotoxicity of the 
cyclometallated complexes has been attributed to their lower positive charge, which 
increases their lipophilicity and uptake by cancer cells with respect to those of the 2+ 
charged Ru(II) complexes,173 as also observed in anticancer active Ir(III) complexes (see 
Chapter II). In addition, it has been shown that cyclometallation of Ru compounds tunes 
the Ru3+/2+ redox potential and allows them to efficiently interfere with oxido-reductase 
enzymes, which is said to be associated with their biological activities. For example, the 
cytotoxic compound [Ru(phpy)(phen)2]+ oxidizes efficiently the reduced form of glucose 
oxidase in the absence of oxygen.175  
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Figure 3. 2 Molecular structures of (a) RDC9, (b) RDC11, (c) [Ru(phpy)(phen)2][PF6], 
and (d) an example of a Ru(II) anticancer compound incorporating both arene and phpy-
type ligands. 
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In light of the very promising biological activities of Ru cyclometallated 
compounds in cancer drug research, we decided to expand this family of compounds by 
coordinating a variety of bidentate ligands to the “Ru(phpy)” fragment. The known 
compound [Ru(phpy)(bpy)2][PF6] (1; bpy = 2,2’-bipyridine) and the four new complexes 
(Figure 3.3) [Ru(phpy)(bpy)(dppn)][PF6] (2; bpy = 2,2’-bipyridine, dppn = 
benzo[i]dipyrido[3,2-a:2′,3′-c]phenazine), [Ru(phpy)(dppn)2][PF6] (3), 
[Ru(phpy)(phendione)2][PF6] (4; phendione = 1,10-phenanthroline-5,6-dione) and  
[Ru(phpy)(biq)2][PF6] (5; biq = 2,2’-biquinoline) were synthesized and fully 
characterized. In addition, the synthesis and acetonitrile ligand substitution studies of the 
new compound [Ru(phpy)(pap)(NCCH3)2][PF6] (6; pap = 2-(phenylazo)pyridine) were 
undertaken to evaluate its suitability as a new precursor for Ru cyclometallated 
compounds. Two new tris-heteroleptic compounds  [Ru(phpy)(pap)(dcmb)][PF6] (7; 
dcmb = 4,4′-dicarboxymethyl-2,2′-bipyridine) and [Ru(phpy)(pap)(dppn)][PF6] (8) were 
prepared from 6. Compounds 2–8 resemble the Ru cyclometallated dyes used in dye-
sensitized solar cells in structure, optical and electrochemical properties. We expect that 
our findings of the cytotoxicity against cancer cells of some of these molecules will 
encourage the study of the cytotoxic properties of reported Ru dyes since many of them 
could display antitumor properties of similar or better magnitude than those discovered 
in this work, making Ru cyclometallated dyes a new and promising class of metal-based 
anticancer drugs.  
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Figure 3. 3 Molecular structures of Ru(II) cyclometallated complexes in this study. 
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Experimental Section 
 
General Methods 
 
Standard Schlenk-line techniques (under a N2 atmosphere) were used to maintain 
anaerobic conditions during the preparation of the compounds. The solvents were of 
reagent grade quality. Ethanol (KORTEP, 200 proof) was dried over Mg/I2, acetonitrile 
was dried over 3Å molecular sieves; both were distilled under nitrogen prior to use. All 
solvents used for chromatography (EMD Chemicals, ACS grade) were used as received 
without further purification. Analytical thin layer chromatography was performed on 
aluminum-backed sheets coated with silica gel (SiO2) 60 F254 adsorbent (0.20 mm 
thickness, EMD Chemicals) or coated with aluminum oxide (Al2O3) neutral 60 F254 
adsorbent (0.20 mm thickness, EMD Chemicals). Flash chromatography (FC) was 
carried out with with SiO2  60 (40-63 m, BDH Chemicals) or Al2O3 (activated, basic, 
Brockmann I, Sigma Aldrich). RuCl3•xH2O (Pressure Chemicals Co.), 1,3-
cyclohexadiene (Sigma Aldrich), 2,2’-bipyridine (Alfa Aesar), 2,2’-biquinoline (TCI) 
were purchased and used without further purification. The compounds 1,10-
phenanthroline-5,6-dione (phendione),176 2-(phenylazo)pyridine (pap),177 dcmb (4,4′-
dicarboxymethyl-2,2′-bipyridine),178 benzo[i]dipyrido[3,2-a:2′,3′-c]phenazine) (dppn)176 
and [Ru(phpy)(bpy)2][PF6] (1)179 were prepared following reported procedures. 
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Instrumentation 
 
NMR spectra were recorded on Mercury 300 MHz or an Inova 500 MHz 
spectrometers. Chemical shifts are reported in δ (ppm) and coupling constants (J) in 
hertz (Hz). For 1H NMR spectra, the residual solvent peak was used as an internal 
reference (δ 1.94 for CD3CN, 2.05 for (CD3)2CO2). Spectra were referenced externally to 
85% H3PO4 (δ 0.00) and CF3COOH (δ −78.5) for For 31P[1H] and 19F NMR, 
respectively. 1H1H COSY experiments were performed to do the assignment of proton 
resonances. Electrospray mass spectra were acquired on an Applied Biosystems PE 
SCIEX QSTAR mass spectrometer (MDS Sciex). Elemental analyses were performed by 
Atlantic Microlab, Inc. (Norcross, GA). Absorption spectra were recorded on a 
Shimadzu UVPC-3001 spectrophotometer. Electrochemical measurements were 
performed under N2 atmosphere with a HCH Electrochemical Analyzer model CH 
1620A using a BAS Pt disk working electrode, Pt wire auxiliary electrode, Ag/AgCl 
(3M KCl(aq)) reference electrode and 0.1 M tetra-n-butylammonium 
hexafluorophosphate ([nBu4N][PF6]) in dry acetonitrile as supporting electrolyte and 0.1 
V/s scan rate. The concentration of the Ru complexes was 0.3–0.5 mM for the 
electrochemical experiments. Ferrocene was used as an internal standard and exhibited a 
E1/2 = 0.44 V vs Ag/AgCl for the Fc+/Fc couple under the same experimental conditions. 
The E1/2 of the Ru complexes were referenced vs NHE using the following expression: 
E1/2 vs NHE = [(E1/2 vs Ag/AgCl of Ru complex) + (0.64 – 0.44)] V, where 0.64 V = E1/2 
[Fc+/Fc] vs NHE and 0.44 V = E1/2 [Fc+/Fc] vs Ag/AgCl.  
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Synthetic Details 
 
[(η6-benzene)RuCl2]2. The Ru complex was prepared following reported procedures.180 
The reagent 1,3-cyclohexadiene (5 mL) was added to a dark brown-orange solution of 
RuCl3•xH2O (1.21 g, 4.63 mmol) in EtOH (50 mL) and the resulting solution was 
refluxed for 4 h. The resulting brown precipitate was collected by filtration, washed with 
EtOH (25 mL) and diethyl ether (25 mL). Yield: 1.00 g (87%). 1H NMR (300 MHz, 
CD3CN): δ 5.70 (s, 6H, η6-benzene). 
 
[Ru(phpy)(NCCH3)4][PF6]. The Ru complex was prepared following reported 
procedures.181,182,183 The compounds [(η6-benzene)RuCl2]2 (760 mg, 1.52 mmol), NaOH 
(143 mg, 3.58 mmol) and KPF6 (1.123 g, 3.2 mmol) were suspended in CH3CN (25 mL) 
and 2-phenyl pyridine (0.44 mL, 3.10 mmol) was added. The light brown mixture was 
heated at 55°C for 22 hours and the resulting dark lime yellow suspension was reduced 
to dryness; the residue was dissolved in the minimal amount of CH2Cl2/CH3CN and was 
purified by FC (basic Al2O3, CH3CN/CH2Cl2, gradient from 5% to 35% CH3CN). The 
first yellow band was collected and reduced to ca. 5 mL. The lime yellow product was 
precipitated upon addition of diethyl ether/hexanes (1:1, 100 mL) and it was collected by 
filtration and washed with diethyl ether/hexanes (1:1, 100 mL). Yield: 1.06 g (62%). 1H 
NMR (500 MHz, CD3CN): δ 8.91 (d, 1H, 3J = 5.5, 4J = 1.0, H-8), 7.97 (dd, 1H, 3J = 7.5, 
4J = 1.0, H-1), 7.87 (d, 1H, 1H, 3J = 8.5, H-5), 7.74 (ddd, 1H, 3J = 8.0, 3J = 8.0, 4J = 1.5, 
H-6), 7.71 (dd, 1H, 3J = 8.0, 4J = 1.0, H-4), 7.15 (ddd, 1H, 3J = 7.5, 3J = 5.5, 4J = 1.5, H-
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7), 7.08 (ddd, 1H, 3J = 8.5, 3J = 8.5, 4J = 1.5, H-2), 6.94 (ddd, 1H, 3J = 8.5, 3J = 8.5, 4J = 
1.0, H-3), 2.51 (s, 3H, NCCH3), 2.14 (s, 3H, NCCH3), 2.00 (s, 6H, 2NCCH3). 
 
[Ru(phpy)(bpy)(dppn)] (2). A brown suspension of 9 (155 mg, 0.24 mmol) and dppn 
(81 mg, 0.24 mmol) in ethanol (20 mL) was heated to reflux. The solution became dark 
red in color within 5 min. After 8 h the dark red solution was reduced to dryness and the 
solid residue was purified by FC (SiO2, CH3CN/toluene, gradient from 10% to 30% 
CH3CN). The second red band was collected and the volume was reduced to ca. 15 mL. 
The dark red solid that precipitated was collected by filtration and washed with diethyl 
ether (25 mL). Yield: 97 mg (45%). 1H NMR (500 MHz, (CD3)2CO): δ 9.50 (dd, 1H, 3J 
= 8.0, 4J = 1.5, H-c or H-c’), 9.31 (dd, 1H, 3J = 8.0, 4J = 1.5, H-c’ or H-c), 8.97 (s, 1H, 
H-d or H-d’), 8.96 (s, 1H, H-d’ or H-d), 8.64 (d, 2H, 3J = 8.0, H-4’, H-5’), 8.52 (dd, 1H, 
3J = 5.5, 4J = 1.5, H-a or H-a’), 8.50 (dd, 1H, 3J = 5.5, 4J = 1.5, H-a’ or H-a), 8.31 (m, 
2H, H-f, H-f’), 8.21 (d, 1H, 3J = 8.0, H-5), 8.08 (d, 1H, 3J = 5.5, H-1’), 8.03-7.97 (m, 
5H, H-b or H-b’, H-4, H-3’, H-6’, H-8’), 7.90 (d, 1H, 3J = 5.5, H-8), 7.77 (m, 2H, H-b’ 
or H-b, H-6), 7.71 (m, 2H, H-e, H-e’), 7.45 (ddd, 1H, 3J = 7.5, 3J = 5.5, 4J = 1.5, H-2’), 
7.29 (ddd, 1H, 3J = 7.5, 3J = 5.5, 4J = 1.5, H-7’), 7.00 (m, 2H, H-3, H-7), 6.91 (ddd, 1H, 
3J = 7.5, 3J = 7.5, 4J = 1.5, H-2), 6.61 (dd, 1H, 3J = 7.5, 4J = 1.0, H-1). HRMS (ESI+): 
Calcd. for [C43H28N7Ru]+ ([M - PF6]+), 744.1450. Found: 744.1457. Anal. Calcd. for 
C43H28F6N7PRu.0.25H2O: C, 57.82; H, 3.22; N, 10.98. Found: C, 57.88; H, 3.21; N, 
10.89.  
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[Ru(phpy)(dppn)2] (3). A light brown suspension of [Ru(phpy)(NCCH3)4][PF6] (101 
mg, 0.18 mmol) and dppn (119 mg, 0.36 mmol) in ethanol (20 mL) was heated to reflux. 
The mixture turned to a dark brown-red solution within 5 minutes and after 8 h the 
resulting dark red solution was reduced to dryness. The solid residue was purified by FC 
(SiO2, CH3CN/toluene, gradient from 10% to 25% CH3CN). The first red band was 
collected and the volume was reduced to ca. 20 mL. The dark red solid precipitate was 
collected by filtration and washed with diethyl ether (25 mL). Yield: 113 mg (60%). 1H 
NMR (500 MHz, (CD3)2CO): δ 9.53 (dd, 1H, 3J = 8.0, 4J = 1.0, H-C), 9.45 (dd, 1H, 3J = 
8.0, 4J = 1.0, H-C), 9.27 (dd, 1H, 3J = 8.0, 4J = 1.0, H-C), 9.17 (dd, 1H, 3J = 8.0, 4J = 1.0, 
H-C), 9.07 (s, 1H, H-D), 9.01 (s, 1H, H-D), 8.98 (s, 1H, H-D), 8.83 (s, 1H, H-D), 8.68 
(dd, 1H, 3J = 5.5, 4J = 1.5, H-A), 8.62 (dd, 1H, 3J = 5.5, 4J = 1.5, H-A), 8.46 (dd, 1H, 3J 
= 5.5, 4J = 1.0, H-A), 8.41 (dd, 1H, 3J = 5.5, 4J = 1.0, H-A), 8.39-8.28 (m, 4H, H-F), 
8.22 (d, 1H, 3J = 8.5, H-5), 8.08 (d, 1H, 3J = 8.0, H-4), 8.06 (d, 1H, 3J = 5.0, H-8), 7.93-
7.83 (m, 3H, 2 H-B, H-6), 7.76-7.66 (m, 6H, 2 H-B, 4 H-E), 7.05 (ddd, 1H, 3J = 7.0, 3J = 
5.5, 4J = 1.5, H-7), 7.00 (ddd, 1H, 3J = 7.5, 3J = 7.5, 4J = 1.0, H-3), 6.92 (ddd, 1H, 3J = 
7.5, 3J = 7.5, 4J = 1.0, H-2), 6.83 (d, 1H, 3J = 7.5, H-1).  HRMS (ESI+): Calcd. for 
[C55H32N9Ru]+ ([M - PF6]+), 920.1824. Found: 920.1820. Anal. Calcd. for 
C55H32F6N9PRu.H2O: C, 61.00; H, 3.16; N, 11.64. Found: C, 60.98; H, 2.79; N, 11.59. 
 
[Ru(phpy)(phendione)2][PF6] (4). The ligand 1,10-phenanthroline-5,6-dione (112 mg, 
0.53 mmol) was added to a yellow suspension of [Ru(phpy)(NCCH3)4][PF6] (150 mg, 
0.26 mmol) in ethanol (15 mL) and the mixture was heated to reflux for 5 h. The 
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resulting dark red solution was reduced to dryness and the residue was purified by FC 
(SiO2, CH3CN/CH2Cl2, gradient from 10% to 35% CH3CN). The main red band was 
collected and reduced to ca. 10 mL. Diethyl ether (15 mL) was added slowly and the 
flask was left in the refrigerator overnight. The dark red (almost black) microcrystalline 
solid was collected by filtration and washed with diethyl ether (3 x 15 mL). Yield: 115 
mg (53%). 1H NMR (500 MHz, CD3CN): δ 8.50 (dd, 1H, 3J = 8.0, 4J = 1.0), 8.33 (m, 
2H), 8.30 (dd, 1H, 3J = 8.0, 4J = 1.0), 8.26 (dd, 1H, 3J = 5.5, 4J = 1.0), 8.23 (dd, 1H, 3J = 
5.5, 4J = 1.0), 8.09 (d, 1H, 3J = 8.0), 8.07 (dd, 1H, 3J = 5.5, 4J = 1.5), 8.04 (dd, 1H, 3J = 
5.5, 4J = 1.0), 7.91 (dd, 1H, 3J = 8.0, 4J = 1.0), 7.78 (ddd, 1H, 3J = 8.0, 3J = 7.5, 4J = 1.5), 
7.70 (d, 1H, 3J = 5.5), 7.66 (dd, 1H, 3J = 8.0, 3J = 5.5), 7.49-7.42 (m, 3H), 7.03-6.95 (m, 
2H), 6.91 (ddd, 1H, 3J = 7.5, 3J = 7.5, 4J = 1.5), 6.60 (dd, 1H, 3J = 7.5, 4J = 1.0). 19F 
NMR (282 MHz, CD3CN): δ −97.1 (d, 1JF-P = 704, PF6−). 31P[1H]  NMR (121 MHz, 
CD3CN): δ −143.2 (septet, 1JP-F = 704, PF6−). HRMS (ESI+): Calcd. for 
[C35H20N5O4Ru]+ ([M - PF6]+), 676.0559. Found: 676.0590. Anal. Calcd. for 
C35H20N5O4F6PRu·4H2O: C, 47.09; H, 3.16; N, 7.85;. Found: C, 47.18; H, 3.06; N, 7.94. 
 
[Ru(phpy)(biq)2][PF6] (5). The ligand 2,2’-biquinoline (100 mg, 0.39 mmol) was added 
to a yellow suspension of [Ru(phpy)(NCCH3)4][PF6] (103 mg, 0.18 mmol) in ethanol 
(15 mL) and the mixture was heated to reflux for 5 h. The resulting dark green solution 
was reduced to dryness and the residue was purified by FC (SiO2, CH3CN/CH2Cl2, 
gradient from 1% to 12% CH3CN). The first green band was collected and reduced to 
dryness. The residue was dissolved with CH2Cl2 (10 mL), hexanes (8 mL) was added 
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slowly and the green precipitate was collected by filtration and washed with  
CH2Cl2/hexanes 1:1 (3 x 20 mL). Yield: 130 mg (78%). 1H NMR (500 MHz, CD3CN): δ 
8.93 (d, 1H, 3J = 8.5), 8.84 (d, 1H, 3J = 8.5), 8.78 (d, 1H, 3J = 9.0), 8.70 (d, 1H, 3J = 8.5), 
8.64 (d, 1H, 3J = 9.0), 8.60 (d, 1H, 3J = 9.0), 8.28 (d, 1H, 3J = 8.5), 8.24 (d, 1H, 3J = 9.0), 
8.04 (dd, 1H, 3J = 8.0, 4J = 1.5), 7.96 (dd, 1H, 3J = 8.0, 4J = 1.5), 7.73 (dd, 1H, 3J = 8.0, 
4J = 1.5), 7.62 (d, 2H, 3J = 8.5), 7.43-7.33 (m, 4H), 7.31 (ddd, 1H, 3J = 8.0, 3J = 6.5, 4J = 
1.0), 7.27 (m, 2H), 7.22 (ddd, 1H, 3J = 8.0, 3J = 6.5, 4J = 1.0), 7.13 (d, 1H, 3J = 8.0), 7.08 
(d, 1H, 3J = 9.0), 6.94 (m, 2H), 6.88 (ddd, 1H, 3J = 8.5, 3J = 7.0, 4J = 1.5), 6.85-6.79 (m, 
3 H), 6.66 (ddd, 1H, 3J = 8.5, 3J = 7.0, 4J = 1.5), 6.31 (ddd, 1H, 3J = 7.5, 3J = 7.5, 4J = 
1.5), 6.25 (dd, 1H, 3J = 8.0, 4J = 1.0). 19F NMR (282 MHz, CD3CN): δ −72.8 (d, 1JF-P = 
704, PF6−). 31P[1H]  NMR (121 MHz, CD3CN): δ −143.2 (septet, 1JP-F = 704, PF6−). 
HRMS (ESI+): Calcd. for [C47H32N5Ru]+ ([M - PF6]+), 768.1701. Found: 768.1691. 
Anal. Calcd. for C47H32N5F6PRu·0.5H2O: C, 61.24; H, 3.61; N, 7.60;. Found: C, 61.40; 
H, 3.66; N, 7.61. 
 
[Ru(phpy)(pap)(NCCH3)2][PF6] (6). [Ru(phpy)(NCCH3)4][PF6] (240 mg, 0.43 mmol) 
was added to an orange solution of 2-phenylazopyridine (78 mg, 0.42 mmol) in CH2Cl2 
(20 mL). The resulting solution acquired a dark red color within 10 minutes. After 18 h 
of stirring at room temperature, the dark magenta solution was reduced to dryness under 
reduced pressure and the residue was purified by FC (basic Al2O3, CH3CN/CH2Cl2, 
gradient from 2% to 20% CH3CN). The second bright magenta band was collected and 
was reduced to ca. 20 mL. A mixture of diethyl ether/hexanes (1:1, 80 mL) was added 
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and the magenta precipitate was collected by filtration and washed with hexanes (3 x 30 
mL). Yield: 214 mg (76%). 1H NMR (500 MHz, CD3CN): δ 9.18 (d, 1H, 3J = 5.5, H-1’), 
8.57 (d, 1H, 3J = 8.0, H-4’), 8.30 (ddd, 1H, 3J = 8.0, 3J = 8.0, 4J = 1.5, H-3’), 8.06 (ddd, 
1H, 3J = 7.0, 3J = 5.5, 4J = 1.5, H-2’), 7.76 (m, 2H, H-1, H-5), 7.67 (ddd, 1H, 3J = 7.5, 3J 
= 7.5, 4J = 1.5, H-6), 7.56 (dd, 1H, 3J = 8.0, 4J = 1.0, H-4), 7.14 (m, 1H, H-p), 7.05 (ddd, 
1H, 3J = 7.5, 3J = 7.5, 4J = 1.0, H-2), 7.00 (m, 2H, H-m), 6.92 (d, 1H, 3J = 5.5, H-8), 6.87 
(ddd, 1H, 3J = 7.5, 3J = 7.5, 4J = 1.0, H-3), 6.83-6.77 (m, 3H, H-7, H-o), 2.40 (s, 3H, 
NCCH3), 2.29 (s, 3H, NCCH3). 19F NMR (282 MHz, CD3CN): δ −71.1 (d, 1JF-P = 704, 
PF6−). 31P[1H] NMR (121 MHz, CD3CN): δ −147.7 (septet, 1JP-F = 704, PF6−). MS 
(ESI+): 439.04 ([M - 2CH3CN - PF6]+), 480.07 ([M - CH3CN - PF6]+).  Anal. Calcd. for 
C26H23F6N6PRu: C, 46.92; H, 3.48; N, 12.63. Found: C, 46.90; H, 3.54; N, 12.64.  
 
[Ru(phpy)(pap)(dcmb)][PF6] (7). A mixture of 6 (650 mg, 0.98 mmol) and 4,4′-
dicarboxymethyl-2,2′-bipyridine (315 mg, 1.16 mmol) in methanol (25 mL) was heated 
to reflux for 24 h. The dark red solution was reduced to dryness and the residue was 
purified by FC (SiO2, CH3CN/CH2Cl2, gradient from 0% to 20% CH3CN). The second 
dark red band was collected and the solvent was removed under reduced pressure. The 
solid residue was triturated with diethyl ether, collected by filtration and washed with 
CH2Cl2/diethyl ether (1:2.5; 3 x 30 mL). Yield: 400 mg (50%). 1H NMR (500 MHz, 
CD3CN): δ 9.01 (d, 1H, 4J = 1.0, H-c or H-c’), 8.98 (d, 1H, 4J = 1.0, H-c’or H-c), 8.53 
(d, 1H, 3J = 8.0, H-4’), 8.30 (dd, 1H, 3J = 5.5, H-a), 8.03 (dd, 1H, 3J = 5.5, H-a’), 7.98 
(m, 2H, H-3 and H-b or H-b’), 7.85-7.78 (m, 4H, H-4, H-5, H-1’ and H-b’ or H-b), 7.57 
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(ddd, 1H, 3J = 8.5, 3J = 7.5, 4J = 1.5, H-6), 7.43 (ddd, 1H, 3J = 7.5, 3J = 5.5, 4J = 1.5, H-
2’), 7.25 (m, 1H, H-p), 7.17 (d, 1H, 3J = 5.5 Hz, H-8), 7.11 (m, 3H, H-m and H-3), 7.05 
(m, 3H, H-o and H-2), 6.72 (ddd, 1H, 3J = 7.5, 3J = 5.5, 4J = 1.5, H-7), 5.95 (dd, 1H, 3J = 
7.5, 4J = 1.0, H-1), 4.00 (s, 3H, -CO2CH3), 3.96 (s, 3H, -CO2CH3). 19F NMR (282 MHz, 
CD3CN): δ −73.7 (d, 1JF-P = 704, PF6−). 31P[1H] NMR (121 MHz, CD3CN): δ −144.6 
(septet, 1JP-F = 704, PF6−). MS (ESI+): 711.14 ([M - PF6 + H]+). Anal. Calcd. for 
C36H29N6O4F6PRu·0.5(C2H5)2O: C, 51.12; H, 3.84; N, 9.41. Found: C, 51.21; H, 3.93; 
N, 9.48. 
 
[Ru(phpy)(pap)(dppn)][PF6] (8). A suspension of 6 (82 mg, 1.12 mmol) and dppn (44 
mg, 0.13 mmol) in methanol (20 mL) was heated to reflux for 24 h. The dark red-
magenta solution was reduced to dryness and the residue was purified by FC (SiO2, 
CH3CN/CH2Cl2, gradient from 5% to 10% CH3CN). The first red band was collected 
and the solvent was removed under reduced pressure. The solid residue was triturated 
with hexanes, collected by filtration and washed with hexanes (50 mL). Yield: 97 mg 
(86%). 1H NMR (500 MHz, CD3CN): δ 9.27 (dd, 1H, 3J = 8.0, 4J = 1.5, H-c or H-c’), 
9.15 (dd, 1H, 3J = 8.0, 4J = 1.5, H-c’ or H-c), 8.63 (s, 1H, H-d or H-d’), 8.57 (m, 2H, H-a 
or H-a’, H-4), 8.52 (s, 1H, H-d’ or H-d), 8.10 (dd, 1H, 3J = 5.5, 4J = 1.5, H-a’ or H-a), 
8.08 (m, 1H, H-e or H-e’), 8.02-7.93 (m, 4H, H-e’ or H-e, H-4, H-5, H-3’), 7.92 (d, 1H, 
3J = 5.5, H-1’), 7.86 (dd, 1H, 3J = 8.0, 3J = 5.0, H-b or H-b’), 7.64-7.59 (m, 2H, H-b’ or 
H-b, H-6), 7.56-7.50 (m, 2H, H-f and H-f’), 7.43-7.39 (m, 2H, H-8, H-2’), 7.33 (m, 1H, 
H-p), 7.26-7.17 (m, 5H, H-3, H-o, H-m), 7.14 (ddd, 1H, 3J = 8.0, 3J = 8.0, 4J = 1.0, H-2), 
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6.72 (ddd, 1H, 3J = 8.0, 3J = 5.5, 4J = 1.5, H-7), 6.12 (dd, 1H, 3J = 5.5, 4J = 1.0, H-1). 
HRMS (ESI+): Calcd. for [C44H29N8Ru]+ ([M - PF6]+), 771.1559. Found: 771.1535. 
Anal. Calcd. for C44H29N8F6PRu·0.5H2O: C, 57.15; H, 3.27; N, 12.12. Found: C, 57.26; 
H, 3.48; N, 12.11. 
 
[Ru(phpy)(bpy)(NCCH3)2] (9). The Ru complex was prepared following reported 
procedures.182,183 A solution of [Ru(phpy)(NCCH3)4][PF6] (200 mg, 0.35 mmol) and bpy 
(51 mg, 0.33 mmol) in CH2Cl2 (15 mL) was stirred at room temperature under reduced 
light conditions. After 20 h, the dark orange solution was reduced to dryness and 
purified by FC (basic Al2O3, CH3CN/CH2Cl2, gradient from 0% to 30% CH3CN). The 
orange band was collected, reduced ca. 2 mL and diluted with CH2Cl2/CH3CN (1:1, 10 
mL). Diethyl ether was added slowly until a small amount of solid precipitated and the 
flask was stored at 0°C overnight. The dark orange crystals that had formed were 
collected by filtration and washed with diethyl ether (30 mL). Yield: 150 mg (77%). 1H 
NMR (500 MHz, CD3CN): δ 9.37 (d, 1H, 3J = 5.0, H-1’), 8.45 (d, 1H, 3J = 8.0, H-4’), 
8.22 (m, 2H, H-1 and H-5’), 8.17 (ddd, 1H, 3J = 8.0, 3J = 8.0, 4J = 1.5, H-3’), 7.90 (d, 
1H, 3J = 6.0, H-8’), 7.87-7.82 (m, 3H, H-4, H-5 and H-2’), 7.67 (ddd, 1H, 3J = 8.0, 3J = 
8.0, 4J = 1.5, H-6’), 7.54 (ddd, 1H, 3J = 8.0, 3J = 8.0, 4J = 1.5, H-6), 7.45 (d, 1H, 3J = 6.0, 
H-8), 7.25 (ddd, 1H, 3J = 7.5, 3J = 7.5, 4J = 1.5, H-2), 7.07 (ddd, 1H, 3J = 8.0, 3J = 8.0, 4J 
= 1.5, H-3), 7.01 (ddd, 1H, 3J = 7.5, 3J = 6.0, 4J = 1.5, H-7’), 6.74 (ddd, 1H, 3J = 7.5, 3J 
= 6.0, 4J = 1.5, H-7), 2.23 (s, NCCH3), 2.18 (s, NCCH3). 
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Figure 3. 4 Numbering scheme used to assign the 1H NMR spectra of selected Ru 
complexes. 
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X-Ray Crystallography 
 
Single crystals of 5 were obtained by slow diffusion of hexanes into a CH2Cl2 
solution of the compound in a thin diameter tube at room temperature. Single crystals of 
6 were obtained by slow diffusion of hexanes into a CH2Cl2/CH3CN solution of the 
compound in a thin tube at room temperature. Single crystals of 7 were obtained by slow 
evaporation of a CH2Cl2/ethyl acetate solution of the compound at room temperature. 
Single crystals of 9 were obtained by keeping a CH2Cl2/CH3CN/diethyl ether solution of 
the compound at 0°C. X-ray data was collected on a Bruker APEX II CCD X-ray 
diffractometer equipped with a graphite monochromated MoKα radiation source (λ = 
0.71073 Å). The data sets were integrated with the Bruker SAINT software package.148 
The absorption correction (SADABS)149 was based on fitting a function to the empirical 
transmission surface as sampled by multiple equivalent measurements. Solution and 
refinement of the crystal structures was carried out using the SHELX150 (2013) suite of 
programs and the graphical interface ShelXle151 was used for the refinement. The 
structures were solved by direct (5, 6, 7) or Patterson methods (9) and all non-hydrogen 
atoms were refined with anisotropic displacement parameters using a full-matrix least-
squares technique on F2. Hydrogen atoms were fixed to parent atoms and refined using 
the riding model. PLATON/SQUEEZE was employed in the case of 6 after attempts to 
model disordered ethyl acetate solvent molecules failed. The SAME, SIMU AND DELU 
restrains were applied during the refinement of the structure of 9 to model the disorder of 
the [PF6]– anion.  
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Cell Culture Details 
 
Cell culture reagents and 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium 
bromide (MTT)  were purchased from Invitrogen.  The HeLa cell line was obtained from 
the American Type Culture Collection, cell line CCL-2.  HeLa cells were cultured in 
Dulbecco’s modified Eagle medium, supplemented with 10% fetal bovine serum (Life 
Technologies), 50 µg/mL gentamicin, 4.5 mg/mL glucose, and 4 mM L-glutamine 
(Invitrogen Life Technology). Cell cultures were incubated in a humidified atmosphere 
containing 5% CO2 at 37°C.  
 
In Vitro Cytotoxicity, SYTOX® Green and MitoProbe® JC-1 Assay 
 
Cytotoxicity and live cell imaging studies of compounds 1, 2, 4, 5 and 8 were 
performed by Amanda David (Dunbar Group, Chemistry Department, Texas A&M 
University) in collaboration with Professor Jean-Philippe Pellois (Department of 
Biochemistry and Biophysics, Texas A&M University). The experimental procedures for 
these assays have been excluded from this dissertation because they will be included in 
Amanda David’s dissertation. Details of the procedure can be found in the literature 
since this work has been recently published (Peña, B; David, A.; Pavani, C.; Baptista, M. 
S.; Pellois, J. P.; Turro, C.; Dunbar, K. R. Organometallics 2014, 33, 1100-1103). 
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Phototoxicity of Complex 5 
 
These experiments were performed in collaboration with Professor Mauricio S. 
Baptista (Department of Biochemistry, University of São Paulo, São Paulo, Brazil). Cell 
viability for phototoxicity studies was undertaken using two 48-well plates with density 
of 1.5 × 104 HeLa cells per well. The plates were maintained in DMEM (Dulbecco's 
Minimum Eagle Medium) supplemented with 10% FCS (fetal calf serum) and 1% 
penicillin/streptomycin, in an incubator at 37oC in a humid atmosphere with 5% CO2 for 
18 to 24 h. The plates were washed with PBS and DMEM 1% FCS solutions containing 
the desired concentration of complex were added to the plates. After 24 h incubation, 
each well was washed with PBS and fresh PBS was added to the wells. One plate was 
then irradiated for 20 min (LED system 633 ± 20nm; 6.50 mW/cm2) while the other was 
kept in the dark during that time. After irradiation, PBS was replaced with DMEM 1% 
FCS, and the plates were kept in the in the incubator at 37oC in 5% CO2 for an additional 
48 h, at which time the MTT assay was conducted using typical methods.   
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Theoretical Calculations 
 
Density functional theory (DFT) calculations were performed with the 
Gaussian09 package184 using the Becke’s three-parameter hydrid functional and the Lee-
Yang-Parr’s gradient-corrected correlation functional (B3LYP).185,186 The Stuttgart RSC 
1997 Electron Core Potential187 (ECP) basis set and effective core potential were used 
for the Ru atom and the split-valence 6-311G* basis set was used for C, H, N and O. The 
geometry optimizations were performed using the polarized continuum medium model 
(PCM, acetonitrile) to include solvent polarization effects and without symmetry 
restraints, with subsequent frequency analysis. The molecular orbitals (MOs) were 
plotted with Ampac GUI 9 (Semichem, Inc; www.semichem.com) with the isovalue = 
0.04. Fragment contributions to the MOs were calculated using the Chemissian v2.2 
software (www.chemissian.com). Time-dependent density functional theory (TD-DFT) 
calculations were performed to arrive at the vertical singlet excited states for each 
complex from the corresponding optimized singlet ground state geometry using the PCM 
model with acetonitrile as the solvent.  
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Results and Discussion 
 
Synthesis and Characterization of Compounds 1–5   
 
Compounds 1,179 [Ru(phpy)(bpy)(NCCH3)2][PF6] (9)182 and the starting material 
to prepare complexes 2–5, [Ru(phpy)(NCCH3)4][PF6]181,182,183  (Figure 3.5), were 
synthesized according to reported procedures.  
 
 
 
 
 
Figure 3. 5 Reaction scheme for the synthesis of 2–5. 
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Compounds 3–5 were prepared in 60%, 78% and 53% yields, respectively, by 
heating a suspension of [Ru(phpy)(NCCH3)4][PF6] and 2 eq of bidentate ligand (dppn, 
phendione and biq, respectively) to reflux in ethanol (Figure 3.5). The synthesis of the 
tris-heteroleptic compound 2 required an additional step. First, 
[Ru(phpy)(bpy)(NCCH3)2][PF6] (9) was prepared by reacting [Ru(phpy)(NCCH3)4][PF6] 
with 1 eq of bpy in CH2Cl2 at room temperature and under reduce light conditions. The 
two remaining acetonitrile ligands in 9 were substituted by dppn in refluxing ethanol to 
afford 2 in a 45% yield (Figure 3.5). Compounds 2–4 were obtained as dark red solids, 
whereas 5 has a dark green color. In all cases, the compounds were purified by flash 
column chromatography with silicagel using CH3CN/CH2Cl2 or CH3CN/toluene 
mixtures as eluent.  
The new complexes were characterized by electrospray ionization mass 
spectrometry (ESI+), elemental analyses and NMR spectroscopies (1H, 1HH COSY, 19F 
and 31P). Their ESI(+) mass spectra contain only one peak corresponding to the [M - 
PF6]+ cation and their C1 symmetric structures were confirmed by 1H NMR 
spectroscopy. There is an upfield doublet resonance in the 1H NMR spectra of 2–5 in the 
6.83–6.25 ppm range that is characteristic of the proton ortho to the organometallic Ru–
C bond in Ru(II) cyclometallated complexes.179  
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The X-ray structures of the compounds 5 and 9 are depicted in Figure 3.6 and the 
crystallographic data is compiled in Tables 3.1–3.3. Single crystals of 5 were grown by 
slow diffusion of hexanes into a dichloromethane solution of the compound at room 
temperature. The compound crystallizes in the monoclinic space group P21/n and there 
are two interstitial dichloromethane molecules in the asymmetric unit. The coordination 
sphere of the metal center consists of five N atoms and one C– atom in a distorted 
octahedral environment. The Ru1–C1 bond length of 2.095(4) Å is longer than the 
corresponding bond distances in [Ru(phpy)(bpy)2]+ (2.044(1) Å188) and 
[Ru(phpy)(phen)2]+ (2.036(7) Å175) which is  attributed to the steric repulsion between 
the biq ligands. Three of the Ru–N bond legths with the biq ligands, Ru1–N2, Ru1–N4 
and Ru1–N5, are similar (~2.09 Å) and within the range of those found in the closely 
related compounds [Ru(bpy)(biq)2]2+ and [Ru(bpy)2(biq)]2+ (2.079(2) to 2.112(3) Å).189 
In contrast, the Ru1–N3 bond located trans to C1 is the longest, 2.148(3) Å, reflecting 
the strong trans influence of the phenyl ring of phpy. The angle between adjacent biq 
ligands (N3–Ru1–N4) is 98.3(1)° and is larger than the angles formed between each biq 
and phpy ligands, viz., N1–Ru1–N3 and C1–Ru1–N4, which are 90.8(1) and 92.4(2)°, 
respectively. The more obtuse N3–Ru1–N4 angle is likely a consequence of steric 
repulsion between the two bulky biq ligands. The biq ligand trans to the C1 atom of 
phpy is twisted about the C–C bond (N2–C20–C21–N3, –9.9(6)°) whereas such a 
distortion is not observed in the other biq ligand (N4–C38–C39–N5, 0.9(6)°). In 
addition, the quinoline moieties of both biq ligands are bent by ~15° out of the plane 
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formed with the metal center, a distortion that was also observed in 
[Ru(biq)2(bpy)][PF6]2.189  
 
 
 
 
Figure 3. 6 Thermal ellipsoid plots at the 50% probability level of the X-ray structures 
of [Ru(phpy)(biq)2][PF6] (5, top) and [Ru(phpy)(bpy)(NCCH3)2][PF6] (9, bottom). The 
[PF6]– anions and H atoms have been omitted for the sake of clarity. 
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Table 3. 1 Crystal Structural Data and Refinement Parameters for the compounds 
[Ru(phpy)(biq)2][PF6]·2CH2Cl2 (5) and [Ru(phpy)(bpy)(NCCH3)2][PF6]·NCCH3 (9). 
 
Compound 5 9 
CCDC number 961134 980890 
Empirical Formula C49H36N5F6Cl4PRu C27 H25 F6 N6 P Ru 
Formula weight 1082.67 679.57 
Temperature, K 291(2) 110(2) 
Crystal system Monoclinic Triclinic 
Space group P21/n P–1 
Unit cell dimensions a = 13.314(3), α = 90 
b = 22.497(5), β = 100.67(3) 
c = 15.709(3), γ = 90 
a = 9.5728(19), α = 102.34(3) 
b = 12.372(3), β = 106.91(3) 
c = 12.792(3), γ = 94.04(3) 
Volume, Å3 4623.8(16) 1401.7(6) 
Z 4 2 
Density, g/cm3 1.555 1.610 
Absorption coefficient, mm-1 0.671 0.685 
F(000) 2184 684 
Crystal color, morphology green, needle orange, needle 
Crystal size, mm3 0.37 × 0.14 × 0.10 0.17 × 0.07 × 0.06  
Reflections collected 49647 15519 
Independent reflections 10375 [Rint = 0.0609] 5921 [Rint = 0.0311] 
Data/restraints/parameters 10375/595/0 5921/ 0 / 373 
Goodness-of-fit on F2 1.075 1.046 
R indices [I>2sigma(I)] R1 = 0.0637 
wR2 = 0.1918 
R1 = 0.0367 
wR2 = 0.0886 
R indices (all data) R1 = 0.0828,  
wR2 = 0.2107 
R1 = 0.0444 
wR2 = 0.0936 
Largest diff. peak, hole, e/Å3 1.82 / –1.23 1.33 / –0.78 
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Table 3. 2 Selected bond dustances and angles for [Ru(phpy)(biq)2][PF6]·2CH2Cl2 (5). 
 
Bond lengths (Å) Bond angles (°) 
Ru1–C1 
Ru1–N1 
Ru1–N2 
Ru1–N3 
Ru1–N4 
Ru1–N5 
2.095(4) 
2.087(4) 
2.092(3) 
2.148(3) 
2.091(4) 
2.096(3) 
C1–Ru1–N1 
N2–Ru1–N3 
N4–Ru1–N5 
N1–Ru1–N3 
N3–Ru1–N4 
C1–Ru1–N4 
78.8(2) 
76.8(1) 
76.7(1) 
90.8(1) 
98.3(1) 
92.4(2) 
Dihedral angles (°) 
N2–C20–C21–N3 
C19–C20–C21–C22 
N4–C38–C39–N5 
C37–C38–C39–C40 
N2–Ru1–N3–C29 
N4–Ru1–N5–C47 
–9.9(6) 
–11.9(8) 
–0.9(6) 
0.9(8) 
–165.1(4) 
166.2(4) 
 
 
 
Table 3. 3 Selected bond distances and angles for 
Ru((phpy)(bpy)(NCCH3)2][PF6]·NCCH3 (9). 
 
Bond lenghts (Å) Bond and dihedral angles (°) 
Ru1–C1 
Ru1–N1 
Ru1–N2 
Ru1–N3 
Ru1–N4 
Ru1–N5 
2.026(3) 
2.055(3) 
2.042(2) 
2.145(3) 
2.028(3) 
2.022(3) 
C1–Ru1–N1 
N2–Ru1–N3 
N4–Ru1–N5 
C1–Ru1–N3 
N1–Ru1–N4 
N2–Ru1–N5 
N1– C7–C6–C1 
N2– C16–C17–N3 
79.8(1) 
77.94(9) 
88.3(1) 
174.7(1) 
173.7(1) 
172.6(1) 
–0.6(3) 
0.3(3) 
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The crystal packing of compound 5 displays π-π stacking interaction between the 
biquinoline moieties of different [Ru(phpy)(biq)2]+ cations (Figure 3.7), with an 
interplanar distance of 3.52 Å and shortest centroid-centroid distance of 4.06 Å. The 
parallel displacement was measured by the angle formed between the ring centroid 
vector and the distance normal to one of the planes157,158 and was calculated as 30°. 
Single crystals of 9 were grown by keeping a solution of acetonitrile/diethyl ether 
of the compound at 0°C. The compound crystallizes in the triclinic space group P–1 with 
one acetonitrile solvent molecule in the asymmetric unit. The distorted octahedral 
coordination sphere around the Ru ion contains by five N and one C– atom donors; the 
Ru–C bond distance (2.026(3) Å) is similar to the value observed in 
[Ru(phpy)(phen)(NCCH3)2]+ (2.029(3) Å).190 The longest Ru–N bond (Ru–N3, 2.145(3) 
Å) is the one trans to the Ru–C bond and the rest of the Ru–N bond distances are similar 
to the distances reported for [Ru(phpy)(phen)(NCCH3)2]+.190 Intermolecular π-π stacking 
interactions are also observed between the cations of this complex (Figure 3.8), where 
the bpy ligands are parallel displaced with an interplanar distance, shortest centroid-
centroid distance and displacement angle of 3.31 Å, 3.76 Å and 28°, respectively.  
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Figure 3. 7 Intermolecular π-π stacking interactions in the crystal packing of compound 
5. (a) Shortest centroid-centroid distance and slippage angle and (b) space filling model 
highlighting the stacking of π -systems of biquinolime moieties. 
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Figure 3. 8 Space filling model highlighting intermolecular π-π interactions in the 
crystal packing of compound 9.  
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Synthesis and Characterization of Compounds 6–8 
 
Compound 6 was prepared by reacting [Ru(phpy)(NCCH3)4][PF6] with 1 eq of 
pap in CH2Cl2 at room temperature under reduced light conditions and was obtained as a 
magenta solid in 76% yield after flash chromatography in basic Al2O3. This compound 
may exist as different geometric isomers due to the asymmetry of both phpy and pap 
ligands, but only one isomer is produced under this experimental conditions. Since the 
longest Ru–N bond in [Ru(phpy)(NCCH3)4][PF6] corresponds to the acetonitrile ligand 
trans to the Ru–C bond,182 this coordination position will be occupied by one of the two 
N atom donors of pap in 6, and if it is assumed that there is a cis configuration of the two 
acetonitrile ligands, two geometric isomers are possible for 6, as shown in Figure 3.9. 
There are two singlet proton resonances at 2.29 and 2.40 ppm in the 1H NMR 
spectrum of 6 which corresponds to the methyl groups of the two acetonitrile ligands, as 
expected for a cis configuration. The proton resonances of the pyridyl moiety of pap (H-
1’ to H-4’, Figure 3.10) appear downfield with respect to the phpy protons. The proton 
ortho to the N atom in the pyridyl ring of pap, H-1’, appears at 9.18 ppm and it is the 
most deshielded; therefore, it must be directed toward one acetonitrile ligand. This 
characteristic has also been observed for the same pyridyl proton of bpy in cis-
[Ru(phpy)(bpy)(NCCH3)2]+ (9.35 ppm)182  and cis-[Ru(phpy4thio)(bpy)(NCCH3)2]+ 
(9.44 ppm, where phpy4thio = orthometallated 5-[3-(pyridin-2-yl)phenyl]thiophene-2-
carbaldehyde).183 Geometric isomer B is ruled out because H-1’ is pointing toward the 
 150 
 
phenyl ring in this geometric isomer and it would appear upfield, at ca. 7–8 ppm, due to 
ring current effects.  
 
 
 
 
 
Figure 3. 9 Possible geometric isomers of compound 6 with cis arrangement of 
acetonitrile ligands 
 
 
 
The proton ortho to the N atom in phpy (H-8) appears at 6.92 ppm, which is ~2 
pm upfield with respect to its chemical shift in [Ru(phpy)(NCCH3)4]+ (8.91 ppm, Figure 
3.10) as a consequence of being shielded by the adjacent pyridyl ring of the pap ligand.  
The proton that is ortho to the Ru–C bond (H-1) has a similar chemical shift in 6 and 
[Ru(phpy)(NCCH3)4]+ (~0.2 ppm difference) confirming that is directed at an 
acetonitrile ligand as in the tetrakis(acetonitrile) compound. It can also be observed that 
protons H-1 to H-7 in both [Ru(phpy)(NCCH3)4]+ and 6 appear at approximately the 
same chemical shift (within 0.03–0.33 ppm), whereas the chemical shift for H-8 is 
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drastically changed as described above. The proposed structure of 6 was confirmed by 
X-ray crystallography (see below). 
 
 
 
 
 
Figure 3. 10 Comparison of the proton resonances in the aromatic region of 
[Ru(phpy)(NCCH3)4]+ and [Ru(phpy)(pap)(NCCH3)2] (6).  
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Substitution of the acetonitrile ligands in 6 was explored to demonstrate its 
suitability as precursor for expanding the structural diversity of Ru cyclometallated 
compounds. Reaction of 6 with 1 eq of dcmb (4,4′-dicarboxymethyl-2,2′-bipyridine) or 1 
eq of dppn in refluxing MeOH afforded the tris-heteroleptic compounds 7 and 8, 
respectively. Both compounds were also obtained as single geometric isomers. The X-
ray structures of compounds 6 and 7 are shown in Figure 3.11 and the crystallographic 
data are compiled in Tables 3.4–3.6. Compounds 6 and 7 crystallize in the monoclinic 
space groups P21/c and C2/c, respectively. The metal center is located in a distorted 
octahedral environment in both compounds. The geometric isomer proposed for 6 is in 
agreement with its X-ray structure.  
The Ru1–C1 bond lengths of 6 and 7 (2.039(4) and 2.047(4) Å, respectively) are 
similar to those observed for related cyclometallated compounds.169,182 The Ru–N bond 
in the trans position to the Ru1–C1 bond is the longest in both complexes (Ru1–N4, 
2.125(4), and Ru1–N2, 2.127(3) Å, respectively) due to the strong trans influence of 
phpy. The Ru–N bond with the azo moiety is the shortest in both compounds (Ru1–N6 
1.960(3) and 1.944(3) Å, respectively) because of increased -backbonding into the azo 
moiety to stabilize the additional electron density on the metal center donated by phpy, 
which is also accompanied by an elongation of the N–N bond of the azo group (1.304(5) 
and 1.306(5) Å, respectively) with respect to uncoordinated pap (1.25 Å).191 There is a 
small deviation from planarity between the pyridyl and phenyl rings (torsion angle ~5°) 
of phpy in 6 and 7. The pyridyl ring and the N–N azo bond of pap are essentially 
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coplanar in both compounds, but this moiety is not coplanar with the phenyl ring within 
the same ligand and they exhibit a torsion angle of 125° and 136°, respectively.  
 
 
 
 
 
Figure 3. 11 Thermal ellipsoid plots at the 50% probability level of the X-ray structures 
of compounds [Ru(phpy)(pap)(NCCH3)2][PF6] (6, top) and [Ru(phpy)(pap)(dcmb)][PF6] 
(7, bottom). The [PF6]– anions and H atoms have been omitted for the sake of clarity.  
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Table 3. 4 Crystal Structural Data and Refinement Parameters for the compounds 
[Ru(phpy)(pap)(NCCH3)2][PF6] (6) and [Ru(phpy)(pap)(dcmb)][PF6] (7). 
 
Compound 6 7 
CCDC number 978317 978318 
Empirical Formula C26H23F6N6PRu C36H29F6N6O4PRu 
Formula weight 665.54 855.69 
Temperature, K 110(2) 110(2) 
Crystal system Monoclinic Monoclinic 
Space group P21/c C2/c 
Unit cell dimensions a = 8.3581(17), α = 90 
b = 13.855(3), β = 92.49(3) 
c = 23.624(5), γ = 90 
a = 47.073(9), α = 90 
b = 7.9141(16), β = 104.83(3) 
c = 22.064(4), γ = 90 
Volume, Å3 2733.1(10) 7946(3) 
Z 4 8 
Density, g/cm3 1.617 1.431 
Absorption coefficient, mm-1 0.701 0.507 
F(000) 1336 3456 
Crystal color, morphology red, block purple, plate 
Crystal size, mm3 0.34 × 0.13 × 0.10 0.23 × 0.10 × 0.03 
Reflections collected 18651 40551 
Independent reflections 4952 [Rint = 0.0309] 8091 [Rint = 0.0810] 
Data/restraints/parameters 4952 / 0 / 363 8091 / 0 / 489 
Goodness-of-fit on F2 1.112 1.045 
R indices [I>2sigma(I)] R1 = 0.044 
wR2 = 0.1054 
R1 = 0.0471 
wR2 = 0.1062 
R indices (all data) R1 = 0.0526 
wR2 = 0.1167 
R1 = 0.0757 
wR2 = 0.1171 
Largest diff. peak/hole, e/Å3 1.40 / –0.77 1.01 / –1.08 
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Table 3. 5 Selected bond distances and angles for [Ru(phpy)(pap)(NCCH3)2][PF6] (6). 
 
Bond lenghts (Å) Bond and dihedral angles (°) 
Ru1–C1 
Ru1–N1 
Ru1–N2 
Ru1–N3 
Ru1–N4 
Ru1–N6 
N5–N6 
2.039(4) 
2.049(4) 
2.047(4) 
2.056(4) 
2.125(4) 
1.960(3) 
1.304(5) 
C1–Ru1–N1 
N2–Ru1–N3 
N4–Ru1–N6 
C1–Ru1–N4 
N1–Ru1–N2 
N3–Ru1–N6 
N1– C7–C6–C1 
N4– C16–N5–N6 
N5– N6–C17–C22 
80.0(2) 
89.9(1) 
75.9(1) 
174.3(2) 
170.6(1) 
172.3(1) 
–5.8(5) 
–1.2(5) 
125.1(4) 
 
 
 
Table 3. 6 Selected bond ditsnaces and angles for [Ru((phpy)(pap)(dcmb)][PF6] (7). 
 
Bond lenghts (Å) Bond and dihedral angles (°) 
Ru1–C1 
Ru1–N1 
Ru1–N2 
Ru1–N3 
Ru1–N4 
Ru1–N6 
N5–N6 
2.047(4) 
2.088(3) 
2.127(3) 
2.094(3) 
2.016(3) 
1.944(3) 
1.306(5) 
C1–Ru1–N1 
N2–Ru1–N3 
N4–Ru1–N6 
C1–Ru1–N2 
N1–Ru1–N4 
N3–Ru1–N6 
N1– C7–C6–C1 
N4– C16–N5–N6 
N5– N6–C17–C22 
N2– C28–C27–N3 
78.9(1) 
76.1(1) 
76.6(1) 
171.7(1) 
170.6(1) 
176.6(1) 
–4.6(5) 
0.6(5) 
136.3(4) 
–5.8(4) 
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Figure 3. 12 Centroid-to-centroid distances in compounds 6 (left) and 7 (right). 
 
 
 
In compound 6, the plane of the phenyl ring of pap forms an angle of 48° with 
the plane that contains phpy and the centroid-centroid distance between the phenyl ring 
of pap and the phenyl ring of phpy is 4.38 Å (Figure 3.12). Similarly, the plane of the 
phenyl ring of pap and the plane of  phpy form an angle of 49° in 7 and the centroid-
centroid distance between the phenyl ring of pap and the pyridyl ring of phpy is 4.31 Å. 
Usual π-π stacking interactions in metal complexes incorporating polypyridyl ligands 
display a parallel displaced stacking of π-systems with centroid-to-centroid distances of 
~3.8–4.0 Å and slipped angles of ~20–30°;157,158 such interactions are not evident in 
either 6 or 7. 
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It is interesting to note that the coordinating moiety that is trans to the pyridyl 
group of the pap ligand in 6 is the orthometallated phenyl ring of phpy, but changes to 
the pyridyl ring of the phpy ligand in 7. Such a difference in the arrangement of the 
ligands suggests that 6 isomerizes prior to coordination of dcmb. Thermal isomerization 
has been recently reported during the formation of tris-heteroleptic compounds of the 
type [Ru(phpy)(phen)(L)]+ (L = bpy and phen derivatives) using 
[Ru(phpy)(phen)(NCCH3)2]+ as the starting material.192 Therefore, the thermal stability 
of 7 was investigated by 1H NMR spectroscopy in CD3CN (the sample was kept in the 
dark during the experiments). One acetonitrile ligand exchanges with CD3CN at 21°C 
and complete mono-substitution occurs within a period of a week, as can be observed 
from the spectra in Figure 3.13. The resonances at 2.40 and 2.29 ppm correspond to the 
two coordinated CH3CN ligands; residual H2O from the solvent appears at 2.14 ppm and 
the quintet at 1.94 ppm corresponds to the residual solvent peak from CD3CN. The 
disappearance of the peak at 2.40 ppm and the increase of a new peak for free CH3CN at 
1.96 pm indicates CH3CN ligand dissociation.  
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Figure 3. 13 1H NMR (500 MHz) spectra of 6 in CD3CN at 21°C: (a) 0 d, (b) 1 d, (c) 3 
d, (d) 7 d. 
 
 
 
The second acetonitrile ligand does not exchange even after one month at 21°C. 
Isomerization is not observed judged by the fact that the aromatic signals remain 
unchanged. The labile acetonitrile ligand is likely to be trans to the azo group since the 
Ru1–N3 bond (2.056(4) Å) is longer than the Ru1–N2 bond (2.047(4) Å). Dissociation 
of the second acetonitrile ligand is observed upon heating at 70°C (Figure 3.14) and it is 
accompanied by isomerization to a new species, 6a; nearly complete formation to this 
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new compound is observed after 6 h (Figure 3.14). This isomer exhibits a doublet 
resonance at 5.64 ppm that corresponds to the proton ortho to the Ru–C bond (H1, 
Figure 3.15). The higher field chemical shift of H1 in 6a with respect to 6 (7.76 ppm) 
indicates that H1 is directed toward the pyridyl ring of pap and it appears at a higher 
field because of ring current effects. In addition, the proton ortho to the N atom (H8) in 
phpy is deshielded (8.65 ppm) in 6a with respect to 6 (6.92 ppm), indicating that it must 
be directed toward an acetonitrile ligand. The proton ortho to the N atom of the pyridyl 
ring of pap (H1’) has a similar chemical shift in both geometric isomers (6: 9.18ppm; 6a: 
9.22 ppm, Figure 3.15), indicating that this proton is directed toward an acetonitrile 
ligand in 6a too.  
Therefore, it is proposed that 6a is formed by dissociation of the pyridyl donor 
moiety of pap in 6 (facilitated by the strong donating properties of the orthometallated 
phenyl ring),192 followed by re-coordination to the metal center in a trans position to the 
pyridyl group of phpy. The orthometallated phenyl ring in 6a labilizes the acetonitrile 
ligand in trans position and facilitates the coordination of the dcmb (or dppn in case of 
8) ligand to afford 7, explaining the relative position of the three bidentate ligands in this 
tris-heteroleptic compound. Coordination of dcmb (or dppn) shields protons H1’ an H8 
and they appear at higher field in 7 (H1’, ~7.8 ppm; H8, 7.17 ppm) and 8 (H1’, ~7.8 
ppm; H8, 7.17 ppm) with respect to 6a (H1’, 9.22; H8, 8.65 ppm, respectively) due to 
ring current effects.  
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Figure 3. 14 Aromatic region of the 1H NMR (500 MHz) spectra of 6 in CD3CN at 
70°C: (a) 0 h, (b) 1 h, (c) 2 h, (d) 4 h, (e) 6 h. 
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Figure 3. 15 Comparison of the aromatic region of the 1H NMR spectra (500 MHz, 
CD3CN) of compounds 6, 6a, 7 and 8. 
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Electrochemistry 
 
The electrochemical properties of complexes 1–8 were assessed by cyclic 
voltammetry in acetonitrile. The half-wave potential values (E1/2) vs Ag/AgCl were 
obtained from the cyclic voltammograms of 1–8; representative voltammograms are 
provided in Figures 3.16–3.18. The E1/2 values have been referenced vs NHE for the 
discussion of the results (NHE = normal hydrogen electrode) as described in the 
Experimental Section and the values are compiled in table 3.7. 
The oxidation events (E1/2 > 0 V) are associated with the metal, whereas the 
reduction events (E1/2 < 0 V) are associated with the ligands in this type of Ru(II) 
complexes.193,194 Compounds 1–5 exhibit quasi-reversible (ipa/ipc ≈ 1) redox events in the 
+1 to –2 V interval (Figures 3.16 and 3.17). Their E1/2 values for the Ru3+/2+ couple (E1/2 
[Ru]3+/2+) is observed in the 0.72–0.93 V range of potential and are less positive with 
respect to their non-cyclometallated counterparts such as [Ru(bpy)3]2+, which has a E1/2 
[Ru]3+/2+ = 1.54 V.159 Such a shift to lower potentials is ascribed to the strong donating 
ability and anionic character of phpy; this metal-ligand interaction destabilizes the metal-
based HOMOs and facilitates the oxidation of the metal.  
In the case of compounds 2 and 3, the first ligand-based reduction wave (E1/2,red1 
= −0.61 V) is assigned to the dppn ligand, whereas the first reduction event in 1 
corresponds to bpy (E1/2,red1 = −1.35 V). The dppn ligand is easier to reduce than bpy 
because of the more delocalized π-system of the former. Similar redox behavior has been 
observed in [Ru(bpy)2(dppn)]2+ (E1/2,red1 = −0.46 V; dppn-based reduction) and 
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[Ru(bpy)3]2+ (E1/2,red1 = −1.07 V; bpy-based reduction).159 Due to the strong donating 
ability and negative charge of phpy, there is greater π-backbonding into the pyridyl rings 
of the dppn/bpy ligands in the cyclometallated compounds 1–3 with respect to their non-
cyclometallated counterparts of formula [Ru(bpy)2(L)]2+ (L = bpy, dppn). As a 
consequence, the bpy/dppn ligands are more difficult to reduce and E1/2 red1 are more 
negative in 1–3 with respect to [Ru(bpy)2(L)]2+ (L = bpy, dppn). The E1/2 [Ru]3+/2+ 
becomes more positive in the order 1 < 2 < 3, indicating the increasing stabilization of 
the metal based HOMOs by π -backbonding with the number of dppn ligands. 
 
 
 
Table 3. 7 Half wave redox potentials (E1/2) of 1–8 recorded in acetonitrile. 
 
Compound E1/2 (V) vs NHE (ΔE = Epa-Epc in mV) 
E1/2 [Ru3+/2+] E1/2,red1 E1/2,red2 E1/2,red3 
[Ru(phpy)(bpy)2][PF6] (1) 0.72 (94) −1.35 (77) −1.62 (83) - 
[Ru(phpy)(bpy)(dppn)][PF6] (2) 0.76 (85) −0.61 (84) −1.23 (63) −1.52 (69) 
[Ru(phpy)(dppn)2][PF6] (3) 0.80 (90) −0.61 (95) −1.27 (133) - 
[Ru(phpy)(phendione)2][PF6] (4) 0.93 (60) −0.02 (135) −0.78 (134) - 
[Ru(phpy)(biq)2][PF6] (5) 0.89 (75) −0.82 (65) −1.09 (80) - 
[Ru(phpy)(pap)(NCCH3)2][PF6] (6) 1.14 (80) −0.61 (70) −1.33 (65) - 
[Ru(phpy)(pap)(dcmb)][PF6] (7) 1.31 (86) −0.59 (60) −1.01 (70) −1.51 (85) 
[Ru(phpy)(pap)(dppn)][PF6] (8) 1.24 (70) −0.55 (65) − 0.76 (60) −1.28 (65) 
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Figure 3. 16 Cyclic voltammograms (vs Ag/AgCl) of compounds 1–3 in acetonitrile (0.1 
M [nBu4N][PF6], 100 mV/s scan rate). ic = cathodic current, ia = anodic current, ox. = 
oxidation, red. = reduction. The black arrows indicate the direction of the scan. 
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Figure 3. 17 Cyclic voltammograms (vs Ag/AgCl) of compounds 4–5 in acetonitrile (0.1 
M [nBu4N][PF6], 100 mV/s scan rate). ic = cathodic current, ia = anodic current, ox. = 
oxidation, red. = reduction. The black arrows indicate the direction of the scan. 
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The E1/2 [Ru3+/2+] of 4 occurs at 0.93 V and it is shifted to more positive 
potentials with respect to those of 1–3. The strong electron-withdrawing properties of the 
phendione ligands stabilize the Ru-based HOMOs of 4, explaining its more positive E1/2 
[Ru3+/2+] than 1–3. This complex also exhibits two phendione ligand-based reduction 
events at E1/2 = –0.02 and –0.78 V, where 2e– (ΔE = Epa-Epc ~ 135 mV) are transferred 
on each redox event, as also reported for [Ru(bpy)(phendione)2]2+ (E1/2 = +0.08 and –
0.65 V).195  
In the case of 5, the E1/2 [Ru3+/2+] is 0.89 V and is also shifted to more positive 
potentials with respect to those of 1–3. The longer Ru–C bond in 5 with respect to those 
reported for related compounds, such as 1, decreases the destabilization of Ru-based 
HOMOs and explains its more positive E1/2 [Ru3+/2+]. Additionally, compound 5 shows 
two biq ligand-based reduction waves at E1/2 = –0.82 and –1.09 V.  
Compound 6 displays a E1/2 [Ru3+/2+] = 1.14 V; this value is shifted to more 
positive potentials with respect to the related compounds of formula 
[Ru(phpy)(L)(NCCH3)2]+, where L = bpy (9) or phen, E1/2 [Ru3+/2+] ~ 0.80 V,182 due to 
the stabilization of the metal-based orbitals of 6 by π-backbonding into the low-lying π* 
MOs of pap. The greater π-acceptor ability of pap with respect to bpy is shown in the 
E1/2,red1 values of 6, which are less negative for pap (E1/2 = −0.61 and −1.33 V).196 The 
E1/2 [Ru3+/2+] of 7 (1.31 V) and 8 (1.24 V) are anodically shifted with respect to that of 6 
since dcmb in 7 and dppn in 8 are better π-acceptors than acetonitrile and stabilize the 
Ru-based HOMOs to a greater extend. The tris-heteroleptic compound 7 possesses three 
reversible ligand reductions tentatively assigned to pap (E1/2 = −0.59 and −1.01 V)196 and 
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dcmb (E1/2 = −1.51 V). The E1/2, red1 (pap0/1-) of 6 and 7 (~ −0.60 V) is similar to the 
E1/2,red1 (dppn0/1−)  of 2 and 3 (−0.61 V), suggesting that the lowest-lying π* MOs of pap 
and dppn have similar energy (also reproduced by DFT calculations, see below). 
Interestingly, compound 8 exhibits two ligand-based reduction events at E1/2 = −0.55 and 
−0.75 V attributed to the reduction of dppn and pap ligands (Figure 3.18), respectively 
(see DFT studies for an explanation of the assignment of these reduction events). 
 
 
 
 
 
Figure 3. 18 Cyclic voltammogram (vs Ag/AgCl) of compound 8 in acetonitrile (0.1 M 
[nBu4N][PF6], 100 mV/s scan rate). ic = cathodic current, ia = anodic current, ox. = 
oxidation, red. = reduction. The black arrows indicate the direction of the scan. 
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Electronic Absorption Spectroscopy Studies 
 
The absorption maxima (λabs) and molar extinction coefficients (ε) of 1–8 in 
acetonitrile are listed in Table 3.8. Pictures of selected compounds in the solid state 
(Figure 3.19) and acetonitrile solution (Figure 3.20) are shown below and clearly 
demonstrates that the electronic structure of Ru(II) complexes can be modulated by the 
choice of ligands. The eight compounds exhibit strong singlet metal-to-ligand charge 
transfer (1MLCT) transitions in the visible region explaining why cyclometallated 
compounds have emerged as great candidates for light harvesting units in dye-sensitized 
solar cells.194,193 
 
 
 
Table 3. 8 Absorption maxima of 1–8 recorded in acetonitrile. 
 
Compound λmax, nm (ε × 104 M–1 cm–1) 
1 546 (0.74), 492 (0.65),  404 (0.82), 369 (0.89), 293 (4.64), 249 (2.88) 
2 546 (1.10), 485 (1.20), 411 (1.87), 391 (1.60), 320 (7.44), 298 (6.91), 248 (5.54) 
3 525 (1.63), 460 (1.79), 412 (2.70), 391 (2.09), 323 (14.3), 247 (7.48) 
4 530 (1.03), 470 (0.90), 428 (0.99), 372 (0.59), 292 (2.68), 251 (5.73) 
5 640 (1.05), 544 (0.44), 406 (0.93), 351 (4.47), 266 (7.80) 
6 523 (0.78), 335 (1.13), 281 (1.89), 247 (2.22) 
7 527 (0.97), 470 (0.66), 315 (2.95), 282 (2.41) 
8 517 (1.08), 410 (1.71), 388 (1.67), 322 (9.00), 284 (4.45), 243 (5.66) 
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Figure 3. 19 Solid state colors of selected Ru cyclometallated compounds. Compounds 
2–4 display the same color of 1 in the solid state; compound 7 displays the same color of 
6 in the solid state. 
 
 
 
 
 
Figure 3. 20 Solution colors of selected Ru cyclometallated compounds in acetonitrile 
(100 µM). Compounds 2 and 4 display the same color of 3 in solution; compound 7 
displays the same color of 8 in solution. 
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The electronic absorption spectra of 1–3 are displayed in Figure 3.21 and differ 
significantly from that of related non-cyclometallated Ru polypyridyl compounds (e.g. 
[Ru(bpy)2(L)]2+, L = bpy, dppn). In particular, 1–3 exhibit substantial bathochromic 
shifts of the 1MLCT transitions: the 1MLCT maxima of 1–3 (546, 546 and 525 nm, 
respectively) are bathochromically shifted by 75–102 nm with respect to [Ru(bpy)2(L)]2+ 
(L = bpy, 1MLCT = 450 nm; L = dppn, 1MLCT = 444 nm).159,197 The 1MLCT transitions 
of 1 at 492 and 546 nm have been previously assigned as Ru(4dπ)→bpy(π*), while those 
at higher energies in the 350–430 nm range arise from Ru(4dπ)→phpy(π*) transitions.179 
Thus, the lower energy 1MLCT bands observed for 2 and 3 between 450 and 600 nm can 
be assigned to Ru(4dπ)→bpy/dppn(π*) transitions whereas the transitions corresponding 
to Ru(4dπ)→phpy(π*) are likely obscured by the 1ππ* dppn ligand-centered (LC) 
transitions in the 320–420 nm range in both compounds. It can be also noticed that the 
1MLCT peaks of 1–3 possess absorption tails that extend beyond 750 nm, a feature that 
is not observed in [Ru(bpy)2(L)]2+ (L = bpy, dppn).159,197 
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Figure 3. 21 Electronic absorption spectra of 1–3 in acetonitrile. 
 
 
 
The 1ππ* dppn ligand-centered (LC) transitions of 2 (411, 391 and 320 nm) and 3 
(412, 391 and 323 nm) do not shift with respect to [Ru(bpy)2(dppn)]2+ (414, 390 and 320 
nm) or the free dppn ligand (412, 390 and 313 nm), consistent with the effect of Ru-
phpy bonding destabilizing “t2g-type” occupied metal orbitals without significant 
perturbations to the energies of the π and π* orbitals of the other ligands in the complex. 
The intensity of the dppn-centered transition at ~410 nm is generally commensurate with 
the number of dppn ligands present in the complex. For example, the intensity of this 
transition is increased in 3 (2.70 × 103 M-1 cm-1) as compared to 2 (1.87 × 103 M-1 cm-1). 
Similarly, the molar extinction coefficients for 3 are higher than those of 2 in the 
ultraviolet (UV) regions. 
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The electronic absorption spectra of 4 and 5 are shown in Figure 3.22. 
Compound 4 displays two absorption maxima at 530 and 470 nm that are assigned as 
1MLCT transitions from the Ru center to the pyridyl moiety of phendione 
(Ru(4dπ)→pyphendione(π*)) and are bathochromically shifted with respect to the non-
cyclometallated analog [Ru(bpy)(phendione)2]2+ (1MLCT at 432 and 352 nm).195 
Compound 4 also possesses a higher energy maxima at 428 that may correspond to a 
Ru(4dπ)→phpy(π*) 1MLCT transition, as also observed in 1. Interestingly, it exhibits 
broad absorption (albeit weak) in the red and near-IR region ascribed to 1MLCT 
transitions to the dione moiety of phendione. In the UV region, 4 exhibits a maximum at  
292 nm corresponding to a phendione-based 1ππ* LC transition, as also reported for 
[Ru(bpy)(phendione)2]2+ (288 nm).195 Compound 5 has two Ru(4dπ)→biq(π*) 1MLCT 
transitions at 640 and 544 nm that are bathochromically shifted with respect to 
[Ru(phen)(biq)2]2+.189 An additional 1MLCT band is observed at 406 nm that is likely to 
correspond to Ru(4dπ)→phpy(π*) transitions. An intense 1ππ* biq LC transition at 351 
nm is present in the UV region.  
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Figure 3. 22 Electronic absorption spectra of 1, 4 and 5. Inset: red and near-IR 
absorption of 4 and 5. 
 
 
 
Compounds 6  exhibits a 1MLCT transition at 523 nm (Figure 3.23) assigned as 
Ru(4dπ)→azo(π*) and it is bathochromically shifted by ~30 nm with respect to 
[Ru(phpy)(L)(NCCH3)2]+ (L = bpy (9), phen), reflecting the lower energy of the azo(π*) 
MOs with respect to bpy or phen.196 The Ru(4dπ)→azo(π*) 1MLCT transition in 7 
occurs at 527 and an additional Ru(4dπ)→dcmb(π*) 1MLCT band is observed at 470 nm 
(Figure 3.23). In the case of 8, the 1MLCT band at 517 nm is likely to correspond to a 
combination of Ru(4dπ)→pap(π*) and Ru(4dπ)→dppn(π*) transition, whereas its 
Ru(4dπ)→bpy(π*) 1MLCT transition may be obscured by the 1ππ* dppn LC transitions 
at 410 and 388 nm (Figure 3.23). Absorption in the near-IR region at ~810 nm is also 
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observed for 6–8 and it is tentatively assigned as Ru(4dπ)→azo(π*) 1MLCT transitions. 
The bpy, dppn and pap 1ππ* LC transitions are observed in the UV region.  
 
 
 
 
 
Figure 3. 23 Electronic absorption spectra of 6–8. Inset: red and near-IR absorption of 
the three complexes. 
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Electronic Structure Calculations 
 
Density Functional Theory (DFT) calculations were undertaken on 1, 2, 4–6 and 
8 and the results were compared to those for [Ru(bpy)3]2+ to gain further insight into the 
electrochemical and optical properties of the cyclometallated complexes. The MO 
diagrams (Figure 3.24), energies of the frontier molecular orbitals (MOs) and the 
contributions from the Ru and the ligands (Tables 3.9 and 3.10), and the electron 
densities of selected MOs (Tables 3.11–3.14) are shown below. 
The HOMO, HOMO-1, and HOMO-2 of 1, 2, 4–6 and 8 are primarily localized 
on the metal center (Tables 3.11 and 3.13) and represent the occupied Ru(dπ) “t2g-type” 
orbitals in a pseudo-octahedral environment. However, there is significant contribution 
of the orthometallated phpy ligand (24 to 48%) to the HOMO. The energies of these 
three HOMOs are greater than in [Ru(bpy)3]2+ (Figure 3.24), in agreement with the less 
positive oxidation potentials (E1/2 [Ru3+/2+]) and bathochromically shifted 1MLCT 
transitions of the cyclometallated compounds with respect to [Ru(bpy)3]2+.179,198 The 
Ru(dπ) HOMOs in the cyclometallated compounds are destabilized with respect to 
[Ru(bpy)3]2+ as a consequence of the electronic repulsion between the anionic phpy 
ligand and these filled d orbitals. In addition, the strong Ru-phpy interaction increases 
the energy of the Ru(dσ) “eg*-type” orbitals with respect to [Ru(bpy)3]2+ (see Figure 
3.25 for a representative example).  
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Figure 3. 24 Molecular orbital diagrams (HOMO-2 to LUMO+3) of 1, 2, 4–6 and 8.
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Table 3. 9 Energies (EMO) and percent contributions of selected MOs of [Ru(bpy)3]2+, 1 and 2 and 4. 
 
MO 
[Ru(bpy)3]2+ [Ru(phpy)(bpy)2]+ (1) [Ru(phpy)(bpy)(dppn)]+ (2) [Ru(phpy)(phendione)2]+ (4) 
% Contribution 
EMO 
(eV) 
% Contribution 
EMO 
(eV) 
% Contribution` 
EMO 
(eV) 
% Contribution 
EMO 
(eV) 
Ru bpy Ru phpy bpy Ru phpy bpy dppn Ru phpy phendione 
LUMO+5 3 97 −1.7024 7 8 85 −1.2896 3 76 18 3 −1.5932 1 0 99 −2.1908 
LUMO+4 3 97 −1.7032 2 21 77 −1.3927 2 24 69 5 −1.6705 3 0 97 −2.2221 
LUMO+3 2 98 −2.0264 7 67 26 −1.6392 11 4 26 59 −2.1641 11 0 89 −2.6390 
LUMO+2 7 93 −2.6719 4 33 63 −1.6683 4 3 5 89 −2.3503 4 1 95 −2.7655 
LUMO+1 6 94 −2.6730 6 14 80 −2.3089 3 3 63 31 −2.4496 0 0 100 −3.8885 
LUMO 2 98 −2.7872 2 3 95 −2.4259 0 0 1 99 −3.2542 0 0 100 −3.9544 
HOMO 72 28 −6.2018 56 26 18 −5.2325 43 24 9 24 −5.2896 62 30 8 −5.5408 
HOMO-1 69 31 −6.3792 60 11 29 −5.4649 70 10 11 9 −5.5114 75 7 18 −5.8192 
HOMO-2 69 31 −6.3806 74 9 17 −5.6350 65 15 13 7 −5.6913 77 10 13 −5.9898 
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Table 3. 10 Energies (EMO) and percent contributions of selected MOs of 4–6 and 8. 
 
MO 
[Ru(phpy)(biq)2]+ (5) [Ru(phpy)(pap)(NCCH3)2]+ (6) [Ru(phpy)(pap)(dppn)]+ (8) 
% Contribution EMO 
(eV) 
% Contribution EMO 
(eV) 
% Contribution EMO 
(eV) Ru phpy biq Ru phpy pap NCCH3 Ru phpy pap dppn 
LUMO+5 2 15 83 −1.5756 5 12 83 0 −0.6743 3 9 46 43 −1.5153 
LUMO+4 5 68 27 −1.7241 6 0 94 0 −0.7099 5 95 0 0 −1.8034 
LUMO+3 2 9 89 −1.8458 3 75 22 0 −1.2610 5 0 0 95 −2.2741 
LUMO+2 3 1 96 −1.8599 4 32 64 0 −1.4956 6 0 7 87 −2.5825 
LUMO+1 9 5 86 −2.8319 6 79 15 0 −1.8094 12 0 77 11 −3.0637 
LUMO 8 1 91 −2.9941 11 5 82 0 −3.2308 0 0 0 100 −3.3281 
HOMO 63 26 11 −5.4154 42 48 6 4 −5.6910 56 28 7 9 −5.7614 
HOMO-1 58 16 26 −5.6110 66 10 15 9 −5.9931 62 18 11 9 −6.0655 
HOMO-2 67 6 27 −5.8429 56 22 18 5 −6.2930 47 23 19 11 −6.1527 
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Table 3. 11 Frontier orbitals (HOMO-2 to LUMO) for [Ru(bpy)3]2+, 1, 2 and 4 (isovalue 
= 0.04). 
 
[Ru(bpy)3]2+ 1 2 4 
HOMO-2 
 
HOMO-2 
 
HOMO-2 
 
HOMO-2 
 
HOMO-1 
 
HOMO-1 
 
 
HOMO-1 
 
HOMO-1 
 
HOMO 
 
HOMO 
 
HOMO 
 
HOMO 
 
LUMO 
 
LUMO 
 
LUMO 
 
LUMO 
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Table 3. 12 Frontier orbitals (LUMO+1 to LUMO+4) for [Ru(bpy)3]2+, 1, 2 and 4 
(isovalue = 0.04). 
 
[Ru(bpy)3]2+ 1 2 4 
LUMO+1 
 
LUMO+1 
 
LUMO+1 
 
LUMO+1 
 
LUMO+2 
 
LUMO+2 
 
LUMO+2 
 
LUMO+2 
 
LUMO+3 
 
LUMO+3 
 
 
LUMO+3 
 
LUMO+3 
 
LUMO+4 
 
LUMO+4 
 
LUMO+4 
 
 
LUMO+4 
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Table 3. 13 Frontier orbitals (HOMO-2 to LUMO) for 5, 6 and 8 (isovalue = 0.04). 
 
5 6 8 
HOMO-2 
 
HOMO-2 
 
HOMO-2 
 
HOMO-1 
 
HOMO-1 
 
HOMO-1 
 
HOMO 
 
HOMO 
 
HOMO 
 
LUMO 
 
LUMO 
 
LUMO 
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Table 3. 14 Frontier orbitals (LUMO+1 to LUMO+4) for 5, 6 and 8 (isovalue = 0.04). 
 
5 6 8 
LUMO+1 
 
LUMO+1 
 
LUMO+1 
 
LUMO+2 
 
LUMO+2
 
LUMO+2 
 
LUMO+3 
 
LUMO+3
 
LUMO+3 
 
LUMO+4 
 
LUMO+4 
 
LUMO+4 
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Figure 3. 25 Ru(dσ) “eg*-type” MOs of [Ru(bpy)3]2+ and 1 (isovalue = 0.04) 
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The LUMO is delocalized on the neutral polypyridyl ligands (Tables 3.11–3.14). 
For 1 and 5, the LUMO is delocalized over both bpy (95% contribution) and biq (91% 
contribution) ligands, respectively. The π-system of the dppn ligand that is distal to the 
metal center (dppndis) is the main contributor to the LUMO of 2 (99% contribution). The 
LUMO of 4 is centered in the dione moiety of one of the phendione ligands (100% 
contribution) and the LUMO+1, which lies close in energy to the LUMO (0.07 eV of 
difference), is centered in the same moiety of the second phendione ligand (100% 
contribution). The LUMO of 6 is delocalized over the pyridyl and azo moieties of pap 
(86% contribution). As also observed for 2, the LUMO of 8 is delocalized over dppndis 
(100% contribution) and the LUMO+1 is delocalized over the pyridyl and azo moieties 
of pap (77% contribution). The ELUMO-ELUMO+1 energy difference (0.26 eV) in 
compound 8 is also in agreement with the difference between the first and second 
reduction potentials (Ered1 – Ered2 = 0.21 V), so it is proposed that dppn is easier to reduce 
than pap when both ligands are present in the same Ru complex. The phpy-based π* 
MOs appear at higher energies in all the complexes, explaining the higher energy of the 
Ru(4dπ)→phpy(π*) transitions with respect to Ru(4dπ)→L(π*) , where L is any of the 
neutral polypyridyl ligands used in this work.  
The relative ordering of the calculated HOMO energies of these compounds, 
EHOMO: 1 (less stabilized) < 2 < 5 < 4 < 6 < 8 (more stabilized), is in very good 
agreement with their experimental metal-based oxidation potentials, E1/2 [Ru3+/2+]: 1 < 2 
< 5 < 4 < 6 < 8. In fact, there is a linear correlation between the EHOMO and E1/2 [Ru3+/2+] 
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(Figure 3.26a), indicating that a more stabilized HOMO is associated with a more 
positive E1/2 [Ru3+/2+].  
Similarly, the calculated LUMO energies, ELUMO: 4 (lower energy) < 8 < 6 ≈ 2 < 
5 < 1 (higher energy) correlate linearly (Figure 3.26b) with the first ligand-based 
reduction events, E1/2,red1: 4 (easier to reduce) < 8 < 6 ≈ 2 < 5 < 1, indicating that a more 
stabilized LUMO is associated with a less negative E1/2,red1. Thus, a series of “ease of 
reduction” of bidentate ligands bound in Ru(II) cyclometallated compounds is proposed 
based on the experimental E1/2,red1 and calculated ELUMO values: bpy < biq < dppn ≈ pap 
<< phendione.  
Time-dependent DFT (TDDFT) calculations were also performed (using the 
optimized geometries of the ground state of 1, 2, 4–6 in acetonitrile) to aid in the 
interpretation of the experimental electronic absorption spectra. The most relevant 
vertical transitions (λcalc) of the singlet excited states (1ESN) calculated in acetonitrile 
(PCM model), along with extinction coefficients (f), percent transition contributions, 
assignments and experimental absorption maxima (λexp) values are summarized in 
Tables 3.15–3.20. The calculated singlet electronic transitions predict qualitatively the 
experimental absorption spectra of the complexes in the near UV/Visible region (Figure 
3.27), although they are hypsochromically shifted with respect to the experimental 
absorption spectra. Overestimation of the energy of the absorption maxima of Ru(II) 
polypyridyl complexes using TDDFT calculations has also been reported by others.198 
The calculated singlet excited states of [Ru(bpy)3]2+ and 1, 2, 4–6 in the visible region 
are mainly 1MLCT in nature, whereas those at λ < 350 nm are predominantly LC (1ππ*).  
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Figure 3. 26 Correlation between (a) E1/2 [Ru3+/2+] vs EHOMO and (b) E1/2 red1 vs ELUMO. 
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Figure 3. 27 Experimental (solid lines) and calculated (dotted lines) electronic 
absorption spectra of 1, 2, 4–6 in acetonitrile.  
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The calculated 1MLCT bands for 1 (Table 3.16) in the 450–600 nm region are 
dominated by Ru(4dπ)→bpy(π*) transitions, whereas those calculated in the 360–400 
nm interval are originated from Ru(4dπ)→phpy(π*) transitions and reflect the 
experimental spectrum. These results are also in good agreement with calculations 
reported by others for the same complex.179  In the case of 2, the experimental broad 
1MLCT bands at 546 and 485 nm are calculated as charge transfer transitions from the 
metal to bpy(π*) and dppnprox(π*), where dppnprox is the moiety of this ligand that is in 
proximity to the metal center. The fact that there are several calculated transitions for 
each experimental λmax value in the visible region reproduces the broadness of the 
observed 1MLCT bands of 2 (Table 3.17). Additionally, there are two calculated (703 
and 798 nm) weak transitions (f < 0.015) in the near-IR region that correspond to 
transitions from Ru-based orbitals to the LUMO, which is delocalized over dppnprox(π*), 
where dppndis is the moiety of this ligand that is further from the metal center. This 
calculated low-energy absorption is in agreement with the absorption tail (plateau-like) 
observed for 2 in the 600–750 nm interval. The poor overlap between the filled Ru(dπ) 
and empty dppndis(π*) orbital explains why an intense 1MLCT transition of λ > 550 nm 
is not observed for 2 in spite of having a lower energy LUMO with respect to 1. 
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Table 3. 15 TDDFT data of [Ru(bpy)3]2+. 
 
N λcalc 
(nm) 
f Major contributionsa Assignment λexp  
(nm) 
1 480.9 0.0017 H → L (96%) MLCT 
450 
5 443.4 0.0158 H-1 → L (83%) MLCT 
6 442.9 0.0167 H-2 → L (81%) MLCT 
7 424.6 0.1257 H-2 → L (17), H-2 → L+2 (40%),  
H-1 → L+1 (40%) 
MLCT 
8 424.4 0.1266 H-2 → L+1 (40%), H-1 → L (16%),  
H-1 → L+2 (41%) 
MLCT 
aPercent contribution = (configuration coefficient)2 × 2 × 100%.  
 
 
 
Table 3. 16 TDDFT data of 1. 
 
N λcalc  
(nm) 
f Major contributionsa  Assignment λexp  
(nm) 
1 617.6 0.0036 H → L (45%), H → L+1 (45%) MLCT 
546 
3 551.6 0.0185 H-1 → L (77%), H-1 → L+1 (12%) MLCT 
5 509.6 0.1183 H-2 → L (16%), H-1 → L (15%),  
H-1 → L+1 (51%) 
MLCT 
492 
6 474.5 0.0732 H-2 → L (35%), H-2 → L+1 (30%),  
H-1 → L+1 (23%) 
MLCT 
11 399.5 0.0125 H-1 → L+3 (20%), H → L+4 (62%) MLCT 
404 12 389.4 0.0500 H-2 → L+2 (39%), H → L+6 (54%) MLCT 
13 385.0 0.0353 H → L+5 (82%) MLCT 
15 377.9 0.0406 H-2 → L+2 (16%), H-2 → L+3 (31%),  
H-1 → L+4 (27%), H → L+6 (13%) 
MLCT 
369 
16 370.2 0.0332 H-1 → L+4 (50%), H-1 → L+6 (25%),  
H → L+4 (4%), H → L+5 (4%),  
H → L+6 (4%)            
MLCT 
17 364.5 0.0252 H → L+7 (88%) MLCT 
aPercent contribution = (configuration coefficient)2 × 2 × 100%.  
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Table 3. 17 TDDFT data of 2. 
 
N λcalc 
(nm) 
f Major contributionsa Assignment λexp  
(nm) 
1 797.3 0.0037 H → L (98%) MLCT 
tail 
2 703.7 0.0149 H-1 → L (98%) MLCT 
6 544.8 0.0302 H-1 → L+1 (67%), H-1 → L+2 (22%) MLCT 
546 
8 513.9 0.0298 H-3 → L (61%), H-1 → L+2 (14%),  
H → L+3 (13%)         
MLCT/LC 
9 513.5 0.0389 H-3 → L (37%), H-1 → L+2 (22%),  
H → L+3 (22%) 
MLCT/LC 
10 489.6 0.2088 H-2 → L+1 (20%), H-2 → L+2 (24%),  
H → L+3 (42%) 
MLCT 
485 
11 464.1 0.0349 H-2 → L+1 (10%), H-2 → L+2 (17%),  
H-1 → L+2 (16%), H-1 → L+3 (30%),  
H → L+3 (16%) 
MLCT 
12 450.7 0.0873 H-1 → L+2 (6%), H-1 → L+3 (52%),  
H → L+4 (28%) 
MLCT 
14 433.6 0.0176 H-2 → L+3 (91%) MLCT 
411 
15 433.0 0.0131 H-4 → L (97%) LC 
20 385.1 0.0957 H-6 → L (15%), H-5 → L (55%),  
H-3 → L+3 (23%) 
LC 
391 
aPercent contribution = (configuration coefficient)2 × 2 × 100% 
 
 
 
The experimental 1MLCT bands of 4 at 530 and 470 nm were calculated to 
originate from Ru(4dπ)→pyphendione(π*) transitions (pyphendione = pyridyl moieties of 
phendione), the band at 428 nm has contributions from Ru(4dπ)→pyphendione(π*), 
Ru(4dπ)→phpy(π*) and  1LLCT (ligand-to-ligand charge transfer) transitions from phpy 
to the diketo moiety phendione (dionephendione), whereas the band at 372 corresponds 
mainly to Ru(4dπ)→phpy(π*) transitions (Table 3.18). The extended absorption tail in 
the near-IR region of 4 is also reproduced by the calculations and corresponds to 
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Ru(4dπ)→dionephendione(π*) transitions, supporting the assignment made for this plateau-
like absorption in the previous section. Since the LUMO and LUMO +1 of 4 is centered 
on dionephendione, the poor HOMO-to-LUMO (and HOMO-to-LUMO+1) overlap explains 
the weak absorption of 4 at λ > 550 nm. 
 
 
 
Table 3. 18 TDDFT data of 4. 
 
N λcalc 
(nm) 
f Major contributionsa  Assignment λexp  
(nm) 
1 1209.09 0.0016 H → L (96%) MLCT 
tail 
2 1142.78 0.0021 H → L+1 (96%) MLCT 
3 970.84 0.0076 H-2 → L (97%) MLCT 
5 855.46 0.0075 H-3 → L (98%) MLCT 
10 548.94 0.0204   H-1 → L+2 (77%), H-1 → L+3 (12%) MLCT 
530 15 504.19 0.1023   H-2 → L+2 (18%), H-1 → L+2 (12%),  
H-1 → L+3 (47%), H → L+5 (7%) 
MLCT 
16 478.54 0.0433   H-2 → L+2 (18%), H-2 → L+3 (17%),  
H → L+4 (55%) 
MLCT 
470 
17 463.52 0.0551   H-2 → L+2 (7%), H → L+4 (19%),  
H → L+5 (60%) 
MLCT 
19 448.74 0.0451   H-1 → L+3 (14%), H-1 → L+4 (20%),  
H → L+4 (17%), H → L+5 (28%) 
MLCT 
21 424.41 0.0326   H-1 → L+4 (18%), H → L+6 (75%) MLCT 
428 
22 422.15 0.0363   H-1 → L+5 (93%) MLCT 
23 416.46 0.0163   H-5 → LUMO (62%), H-1 → L+4 
(15%) 
MLCT/LC 
24 415.57 0.0478   H-5 → L (23%), H-2 → L+5 (9%), 
 H-1 → L+4 (34%), H → L+6 (11%) 
MLCT/LC 
26 408.00 0.0100   H-5 → L+1 (79%), H-2 → L+4 (10%) LC 
38 350.97 0.0472 H-2 → L+6 (42%), H → L+7 (42%) MLCT 372 
aPercent contribution = (configuration coefficient)2 × 2 × 100%.  
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The experimental electronic absorption spectrum of 5 shows an intense 1MLCT 
band at a lower energy (640 nm) than those of 2 (546 nm) and 4 (530 nm) despite of 
possessing a higher energy LUMO. The corresponding intense calculated transition (592 
nm, f ~ 0.12) is blue-shifted with respect to the experimental 1MLCT band and it 
originates from Ru(dπ)→biq(π*) transitions (Table 3.19). This low energy 1MLCT band 
in the 600–650 nm region for 5 can be explained by increased overlap between the Ru-
based HOMOs with the LUMO and LUMO+1, which are delocalized over the entire π 
system of the biq ligands (with a higher contribution on the central pyridyl rings 
proximal to the metal center). The experimental 1MLCT band at 544 nm is also 
calculated as Ru(dπ)→biq(π*) transitions and the band at 406 nm has contributions from 
Ru(dπ)→biq(π*), Ru(dπ)→phpy(π*) and 1ππ* biq LC transitions. In contrast, the higher 
energy band at 351 nm is calculated to be mainly of biq character (biq(π*)→biq(π*)). 
 Finally, the calculated 1MLCT transition at 484 nm for 6 (Table 3.20) is blue 
shifted with respect to the experimental value (523 nm) and corresponds to 
Ru(dπ)→pap(π*) transitions, whereas the experimental band at 335 nm is calculated to 
originate from a combination of Ru(dπ)→phpy(π*), pap(π)→pap(π*), phpy(π*)→pap(π) 
transitions.  
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Table 3. 19 TDDFT data of 5. 
 
N λcalc 
(nm) 
f Major contributionsa  Assignment λexp  
(nm) 
1 792.94 0.0054   H → L (87%) MLCT 
tail 
2 712.97 0.0106   H → L+1 (84%) MCLT 
3 665.97 0.0056   H-1 → L (73%), H-1 → L+1 (22%) MLCT 
640 
4 622.39 0.0031   H-2 → L (49%), H-2 → L+1 (35%) MLCT 
5 592.54 0.1227   H-2 → L (27%), H-1 → L (13%),  
H-1 → L+1 (50%) 
MLCT 
6 528.05 0.0378   H-2 → L (12%), H-2 → L+1 (52%),  
H-1 → L+1 (16%) 
MLCT 544 
9 424.91 0.0270   H → L+2 (73%), H → L+4 (15%) MLCT 
406 
10 423.07 0.0521   H-3 → L (39%), H-1→ L+4 (4%), 
H → L+3 (41%) 
MLCT/LC 
11 404.95 0.0250   H-3 → L+1 (49%), H-1 → L+3 (36%) MLCT/LC 
12 402.59 0.0409   H-3 → L+1 (35%), H-1 → L+3 (36%), 
H-1 → L+4 (18%) 
MLCT/LC 
30 347.82 0.1573 H-9 → L (29%), H-2 → L+5 (44%) MLCT/LC 
351 
31 344.98 0.2349   H-10 → L (5%), H-8→ L (48%),  
H-7→ L (15%), H-6→ L (5%) 
LC 
41 329.21 0.2739   H-11 → L (16%), H-9 → L+1 (7%),  
H-8 → L+1 (41%), H-7→ L+1 (6%) 
LC 
42 328.06 0.1254   H-9 → L+1 (72%) LC 
aPercent contribution = (configuration coefficient)2 × 2 × 100%.  
 
 
 
Table 3. 20 TDDFT data of 6. 
 
N λcalc 
(nm) 
f Major contributionsa  Assignment λexp  
(nm) 
1 817.31 0.0038   H → L (92%) MLCT 
tail 
2 737.31 0.0005   H-1 → L (97%) MLCT 
3 484.58 0.1559   H-2 → L (90%) MLCT 523 
9 358.95 0.0680 H-5 → L (76%), H-4 → L (8%) LC 
335 
11 349.43 0.1035 H-7 → L (10%), h-6 → L (62%)         LC 
13 332.11 0.0893   H-2 → L+1 (47%), H-1→ L+2 (22%), 
H → L+3 (14%)         
MLCT 
aPercent contribution = (configuration coefficient)2 × 2 × 100%. 
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Cytotoxicity Studies 
 
  The chloride salts of 1, 2, 3 and 5 were prepared by anion metathesis with 
[nBu4N][Cl] in acetone to improve the water solubility of these complexes. The 
reduction of viability of HeLa cervical cancer cells by compounds 1, 2, 3 and 5 was 
tested using the colorimetric MTT assay as a preliminary study to determine the 
suitability of using this type of cyclometallated compounds as cytotoxic agents against 
cancer cells and the results were compared to cisplatin.  
 
 
 
 
 
Figure 3. 28 Reduction of MTT. 
 
 
 
The MTT reagent ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide, Figure 3.28) is a permeable water soluble dye (pale yellow color) that is 
reduced by the NADH cofactor (reduced nicotinamide adenine  dinucleotide) in the 
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cytosol or by NAD(P)H-dependent oxido-reductases and succinate dehydrogenase in 
mitochondria of living cells,199 and forms insoluble dark blue-purple formazan crystals 
that are impermeable to cell membranes and accumulates inside the cells.200 The amount 
of formazan that is produced is determined by absorption spectroscopy after 
solubilization with dimethylsulfoxide using a microplate absorbance reader, where the 
formazan absorbance is directly proportional to the number of living, metabolically 
active cells.   
 
 
 
Table 3. 21 Cytotoxicity data of Ru complexes against HeLa cells. 
 
Compound IC50 (µM)a 
[Ru(phpy)(bpy)2][Cl] (1) 34 ± 3 
[Ru(phpy)(bpy)(dppn)][Cl] (2) 7 ± 1 
[Ru(phpy)(phendione)2][Cl] (4) 57 ± 7 
[Ru(phpy)(biq)2][Cl] (5) 51 ± 8 
cisplatin 40 ± 9 
aIncubation time = 2 h. Results are the means of three 
independent experiments and are expressed as mean ± SD. 
 
 
 
The IC50 values (concentration of compound required to inhibit 50% of cell 
survival) were calculated after 2 h of incubation under reduced light conditions and are 
listed in Table 3.21. In general, 1, 4 and 5 exhibit toxicity toward HeLa cells similar to 
cisplatin, but 2 is ~6 times more active than cisplatin under similar experimental 
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conditions. The higher cytotoxicity of the tris-heteroleptic compound can be attributed to 
its greater lipophilicity and cellular uptake due to the presence of the dppn ligand and 
monocationic charge, as described in Chapter 1.   
The ability of compound 2, the most cytotoxic of this series, to induce the loss of 
inner mitochondrial membrane potential (ΔΨm) was studied using the JC-1 probe. As 
described in Chapter 2, this lipophilic cationic dye accumulates selectively in 
mitochondria and exhibits dual fluorescence: red fluorescence (λem = 590 nm) from dye 
aggregate and green fluorescence (λem = 527 nm) from dye monomers. Since JC-1 
aggregates are formed due to the negative ΔΨm, mitochondrial depolarization and 
permanent depletion of ΔΨm is indicated by a reduction of red fluorescence and 
simultaneous increase in green fluorescence. Incubation of HeLa cells with 2 showed a 
time-dependent mitochondrial depolarization as can be observed in Figure 3.29, where a 
shift in the fluorescence emission wavelength from red to green occurs in a 2 h period. 
These findings suggest that mitochondria are possible cellular targets of compound 2 in 
HeLa cells and that it could induce apoptosis via the mitochondrial pathway.122,123 
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Figure 3. 29 JC-1 fluorescence (overlay of green and red channels) images of HeLa cells 
treated with 2 (7 μM) at (a) 0 h, (b) 30 min, (c) 1 h and (d) 2 h.  
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Table 3. 22 Cytotoxicity data of compounds 2 and 8 against ovarian cancer cells.  
 
Compound 
IC50 (µM)a 
OVCAR-8 NCI/ADR-RES 
[Ru(phpy)(bpy)(dppn)][Cl] (2) 10 ± 4 16 ± 1 
[Ru(phpy)(pap)(dppn)][PF6] (8) 15 ± 7 12 ± 4 
aIncubation time = 2 h. Results are the means of three independent experiments and are 
expressed as mean ± SD. 
 
 
 
The cytotoxicity of compounds 2 and 8, both possessing the dppn ligand, was 
evaluated in the human ovarian adenocarcinoma cell lines OVCAR-8 and NCI/ADR-
RES using the MTT assay. NCI/ADR-RES is a cell line derived from OVCAR-8 that is 
resistant to doxorubicin (also known as adriamycin, a broad-spectrum chemotherapeutic 
agent), cisplatin and paclitaxel. The resistance of this cell line towards chemotherapeutic 
agents is owing to its high expression level of P-glycoprotein (multidrug resistance 
protein 1, MDR1), which is an ATP-dependent efflux pump of the cell membrane that 
has a broad substrate specificity and is able to pump the above mentioned drugs out of 
the cells.201,202,203,204 In addition, OVCAR-8 and NCI/ADR-RES are included in The 
U.S. National Cancer Institute 60 human tumor cell line panel (NCI60), which is a 
platform high throughput screening of the cytotoxicity of potential anticancer 
drugs.205,206 Both compounds exhibit IC50 values in the low micromolar range (10–15 
µM, Table 3.22) against OVCAR-8 cells. Moreover, its cytotoxic properties did not 
decrease when incubated with the resistant NCI/ADR-RES cell line. For comparison, the 
reported IC50 values (74 h of incubation) of doxorubicin in OVCAR-8 and NCI/ADR-
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RES cells are 0.6 µM and >20 µM, respectively.204 Therefore, compounds 2 and 8 are 
more active than doxorubicin against NCI/ADR-RES and require only 2 h to display 
cytotoxic effects. 
Because of the intense absorption of 5 with a maximum at 640 nm (ε = 1.05 × 
104 M–1 cm–1), the complex was investigated as a potential agent for photochemotherapy 
(PCT) in collaboration with Prof. Claudia Turro (The Ohio State University) and Prof. 
Mauricio S. Baptista (University of São Paulo, Brazil). PCT has emerged as a non-
invasive treatment with low systemic toxicity for the treatment and cure of early stage 
lesions of endoscopically accessible tumors207 and excitation in the 600−850 nm range is 
desirable for deeper tissue penetration of light.208 Thus, HeLa cells were incubated with 
5 for a longer period of time (48 h) than the previous experiment, under reduced light 
conditions, and the calculated IC50 using the MTT assay was 7 µM. In a different 
experiment, when the cells treated with 5 were irradiated for 20 min with light of 633 nm 
(red light) followed by 48 h incubation in the dark, the IC50 decreased to 1 µM. 
Therefore, the cytotoxicity of compound 5 increased 7-fold upon red light irradiation, 
showing the potential of Ru cyclometallated compounds as PCT agents. 
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Conclusions 
 
 Seven new Ru(II) cyclometallated compounds (2–8) displaying rich 
electrochemical and optical properties have been synthesized and thoroughly 
characterized. These molecules exhibit lower energy 1MLCT transitions 
(Ru(4dπ)→L(π*), L = neutral polypyridyl ligand) than their non-cyclometallated 
counterparts (e.g. [Ru(bpy)3]2+) due the destabilization of the Ru(4dπ) HOMOs, which in 
turn explains their strong absorption in the visible region (ε ~ 1–2 × 104 M-1 cm-1), as 
well as plateau-like absorptions in the near-IR region. The metal-based oxidation 
potentials (E1/2 [Ru3+/2+]) of these complexes occur in the 1.5–0.70 V (vs NHE) range, 
whereas the ligand-based reduction events occur at negative potentials (< –0.5 V vs 
NHE). Interestingly, E1/2 [Ru3+/2+] and the first ligand-based reduction potential (E1/2,red1) 
are linearly correlated with the calculated (DFT) HOMO and LUMO energies and such 
correlation could be used in the future to predict experimental half-wave potentials using 
results from theoretical calculations (at the same theoretical level) of related compounds.  
It has been also shown that compounds 1, 4 and 5 display cytotoxicity 
comparable to cisplatin against HeLa cancer cells, whereas compound 2 is 6-fold more 
active than cisplatin at very short incubation times (2 h). The latter compound caused 
loss of the mitochondrial membrane potential indicating that apoptosis via the 
mitochondrial pathway may be the mechanism of cancer cell death. Compounds 2 and 8 
were also found to be cytotoxic against the sensitive OVCAR-8 and multidrug resistant 
NIC/ADR-RES cancer cell lines, revealing the high potential of Ru cyclometallated 
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compounds incorporating the lipophilic dppn ligand as chemotherapy agents. In 
addition, a 7-fold increase in the cytotoxicity of 5 was observed when irradiated with 
low energy red light, making it potentially useful as a photochemotherapy agent.  
These findings show that coordinately saturated Ru(II) cyclometallated dyes 
typically used in solar energy applications could emerge as a new family of antitumor 
drugs since the compounds shown here resemble them in structure, optical and 
electrochemical properties. The cytotoxicity and thorough investigation of potential 
mechanism(s) of cell death for a more extensive series of compounds including 
derivatives of the newly synthesized precursor 6 are currently under investigation in the 
laboratories of Prof. Kim R. Dunbar.  
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CHAPTER IV 
LIVE CELL IMAGING STUDIES OF A FLUOROPHORE-LABELED  
METAL-METAL BONDED DIRHODIUM COMPOUND* 
 
Multiple Bonds Between Metal Atoms 
 
Compounds with direct metal-metal (M–M) bonds are a fascinating class of 
inorganic molecules that are considered to be part of a second kind of transition metal 
chemistry or non-Wernerian transition metal chemistry, as described by F. A. Cotton, C. 
A. Murillo and R. A. Walton,209 in the sense that they do not fit into the conceptual 
framework of a single metal atom surrounded by a set of ligands (one-center 
coordination chemistry) established by Alfred Werner in the early 1900’s. A milestone 
of this multicenter transition chemistry was established in 1963–1965 when the structure 
of the octachlorodirrenate(III,III) anion, [Re2Cl8]2- (Figure 4.1) was correctly elucidated 
and the first quadruple bond was recognized by F. A. Cotton and coworkers.210,211 Such a 
discovery stimulated the exploration of M–M bonding across the transition metal series 
with a rapid expansion of the field ensuing. Since then, these type of molecules have 
found many applications in catalysis,212,213,214,215,216,217 medicinal chemistry,218,219 
magnetism220,221 and spectroscopy.222  
*Reprinted with permission from Peña, B.; Barhoumi, R.; Burghardt, R. C.; Turro, C.; 
Dunbar, K. R. “Confocal Fluorescence Microscopy Studies of a Fluorophore-labeled Dirhodium 
Compound: Visualizing Metal-Metal Bonded Molecules in Lung Cancer (A549) Cells”. J. Am. 
Chem. Soc. 2014, 136 (22), 7861-7864. Copyright 2014 American Chemical Society. 
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Figure 4. 1 Schematic representation of the molecular structure of the [Re2Cl8]2- anion. 
Distances are indicated in Å. 
 
 
 
A qualitative picture of the M–M quadruple bond in [Re2Cl8]2- is shown in Figure 
4.2 and can also be used to explain the bonding in the general class of face-to-face M–M 
bonded compounds.209,223 Multiple bonds between two metal atoms are formed by the 
positive overlap of their d orbitals: one σ molecular orbital (MO) is formed by overlap of 
two dz2 orbitals, two equivalent and orthogonal π MOs are formed by overlap of two dxz 
and two dyz orbitals, and one δ MO is produced by the face-to-face overlap of two dxy 
orbitals. There are also four antibonding MOs (one σ*, two π* and one δ*) formed by the 
negative overlap of the above mentioned d orbitals. The dx2-y2 orbitals on each metal 
atom are not involved in the M–M bonding because they are primarily involved in the 
bonding with the ligands (Cl– ligands in the case of [Re2Cl8]2-). The eight electrons of 
the Re26+ core (Re2(III,III)) fill the bonding MOs giving a (σ)2(π)4(δ)2 configuration and 
a bond order of 4, a quadruple bond.209 
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Figure 4. 2 Qualitative molecular orbital diagram in M–M bonded compounds.  
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Anticancer Active Dirhodium Compounds 
 
Dirhodium Tetraacetate and its Derivatives 
 
Within the field of cancer drug research, dirhodium complexes based in Rh24+ 
core (Rh2(II,II), 14 electrons) are the most studied M–M bonded compounds. Such 
molecules exhibit the (σ)2(π)4(δ)2(δ*)2(π*)4 electronic configuration corresponding to a 
bond order of 1 (a single bond). The first compound to be tested as an antineoplastic 
agent is dirhodium tetraacetate (1; Rh2(μ-O2CCH3)4, Figure 4.3). The report appeared in 
1972, three years after the discovery of the antitumor properties of cisplatin (cis-
Pt(NH3)2Cl2, Figure 4.3),18 in which John Bear and coworkers (University of Houston, 
Texas) reported that 1, in combination with arabinosylcitosine (Cytarabine, Cytosar-U®, 
an anticancer drug used to treat different forms of leukemia), increased the survival time 
of mice bearing lymphocytic leukemia (L1210) tumors.224 
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Figure 4. 3 Molecular structures of cisplatin and compound 1. One of the equatorial 
carboxylate ligands in 1 is highlighted in red.  
 
 
 
Compound 1 adopts the “so-called” paddlewheel structure; it possesses four 
bridging acetate (CH3CO2–) ligands occupying equatorial positions and two weakly 
bound axial ligands, typically solvent molecules such as water (Figure 4.3). After their 
initial report of the anticancer properties of the acetate derivative, Bear and coworkers 
later reported that other dirhodium tetracarboxylate compounds such as dirhodium 
tetrapropionate (2; Rh2(μ-O2CCH2CH3)4, Figure 4.4), dirhodium tetrabutyrate (3; Rh2(μ-
O2CCH2CH2CH3)4, Figure 4.4) and dirhodium tetrapentanoate (4; Rh2(μ-
O2CCH2CH2CH2CH3)4, Figure 4.4), were more effective than 1 at increasing the 
survival time of mice bearing the Ehrlich ascites tumors. In addition, compounds 1–4 
were able to inhibit DNA and RNA synthesis in vitro.225,226,227 Structure–activity 
relationship studies showed that the antitumor activity and cellular uptake of dirhodium 
tetracarboxylate compounds increases with the length (and lipophilicity) of the bridging 
carboxylate ligand, 1 < 2 < 3 < 4, but a further lengthening of the alkyl chain beyond the 
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pentanoate group decreases their activity,228,229 underscoring the dependence of the 
cytotoxicity on the ability of the compounds to traverse the plasma membrane.  
Following these series of reports, the structural diversity of cytotoxic dirhodium 
compounds was expanded when four new studies appeared during the 1990’s (Figure 
4.5). The formamidinate compound cis-Rh2(μ-O2CCF3)2(form)2 (5; form = N,N’-di-p-
tolylformamidinate) was shown to have similar antineoplastic activity to cisplatin in 
mice bearing tumors (Guerink T8 and Yoshida ascites sarcoma), with the advantage of 
exhibiting considerably lower side effects.230 The dicationic compounds [Rh2(μ-
O2CCH3)2(bpy)2]2+ (6; 2,2’-bipyridine (bpy)) and [Rh2(μ-O2CCH3)2(phen)2]2+ (7; 1,10-
phenanthroline (phen) were shown to display cytotoxic properties against a human oral 
carcinoma (KB) cancer cell line.231 Dirhodium tetrakistrifluoroacetate, Rh2(μ-O2CCF3)4  
(8), was found to increase the survival rate of mice bearing Ehrlich ascites cells,232 and 
the dirhodium tetrakisacetamidate compound Rh2(μ-NHCOCF3)4  (9) was reported to be 
more active than cisplatin both in vitro (human leukemia cells (U937 and K562) and 
Ehrlich ascite cancer cells) and in vivo (Erlich ascite tumors implanted in mice).233 In 
2001, a dirhodium compound incorporating a O-methallated methoxyphenylphosphine 
ligand, [Rh2(μ-O2CCH3)3(μ-(o-OC6H4)P(o-OCH3C6H4)2)] (10), was also shown to be 
more active than cisplatin against several tumor cell lines (oral carcinoma (KB), bladder 
cancer (Hu1703), colon adenocarcinoma (SW707) and breast cancer (T47D)).234  
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Figure 4. 4 Molecular structures of compounds 2–4. One of the equatorial carboxylate 
ligands is highlighted in red.  
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Figure 4. 5 Molecular structures of cytotoxic dirhodium compounds developed during 
the 1990–2001 period. The axial ligands have been omitted for the sake of clarity. 
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Interactions of Dirhodium Compounds with DNA 
 
Over the past 20 years, considerable efforts mainly from the Dunbar group but 
also from other research groups have been devoted to elucidate the interactions of Rh–
Rh bonded compounds with DNA models. The results from these studies have been 
thoroughly reviewed218 and have led to the main conclusion that dirhodium compounds 
are able to bind covalently to DNA purines, nucleotides, dinucleotides, single-stranded 
and double-stranded DNA, suggesting that nuclear DNA is a potential target of 
dirhodium compounds in vivo. A summary of the most relevant results is provided 
below.  
 
Interactions with DNA Base Models and Dinucleotides 
 
The nucleobase adenine binds axially to the Rh24+ core and forms adducts that are 
stabilized by the formation of hydrogen bonds between the N6 amino group of adenine 
(Figure 4.6a) and the O atom of the carboxylate ligand bound to the dimetal unit. Two 
crystal structures showing this type of interaction have been reported: Rh2(µ-
O2CCH3)4(1-MeAdo)2235 (1-MeAdo = 1-methyladenosine, Figure 4.6b) and [Rh2(µ-
O2CCH3)2(µ-HNCOCF3)2(9-MeAdeH2)2](NO3)2. (9-MeAdeH2 = 9-methyladenine 
protonated at the N1 position).236 In contrast, guanine do not form axial adducts with 
dirhodium tetracarboxylate compounds (Rh2(µ-O2CR)4, R = alkyl, aryl) due to 
electrostatic repulsions between the O6 atom of guanine (Figure 4.6c) and the O atom of 
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the carboxylate ligands bound to the Rh24+ core. Guanine, however, binds axially via the 
N7 atom to the dimetal unit when at least two of the carboxylate ligands are replaced by 
equatorial bridging ligands possessing hydrogen-bonding donor moieties (such as 
acetamidate). The X-ray structures of trans-Rh2(µ-O2CCH3)2(µ-HNCOCF3)2(9-
EtGuaH)2 (9-EtGuaH = 9-ethylguanine, Figure 4.6d)236 and Rh2(µ-HNCOCF3)4(dGuo)2 
(dGuo = deoxyguanosine)236 reveal this type of interaction. 
 
 
 
 
 
Figure 4. 6 Axial interactions of the Rh24+ core with purines. Adapted with permission 
from reference 218. Copyright 2005 American Chemical Society. 
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Guanine displays a second binding mode that involves the displacement of equatorial 
bridging ligands. Such an unprecedented binding mode involving the N7 and O6 atoms 
(Figure 4.7a) occurs in the crystal structures of H–T cis-Rh2(µ-O2CCH3)2(µ-9-
EtGua)2(CH3OH)2 (9-EtGua = deprotonated 9-ethylguanine, Figure 4.7a),237 H–T cis-
Rh2(µ-O2CCF3)2(µ-9-EtGuaH)2((CH3)2CO)2](CF3CO2)2 (Figure 4.7b),237 and H–H cis-
[Rh2(µ-O2CCH3)2(µ-9-EtGuaH)2(H2O)((CH3)2CO)](BF4)2 (Figure 4.7c).238 A similar 
bridging mode for guanine have been reported for the formamidinate compound H–H  
cis-[Rh2(µ-form)2(µ-9-EtGuaH)2(NCCH3)](BF4)2239 and when 1 is reacted with 
guanosine-5’-monophosphate (GMP, Figure 4.7d).240 The H–T geometry (head-to-tail) 
indicates that each Rh atom is bound to a O6 and a N7 atom; the H–H geometry (head-
to-head) indicates that one Rh atom is bound to two N7 atoms and the other Rh atom is 
bound to two O6 atoms. A third binding mode has been observed for guanine, where it 
binds to the Rh24+ core at an equatorial position as a monodentate ligand, as shown in the 
X-ray crystal structure of Rh2(µ-O2CCH3)2(bpy)(9-EtGuaH)(H2O)2(CH3SO4)](CH3SO4) 
(Figure 4.7e).241 In the case of adenine, it also able to bind the dimetal unit in a 
equatorial bridging mode, as shown in the X-ray structure of [Rh2(µ-form)2(µ-9-
EtAdeH)2(NCCH3)](BF4)2 (9-EtAdeH = 9-ethyl adenine, Figure 4.7g), where 9-EtAdeH 
binds in its unusual imino form (Figure 4.7f).239,242 
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Figure 4. 7 Equatorial binding of guanine and adenine base models to the Rh24+ core. 
Adapted with permission from reference 218. Copyright 2005 American Chemical 
Society. 
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The reaction of dirhodium tetraacetae (1) with deoxydinucleotides (d(GpG) or 
d(pGpG), Figure 4.8a) affords Rh2(µ-O2CCH3)2(deoxydinucleotide), where the two 
guanine (G) bases of the dinucleotide are bound to the dimetal core in a bridging 
equatorial mode (via N7/O6 donor atoms) and adopt a H–H arrangement, as determined 
by 1D and 2D NMR experiments.240,243 The structural conformations of Rh2(µ-
O2CCH3)2(d(GpG)) and Rh2(µ-O2CCH3)2(d(pGpG)) (Figure 4.8b) resemble the X-ray 
structure of cisplatin bound to d(pGpG) reported by Stephen Lippard and 
coworkers,41,244 establishing that dirhodium tetraacetate could bind to nuclear DNA in 
vivo in a similar fashion as cisplatin. 
 
 
 
 
 
Figure 4. 8 Molecular structures of (a) d(GpG) and d(pGpG) and (b) H–H conformation 
of Rh2(µ-O2CCH3)2(deoxydinucleotide). 
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Interactions with Single-stranded and Double-stranded DNA  
 
The interactions between 1, 8 and [Rh2(µ-O2CCH3)2(NCCH3)6](BF4)2 with single-
stranded oligonucleotides of different lengths (tetra- to dodecamers) containing dipurine 
sites (AA, AG, GA and GG) were studied by matrix-assisted laser desorption ionization 
(MALDI) mass spectrometry and nanoelectrospray ionization (nanoESI) coupled to 
time-of-flight (TOF) mass spectrometry to determine the binding site of these metal 
compounds.245,246 Cisplatin (cis-Pt(NH3)2Cl2), its activated form (cis-
[Pt(NH3)2(H2O)2]2+) and carboplatin (cis-Pt(C6H6O4)(NH3)2) were included for 
comparison. It was found that GG and AA sites are the preferred binding sites for the 
three dirhodium complexes and that the main products of the reactions are dirhodium 
bis-acetate oligonucleotides. In addition, their reactivity towards single-stranded DNA 
decreased in the following order: cis-[Pt(NH3)2(H2O)2]2+ ≈ Rh2(µ-O2CCF3)4 (8) > cis-
Pt(NH3)2Cl2 >> [Rh2(µ-O2CCH3)2(NCCH3)6](BF4)2 > Rh2(µ-O2CCH3)4 (1) ≈ 
Pt(C6H6O4)(NH3)2, which is associated with the relative lability of the leaving groups.  
Compounds 1, 8 and [Rh2(µ-O2CCH3)2(NCCH3)6](BF4)2 were also capable of binding 
covalently to double-stranded DNA forming stable intrastrand and interstrand 
crosslinks,247 refuting early claims that Rh2(µ-O2CCH3)4 does not bind to double-
stranded DNA.225,226 
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Dirhodium Anticancer Drugs Containing Polypyridyl Ligands 
 
In 2009, the cytotoxic properties against cancer cells of the monocationic 
compounds of general formula [Rh2(μ-O2CCH3)2(η1-
O2CCH3)(N^N)(CH3OH)3][O2CCH3], where N^N are polypyridyl ligands (bpy, phen, 
dpq, dppz, dppn), were reported (Figure 4.9a).248 The five compounds showed IC50 
values (IC50 is the concentration of compound required to inhibit 50% of cell survival) in 
the 80–130 µM and 50–70 µM range against HeLa and COLO-316 tumor cells, 
respectively. Those incorporating the dppz and dppn ligands (11 and 12, respectively, 
Figure 4.9b) were the most active. These two compounds interact strongly with DNA 
through intercalation in vitro and induce DNA strand breaks in cellulo, as assessed by 
the comet assay (a cell-based assay that detects single- and double-strand breaks, as well 
as DNA crosslinking after treatment of cells with a cytotoxic compound249). It was also 
proven that the generation of reactive oxygen species is not responsible for the observed 
DNA damage. Therefore, it was concluded that nuclear DNA is a potential cellular target 
for these type of compounds and that the DNA strand breaks that were observed are a 
consequence of a direct interaction of nuclear DNA with the dirhodium compounds.248 
Substitution of the η1-O2CCH3 ligand in 12 by N^N (bpy, phen, dpq, dppz, dppn) 
afforded the dicationic compounds of general formula [Rh2(μ-
O2CCH3)2(dppn)(N^N)(CH3OH)2][O2CCH3]2 (Figure 4.10a).250 Among this series, 
compound 13 (N^N = dppz, Figure 4.10b) neither intercalates into DNA nor produces 
significant DNA strand breaks. Nevertheless, it is the most cytotoxic among these five 
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compounds with IC50 values of 82 and 68 µM against HeLa and COLO-316 cells, 
respectively, supporting the contention that other cellular targets/mechanism of action 
are possible by changing the ligand environment around the dimetal unit, a finding that 
opens up new opportunities for dirhodium compounds in cancer drug research.250 
 
 
 
 
 
Figure 4. 9 Dirhodium compounds with one polypyridyl bidentate ligand (N^N) in the 
equatorial position. L denotes an equatorially bound methanol ligand; the axial methanol 
ligands have been omitted for the sake of clarity.  
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Figure 4. 10 Rh24+ compounds with two polypyridyl bidentate ligand (N^N) in the 
equatorial position. L denotes an equatorially bound methanol ligand; the axial methanol 
ligands have been omitted for the sake of clarity. 
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Ubiquitin-Proteasome System as a Potential Target 
 
Che and coworkers very recently reported (2012) a new target for compounds 1 
and 3.251 They first determined the global transcriptional changes and the cytotoxicity 
profiles of these dirhodium compounds against the NCI-60 cancer cell line panel 
(National Cancer Institute, USA; it represents 60 cell lines from nine tumor types). The 
gene expression patterns altered by 1 and 3, and their cytotoxicity profiles, were 
compared with those of known drugs using a bioinformatics approach to find similar 
patterns of activity. It was found that the signatures of 1 and 3 are similar to that of the 
cell permeable proteasome inhibitor MG-262 (Z-Leu-Leu-Leu-B(OH)2, Figure 4.11a), 
indicating that the ubiquitin-proteasome system (UPS; a system that consists of the 
degradation of ubiquitinated proteins by proteasome) may be a target of these dirhodium 
compounds. They also found that the cytotoxicity profile of 3 against the NCI-60 panel 
is very different than that of cisplatin, suggesting a different mechanism of action 
between 3 and the platinum (Pt) drug. 
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Figure 4. 11 Molecular structures of (a) MG-262, (b) dirhodium tetracarboxylate 
compounds that behave as UPS inhibitors, and (c) dirhodium tetrapyrrolidinonato (14). 
The axial ligands have been omitted for the sake of clarity. 
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Subsequently, the authors determined that the highly cytotoxic compound 3 
induces the accumulation of polyubiquitinylated proteins in HeLa cells in a similar 
fashion as MG-262, whereas cisplatin is not able to produce the same effect, which 
further supports the different mechanism of action of 3 and cisplatin.251  Additional in 
vitro experiments revealed that 3 inhibits both the proteolytic activity of proteasome 
(purified 20S proteosome) and the deubiquitinylating activity of proteasomal 
deubiquitinating enzymes (UCH-L5), indicating that 3 may interact directly with UPS. 
They extended the study to other dirhodium tetracarboxylates (Figure 4.11b) and found a 
significant correlation between the cytotoxicity of all the tested compounds and their 
proteasome inhibitory activities, as well as their ability to indcuce the accumulation of 
ubiquitinated proteins, concluding that the inhibition of UPS is an important mechanism 
of action of the dirhodium tetracarboxylate compounds evaluated in that study.251  
The authors also assessed the ability of 3 to damage DNA in cellulo by using the 
comet assay. In contrast to doxorubicin or cisplatin (which rapidly produced DNA 
damage), compound 3 did not affect the DNA of HeLa cells at its cytotoxic IC50 
concentration (0.5 µM). Significant DNA damage was observed only at concentrations 
higher (~10-fold) than that required to inhibit UPS activity or to induce cell death. 
Additionally, HeLa cells were incubated with the six dirhodium tetracarboxylate 
compounds (Figure 4.11b); the nuclear and cytoplasmic fractions were isolated and the 
metal content was analyzed by inductively coupled plasma mass spectrometry (ICP-
MS). Only 10–25% rhodium content was found in the nuclear fraction, whereas the 
remaining ~80% was found in cytoplasmic fractions,251 supporting that contention that 
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UPS inhibition plays an important role in the cytotoxic effect of dirhodium 
tetracarboxylates and complementing the DNA binding studies reported before. 
The UPS inhibitory activity of the highly cytotoxic tetrapyrrolidinonato 
compound Rh2(µ-NObutyl)4  (14; Figure 4.11c, IC50 ~ 1 µM against several cancer cell 
lines) was also evaluated. It was found that incubation of cancer cells with 14 neither 
induced the accumulation of polyubiquitinylated proteins nor affected the proteolytic 
activity of proteasome. Compound 14 does not induce DNA damage (as determined by 
the comet assay) at its IC50 concentration, but it is does it at higher concentrations (~10-
fold) as in the case of 3, and it shows low accumulation in the nucleus (< 20%) of HeLa 
cells. Therefore, these studies also reveal that other cellular targets may be reached by 
fine-tuning the nature of the equatorial ligands,251 as was demonstrated by the studies 
from the Dunbar group in previous cases.250 
 
Other M–M Bonded Anticancer Compounds 
  
Diruthenium and dirhenium compounds have been less studied than their 
dirhodium counterparts, but there are remarkable examples of potential antitumor 
compounds. For instance, the tetracarboxylate Ru25+ compound Ru2(aGLA)Cl (15; 
aGLA = deprotonated γ-linolenic acid, Figure 4.12a) inhibits C6 rat glioma cell 
proliferation and induces apoptosis in vitro.219,252 The Re26+ compound cis-
[Re2(GABA)2Cl5]+ (16, Figure 4.12b) was shown to be effective at inhibiting tumor 
growth (Guerink T8) in mice253 and the combination of cis-Re2(μ-O2CC(CH3)3)2Cl4 (17; 
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Figure 4.12c) and cisplatin lead to suppression of tumor growth or complete tumor 
elimination in mice.254 
 
 
 
 
 
Figure 4. 12 Molecular structures of antitumor diruthenium and dirhenium compounds. 
The axial solvent molecules have been omitted for the sake of clarity. 
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Intracellular Distribution of Metal-Based Drugs 
 
Although the interactions of dirhodium compounds with DNA have been  studied 
extensively,218 less is known about the cellular distribution of this class of inorganic 
molecules in living cancer cells. Tethering an organic fluorophore to non-
photoluminescent metal anticancer drugs is a successful strategy to map their 
intracellular distribution using fluorescence microscopy.255 In fact, this approach has 
been vital for understanding the intracellular behavior of Pt drugs. For example, live cell 
imaging studies of fluorescein-labeled cisplatin analogs (Figure 4.13a) in human 
osteosarcoma and ovarian carcinoma cells showed that these Pt drugs were sequestered 
into lysosomes, accumulated in the nucleus and Golgi-derived vesicles, and colocalized 
with the copper efflux transporters ATP7A and ATP7B.256,257,258 Also Pt drugs formed 
by linking cisplatin units with the fluorescent intercalator anthraquinone259 (Figure 
4.13b) or with fluorescein-labeled diamine linkers260 have also been shown to 
accumulate in the nucleus of human osteosarcoma cells. 
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Figure 4. 13 Molecular structures of fluorophore-labeled metal complexes. 
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In vivo fluorescence imaging studies of a NBD-tethered Pt drug (NBD = 
nitrobenzoxadiazole, Figure 4.13c) in zebrafish larve (a transparent small animal model) 
has also been reported.261 More recently, mononuclear ruthenium(II), osmium(II) and 
gold(I) anticancer complexes were tagged with a bodipy-phosphine (bodipy = 4,4-
difluoro-4-bora-3a,4a-diaza-s-indacene) fluorescent monodentate ligand (Figure 
4.13d).262 Lippard and coworkers reported in 2004 that dirhodium acetate can be labeled 
with dansyl-imidazole (Figure 4.13e) or dansyl-piperazine (Figure 4.13f) via 
coordination to the axial position.263 Such compounds were not photoluminescent due to 
fluorescence quenching by the dimetal core. However, reaction with nitric oxide (NO) in 
CH2Cl2 releases the axial ligands and “turns-on” the fluorescence of either free dansyl-
imidazole or dansyl-piperazine, making these compounds useful NO sensors. If 
dissolved in water, these Rh2-fluorophore adducts are not stable since water, as well as 
N-donor ligands such as pyridine, can easily displace the fluorophore from the labile 
axial positions.263 
In an effort to obtain further insight into the intracellular fate of dirhodium 
compounds and identify other key targets, and taking into consideration the fact that 
close attachment of a fluorophore to the Rh24+ core leads to fluorescence quenching, we 
sought to attach a bidentate ligand tagged with a fluorophore to the equatorial position 
Rh24+ core (Figure 4.14a). Therefore, a 1,10-phenanthroline derivative tethered to a 
bodipy fluorescent tag, phenbodipy (Figure 4.14b), was synthesized and coordinated to 
the dirhodium unit to afford the fluorophore-labeled compound [Rh2(μ-O2CCH3)2(η1-
O2CCH3)(phenbodipy)(H2O)3][O2CCH3] (Rh2phenbodipy, Figure 4.14c). The 
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subcellular localization of this novel fluorescent dirhodium compound has been studied 
in human lung adenocarcinoma (A549) cells using laser scanning confocal fluorescence 
microscopy. To our knowledge, Rh2phenbodipy constitutes the first fluorescent M–M 
bonded compound. 
 
 
 
 
 
Figure 4. 14 (a) Schematic representation of a dirhodium compound tagged with a 
fluorophore in the equatorial position. Molecular structures of (b) phenbodipy and (c) 
Rh2phenbodipy.  
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Experimental Section 
 
General Methods 
 
The solvents used were of reagent grade quality. Dichloromethane (CH2Cl2, 
EMD Chemicals) was dried over 4Å and diisopropylamine (Alfa Aesar) was dried with 
CaH2, which were distilled prior to use. The solvents methanol (MeOH, EMD 
Chemicals) and acetone (EMD Chemicals) were used as received without further 
purification. Standard Schlenk-line techniques (N2 atmosphere) were used to maintain 
anaerobic conditions during preparation of the compounds. Analytical thin layer 
chromatography (TLC) was performed on aluminum-backed sheets coated with silica 60 
F254 adsorbent (0.20 mm thickness, EMD Chemicals). Flash chromatography (FC) was 
carried out with silica gel 60 (40-63 µm, Fluka). RhCl3•nH2O (Pressure Chemical Co.), 
anhydrous DMF (Sigma Aldrich), 1,10-phenanthroline (Alfa Aesar), 3-butyn-1-ol 
(Sigma Aldrich), Pd(PPh3)2Cl2 (Sigma Aldrich), CuI (Spectrum Chemicals), KCN (Alfa 
Aesar), DMAP (Acros Organics) and EDAC•HCl (AKScientific) were purchased and 
used without further characterization. The compounds 5-bromo-1,10-phenanthroline 
(18),264 Rh2(µ-O2CCH3)4•2MeOH,265 [Rh2(μ-O2CCH3)2(η1-
O2CCH3)(L)(CH3OH)3][O2CCH3] (L= bpy, phen)266 and bodipy-COOH267 were 
prepared according to published procedures. 
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Instrumentation 
 
1H NMR spectra were recorded on Mercury 300 MHz or Inova 500 MHz 
spectrometers. Chemical shifts are reported in δ (ppm) and coupling constants (J) in 
hertz (Hz). The residual solvent peak was used as an internal reference (δ 3.31 for 
CD3OD, δ 7.26 for CDCl3). Electrospray mass spectra were acquired on an Applied 
Biosystems PE SCIEX QSTAR mass spectrometer (MDS Sciex). Elemental analyses 
were performed by Atlantic Microlab, Inc. (Norcross, GA). Absorption spectra were 
recorded on a Shimadzu UVPC-3001 spectrophotometer.  
A PTI QuantaMaster series spectrophotometer was used to perform the steady-
state fluorescence spectroscopic studies at room temperature. Measurements were taken 
in aereated solutions. The slit width was set to 1 nm for both excitation and emission, the 
step size was set to 1 nm and the integration time to 0.1 s. All the spectra were corrected 
(real time correction) to account for variances in the arc lamp intensity and PMT voltage 
across the range of wavelengths. A long pass filter (455 nm) was placed between the 
sample and detector before the acquisition of the spectra. The relative fluorescence 
quantum yields (Φ) were calculated using fluorescein (Sigma Aldrich) as reference (ΦF = 
0.95 in 0.1M NaOH) and the following equation:  
  
𝛷𝑥 = 𝛷𝑟 [(
𝐼𝑥
𝐴𝑥
) / (
𝐼𝑟
𝐴𝑟
)] (
𝜂𝑥
𝜂𝑟
)
2
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where the subscripts “r” and “x” are used to denote the reference and the sample, 
respectively, I is the integrated sum of the emission intensity, A is the absorbance at the 
excitation wavelength (λex = 496 nm) and η is the refractive index of the solvents used.  
 
Synthetic Procedures 
 
4-(1,10-phenanthrolin-5-yl)but-3-yn-1-ol (20). A Schlenk flask was charged with 
Pd(PPh3)2Cl2 (109 mg, 0.15 mmol), CuI (30 mg, 0.16 mmol) and DMF (3 mL). Then, 5-
bromo-1,10-phenanthroline (400 mg, 1.54 mmol), diisopropyl amine (2 mL) and 3-
butyn-1-ol (235 μL, 3.08 mmol) were added. The resulting dark brown solution was 
heated at 80°C for 2 h and the solvent was removed under reduced pressure to give a 
dark brown oily residue, which was dissolved in MeOH (10 mL). A solution of KCN 
(100 mg, 1.54 mmol) in H2O (5 mL) was added and the color of the solution changed 
instantaneously from dark brown to light yellow. The resulting solution was stirred for 1 
h and then was diluted with H2O (30 mL) and extracted with CH2Cl2 (5 x 40 mL). The 
combined organic layers were dried with MgSO4, and reduced to dryness. The residue 
was purified by FC (SiO2, CH2Cl2/MeOH/Et3N 91:8:1) to afford 3 as a light beige solid. 
Yield: 307 mg (80%). 1H NMR (300 MHz, CDCl3): δ 9.20 (dd, 1H, 3J = 4.2, 4J = 1.8, H-
1 or H-1’), 9.17 (dd, 1H, 3J = 4.2, 4J = 1.8, H-1’ or H-1), 8.70 (dd, 1H, 3J = 8.1, 4J = 1.5, 
H-3), 8.17 (dd, 1H, 3J = 8.1, 4J = 1.5, H-3’), 7.92 (s, 1H, H-4), 7.68 (dd, 1H, 3J = 8.1, 3J 
= 4.2, H-2 or H-2’), 7.63 (dd, 1H, 3J = 8.1, 3J = 4.2, H-2’ or H-2), 3.99 (t, 2H, 3J = 6.3, 
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H-6), 2.89 (t, 2H, 3J = 6.3, H-5), 2.27 (s, 1H, -OH). HRMS (ESI+): Calcd for C16H13N2O 
([M + H]+), 249.1028. Found 249.1035. 
 
Phenbodipy. A solution of bodipy-COOH (67 mg, 0.18 mmol) and 20 (55 mg, 0.22 
mmol) in CH2Cl2 (25 mL) was cooled to 0°C, and EDAC•HCl (62 mg, 0.32 mmol) and 
DMAP (23 mg, 0.19 mmol) were added. The resulting green-orange solution was stirred 
at 0°C for 6 h and then warmed up to ambient temperature slowly before being stirred 
for a further 48 h. The solution was washed with 0.1 M HCl (20 mL) and a saturated 
solution of NaHCO3 (20 mL). The organic phase was dried with anhydrous MgSO4 and 
purified by FC (SiO2, CH2Cl2/EtOAc/MeOH/Et3N 50:46:2:2) to afford phenbodipy as a 
bright orange solid. Yield: 93 mg (85%). 1H NMR (300 MHz, CDCl3): δ 9.19 (m, 2H, H-
1 and H-1’), 8.74 (d, 1H, 3J = 8.4, H-3), 8.26 (d, 2H, 3J = 7.8, H-7,  H-7’), 8.19 (d, 1H, 
3J = 8.1, H-3’), 7.99 (s, 1H, H-4), 7.65 (m, 2H, H-2, H-2’), 7.43 (d, 2H, 3J = 7.8, H-8, H-
8’), 5.98 (s, 2H, H-9, H-9’), 4.70 (t, 2H, 3J = 6.6, H-6), 3.15 (t, 2H, 3J = 6.6, H-5), 2.56 
(s, 6H, CH3B), 1.33 (s, 6H, CH3A). HRMS (ESI+): Calcd for C36H30BF2N4O2 ([M + H]+), 
599.2430. Found 599.2457. 
 
Rh2phenbodipy. Rh2(µ-O2CCH3)4•2MeOH (60 mg, 0.12 mmol) and phenbodipy (71 
mg, 0.12 mmol) were dissolved in acetone (20 mL). The resulting dark green-orange 
solution was stirred at ambient temperature. An orange solid precipitated within 30 
minutes and the mixture was left stirring for 24 h. The bright orange-red solid was 
collected by filtration and washed with acetone (3 x 10 mL) and then suspended in 
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MeOH (40 mL) and stirred for 24 h at ambient temperature. The resulting dark green-
orange solution was concentrated to ca. 2 mL and diethyl ether (20 mL) was added 
slowly while stirring. The hygroscopic brown-orange precipitate was collected by 
filtration and washed with copious amounts of diethyl ether. Yield: 32 mg (25%). This 
compound was obtained as a 1:1 mixture of two geometric isomers. 1H NMR (500 MHz, 
CD3OD): δ 8.98 (m, 2H, H-1 or H-1’), 8.83-8.68 (m, 4H, H-1’ or H-1, H-3 or H-3’), 
8.65 (d, 2H, 3J = 8.5, H-3’ or H-3), 8.29 (m, 6H, H-7, H-7’, H-4), 8.00 (m, 2H, H-2 or H-
2’), 7.95 (m, 2H, H-2’ or H-2), 7.51 (d, 2H, 3J = 8.5, H-8, H-8’), 6.06 (s, 4H, H-9, H-9’), 
4.72 (t, 4H, 3J = 6.0, H-6),  3.21 (m, 4H, H-5), 2.49 (s, 12H, CH3B), 2.37 (s, 3H, μ-
O2CCH3–), 2.36 (s, 3H, μ-O2CCH3–), 2.32 (s, 3H, μ-O2CCH3–), 2.31 (s, 3H, μ-O2CCH3–), 
1.88 (s, 6H, O2CCH3–), 1.35 (s, 12H, CH3A), 1.06 (s, 3H, η1-O2CCH3–), 1.02 (s, 3H, η1-
O2CCH3). MS (ESI+): 921.06 ([M - O2CCH3 - H]+), 981.01 ([M]+), 1013.12 ([M + 
CH3OH]+), where M is [Rh2(μ-O2CCH3)2(η1-O2CCH3)(phenbodipy)]+. Anal. Calcd. for 
C44H47BF2N4O13Rh2·2H2O: C, 46.75; H, 4.55; N, 4.96. Found: C, 46.45; H, 4.47; N, 
5.19.  
 
 
 
 
 
 
 233 
 
 
Figure 4. 15 Numbering scheme used to describe the 1H NMR spectra of 20 and 
phenbodipy.  
 
 
 
Cell Culture 
 
The A549 cell line, derived from type II pneumocytes (CCL 185), was obtained 
from American Type Culture Collection (Manassas, VA). The cells were cultured in 
DMEM-F12 medium (Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12) with 
10% FBS. Cultures were approximately 80% confluent at the time of analysis. Cell 
cultures were incubated in a humidified atmosphere containing 5% CO2 at 37°C. 
 
In vitro Cytotoxicity 
 
Cells were plated in 96 well plate and were pre-incubated at 37°C for 24 h. 
Solutions of Rh2phenbodipy complex in DMEM/F12 medium were added at different 
concentrations (final concentrations: 0–100 µM range) and the cells were incubated for 
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another 48 h. Cells were then washed twice with PBS and fixed with methanol for 30 
min. Following fixation, Janus green B (1 mg/mL, Alfa Aesar) was added to each well 
and incubated at room temperature for 5 min. Cells were again washed twice with PBS 
and 100 μL of methanol was added to each well to extract the dye. Janus green B signal 
was then measured using a BioTek Synergy 4 plate reader set to an absorbance of 630 
nm. The experiment was performed in triplicate.  
 
Confocal Fluorescence Microscopy Studies 
 
Live cell imaging studies were performed using a Zeiss 510 META NLO 
multiphoton system consisting of an Axiovert 200 MOT inverted laser scanning confocal 
microscope (Carl Zeiss Microimaging, Thornwood, NY). A Zeiss Plan-Apochromat 
63x/NA=1.4 oil immersion objective was used to acquire the images. 
The compounds phenbodipy and Rh2phenbodipy were excited with an Ar–ion 
laser at 488 nm and emission was monitored using a band pass 500–550 filter. To collect 
Hoechst 33258 (Invitrogen) fluorescence, cells were irradiated with the Chameleon 
tunable Ti:Sapphire laser (Coherent Inc., Santa Clara, CA) at an excitation wavelength 
of 740 nm (which is roughly equivalent to 370 nm in single photon excitation with a 
continuous wavelength laser system) and emission was collected at 430–480 nm. 
Lysotracker Red DND-99 (Invitrogen) was excited with a He–Ne laser at 543 nm and 
emission was monitored using a BP 565–615 filter. Mitotracker Deep Red FM 
(Invitrogen) was excited with a He–Ne laser at 633 nm and emission was collected using 
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a BP 650–710 filter. Image acquisition was performed sequentially to reduce the 
possibility of bleedthrough between channels. 
 The cellular distribution of phenbodipy and Rh2phenbodipy was studied in 
A549 lung cancer cells. Cells were incubated (37°C) with either phenbodipy or 
Rh2phenbodipy at 1 µM concentration for 2 and 24 h and the cells were washed before 
collecting the images. In the case of the localization experiments with lysosomes, cells 
were incubated with Rh2phenbodipy (10 and 100 µM) for 5 and 24 h. Cells were then 
washed with PBS and loaded with 1µg/mL Hoechst 33258 and 50 nM Lysotracker Red 
DND-99 for 30 min. Cells were then washed and imaged. At least 10 images were 
collected per time point per treatment. For analyzing the localization with mitochondria, 
cells were incubated with Rh2phenbodipy (10 and 100 µM) for 5 and 24 h. Cells were 
then washed with PBS and loaded with 1µg/mL Hoechst 33258 and 100 nM Mitotracker 
Deep Red FM for 30 min. Cells were then washed and imaged. At least 10 images were 
collected per time point per treatment. Mander’s colocalization coefficients of 
Rh2phenbodipy with either Lysotracker or Mitotracker were determined using the 
Image J software (National Institutes of Health, USA). 
To monitor the cellular uptake of Rh2phenbodipy, cells were incubated with the 
metal complex at 10, 50 and 100 µM for 24 h. Cells were then washed and at least 8 
images per concentration were collected and fluorescence intensities were recorded. 
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Results and Discussion 
 
Synthesis and Characterization 
 
The synthetic route to prepare phenbodipy is shown in Figure 4.16. First, 1,10-
phenanthroline was brominated in the 5-position using  Br2 in 30% oleum (30% SO3 in 
concentrated H2SO4) as previously described,264 affording 9 in > 90% yield. The alcohol 
intermediate 20 was obtained in 80% yield by coupling 18 and the alkyne 19 by means 
of a Pd-catalyzed Sonogashira cross-coupling reaction using Pd(PPh3)2Cl2/CuI as 
catalyst system.268 The synthesis of 20 has been reported using Pd(PPh3)4 as catalyst, 
albeit in  lower yield (58%).269 The fluorescent compound bodipy-COOH was prepared 
following reported procedures267 and was coupled to 20 via ester bond formation using 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC). The desired ligand 
phenbodipy was obtained in 85% yield as a bright orange solid after column 
chromatography and was characterized by mass spectrometry (HR-MS-ESI, m/z = 
599.2457 for [phenbodipy + H]+) and NMR. 
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Figure 4. 16 Synthesis of phenbodipy.  
 
 
 
The fluorophore-labeled dirhodium compound was synthesized following the 
same synthetic methodology developed for the preparation of [Rh2(μ-O2CCH3)2(η1-
O2CCH3)(N^N)(CH3OH)3][O2CCH3].248,266 The Rh2(μ-O2CCH3)4 compound was first 
reacted with 1 eq of phenbodipy in acetone for 24 h. The resulting orange precipitate 
was isolated, suspended in methanol and stirred for further 24 h. Rh2phenbodipy was 
obtained as a orange-brown solid upon precipitation with diethyl ether and it was 
characterized by elemental analysis, mass spectrometry (ESI+) and 1H NMR. The mass 
spectrum of Rh2phenbodipy (Figure 4.17) showed three main peaks corresponding to 
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[M - O2CCH3 - H]+ (m/z = 921.06), [M]+ (m/z = 981.01), and [M + CH3OH]+ (m/z = 
1013.12), where M is [Rh2(μ-O2CCH3)2(η1-O2CCH3)(phenbodipy)]+.  
A section of the 1H NMR spectrum of Rh2phenbodipy is shown in Figure 4.18, 
including the spectra of the related compounds [Rh2(μ-O2CCH3)2(η1-
O2CCH3)(phen)(CH3OH)3][O2CCH3] (Rh2phen) and [Rh2(μ-O2CCH3)2(η1-
O2CCH3)(bpy)(CH3OH)3][O2CCH3] (Rh2bpy)248 and the full spectrum of 
Rh2phenbodipy  is shown in Figure 4.20. Rh2phenbodipy exhibits two singlet 
resonances at 1.02 and 1.06 ppm for the methyl group of the η1-O2CCH3 ligand, in 
contrast to the single singlet resonance observed in Rh2phen (1.05 ppm), Rh2bpy (1.31 
ppm), 12 (1.11 ppm)270 and 13 (1.23 ppm)271 for the same ligand. Since phenbodipy does 
not possess the C2v symmetry of phen or bpy, Rh2phenbodipy exists as a 1:1 mixture of 
two geometric isomers that differ just by the relative position of the η1-O2CCH3– ligand 
with respect to the triple bond of phenbodipy (Figure 4.19). The presence of four singlet 
resonances for the bridging ligands (µ-O2CCH3–, Figure 4.18) at 2.31, 2.32, 2.36 and 
2.37 ppm supports the formation of two isomers. 
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Figure 4. 17 ESI(+) mass spectrum of Rh2phenbodipy in methanol. 
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Figure 4. 18 Portion of the spectra of (a) Rh2phenbodipy, (b) Rh2phen and (c) Rh2bpy 
(500 MHz, CD3OD). The proton resonances marked with (*) correspond to the methyl 
groups of bound phenbodipy.   
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Figure 4. 19 Molecular structures of the two geometric isomers of Rh2phenbobipy. L 
denotes a solvent molecule. 
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Figure 4. 20 1H NMR spectrum of Rh2phenbodipy (500 MHz, CD3OD). See 
experimental section for complete proton assignments. 
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Electronic Absorption Spectroscopy and Fluorescence Spectroscopy Studies 
 
The electronic absorption spectra of phenbodipy and Rh2phenbodipy are shown 
in Figure 4.21. Both compounds exhibit an absorption maximum at 500 nm with similar 
intensities (ε = 6.7 × 104 and 5.9 × 104 M-1 cm-1, respectively) that corresponds to 1ππ* 
ligand-centered (LC) transitions from the bodipy moiety. The absorption maxima of both 
compounds in the UV region arise from superposed 1ππ* LC transitions of both bodipy 
and phenanthroline moieties. 
Rh2phenbodipy exhibits a metal-to-ligand charge transfer (1MLCT) transition in 
the 400–450 nm region (ε ~ 4  × 103 M-1 cm-1) involving the Rh24+ core and the 
phenanthroline moiety of phenbodipy (Rh2(π*)→phen(π*)), as also reported for Rh2phen 
(415 nm, ε = 2.4 × 103 M-1 cm-1) and Rh2bpy (424 nm, ε = 2.1 × 103 M-1 cm-1).266 
Additionally, Rh2phenbodipy exhibits a weak metal-centered (MC) Rh2(π*)→Rh2(σ*) 
transition at 625 nm (360 M-1 cm-1) which is also observed in Rh2phen (600 nm, 220 M-1 
cm-1), Rh2bpy (598 nm, 215 M-1 cm-1) and related dirhodium compounds.266,272,273 
The ligand phenbodipy exhibits green fluorescence emission in methanol 
solution (Figure 4.22b) with a maximum at 512 nm (λex = 496 nm) and a fluorescence 
quantum yield (ΦF) of 20%. Rh2phenbodipy also exhibits green fluorescence emission 
with a maximum at 514 nm (Figure 4.22a) and ΦF of 0.05 (λex = 496 nm) in the same 
solvent. Although the emission from phenbodipy is partially quenched when bound to 
the dimetal unit, it allows us to perform live cell imaging studies in the 1–100 µM range. 
 244 
 
Therefore, increasing the distance between the Rh24+ core and the fluorophore was a 
successful strategy to afford a fluorescent dirhodium compound.  
 
 
 
 
 
Figure 4. 21 Electronic absorption spectrum of phenbodipy and dirhodium compounds 
in methanol. Inset: absorption maxima in the 500–700 nm region corresponding to the 
MC Rh2(π*) → Rh2(σ*) transition. 
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Figure 4. 22 (a) Absorption (blue) and normalized emission (green, λex = 496 nm) 
spectra of Rh2phenbodipy in methanol. (b) Photograph depicting green fluorescence 
(λex = 254 nm from a hand-held UV lamp) of a 1 µM solution of phenbodipy in 
methanol. 
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Laser Scanning Confocal Fluorescence Microscopy Studies 
 
 Human lung adenocarcinoma (A549) cells were incubated with phenbodipy (1 
µM) and Rh2phenbodipy (1 µM) at 37°C. As shown in Figure 4.23, the cellular 
distribution of both compounds were different. The green fluorescence emission from 
phenbodipy indicates that the organic ligand is diffused throughout the cytoplasm, 
whereas the dirhodium compound showed a punctuate distribution pattern after 2 h of 
incubation. The same subcellular distribution of each compound is observed after 24 of 
incubation (Figure 4.24). The distribution pattern of Rh2phenbodipy is similar to that 
reported for Ru-polyarginine conjugates and could indicate that endocytosis is the 
mechanism of uptake.274,275,276  The fact that the fluorescence distribution of phenbodipy 
and Rh2phenbodipy are different suggests that the fluorophore is not detached from the 
dirhodium core during the time frame of the experiments and that the cellular 
localization of Rh2phenbodipy is dictated at least in part by the dimetal moiety.255 If 
detachment of the fluorophore was occurring, its emission intensity would increase 
considerably (since the ΦF for phenbodipy is 4-fold greater than when it is bound to the 
Rh24+ fragment) and the cellular distribution would change, but that was not observed. 
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Figure 4. 23 Microscopy images of (a) phenbodipy (1 µM) and (b) Rh2phenbodipy (1 
µM) after 2 h of incubation. DIC = differential interference contrast. Field of view = 143 
µm × 143 µm. 
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Figure 4. 24 Microscopy images of (a) phenbodipy (1 µM) and (b) Rh2phenbodipy (1 
µM) after 24 h of incubation. DIC = differential interference contrast. Field of view = 
143 µm × 143 µm. 
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In order to obtain further information on the subcellular localization of 
Rh2phenbodipy, colocalization experiments with Lysotracker and Mitotracker 
(lysosome- and mitochondria-specific fluorescent trackers, respectively, Figure 4.25) 
were performed. These experiments were carried out at 10 and 100 µM concentrations 
since Rh2phenbodipy is not cytotoxic in the 1–100 µM range. As shown in Figure 4.26, 
there is a good superposition pattern between the green fluorescence from 
Rh2phenbodipy and the red fluorescence from Lysotracker after 5 h of incubation. The 
Mander’s colocalization coefficient is 39.9 ± 4.0% (mean ± SD) at 10 µM 
Rh2phenbodipy, indicating that there is ~40% colocalization of the green fluorescence 
signal of Rh2phenbodipy with the red fluorescence signal of Lysotracker. The 
coefficient is slightly greater (44.8 ± 4.4%) when the cells are incubated with 100 µM 
Rh2phenbodipy for 5 h. After 24 h of incubation, the colocalization coefficients with 
Lysotracker decrease to 33.5 ± 6.0% and 32.3 ± 3.8% for 10 µM and 100 µM 
Rh2phenbodipy, respectively (Figure 4.28a). 
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Figure 4. 25 Molecular structures of organic fluorescent dyes used on the colocalization 
experiments. 
 
 
 
 251 
 
 
 
Figure 4. 26 Confocal fluorescence images of 10 µM Rh2phenbodipy (left), Lysotracker (middle), and overlay (right) after 5 
h incubation. Field of view = 105 × 105 µm. 
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Figure 4. 27 Confocal fluorescence images of 10 µM Rh2phenbodipy (left) Mitotracker (middle), and overlay (right) after 5 h 
incubation. Field of view = 105 × 105 µm. 
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Figure 4. 28 Mander’s colocalization coefficients of (a) Rh2phenbodipy over 
Lysotracker signals and (b) Rh2phenbodipy over Mitotracker signals. The graphs 
represent means with standard deviation. The asterisk (*) indicates significant difference 
(at p < 0.05) between the colocalization coefficients at 5 and 24 h for 100 µM 
Rh2phenbodipy. 
 
 
 
In the case of the localization of Rh2phenbodipy in mitochondria (Figure 4.27), 
the colocalization coefficients with Mitotracker were calculated as 24.8 ± 2.3% and 31.0 
± 2.7% for 10 µM and 100 µM Rh2phenbodipy, respectively, after 5 h of incubation. 
They remain essentially the same after 24 h of incubation at both concentrations (23.7 ± 
3.5% and 27.2 ± 2.3% for 10 µM and 100 µM Rh2phenbodipy, respectively, Figure 
4.28b). These results indicate that Rh2phenbodipy localizes preferentially in lysosomes 
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over mitochondria and that increasing the incubation time or concentration of the 
dimetal compound does change its subcellular localization. Lysosomal or mitochondrial 
localization has also been reported for Ru compounds incorporating the dppz ligand127 
and free-base porphyrin-Ru conjugates.277 
Interestingly, green fluorescence emission from Rh2phenbodipy was not 
observed in the nucleus of the cells in the 1–100 µM range of concentrations (Figure 
4.29). Although the intracellular distribution of Rh2phenbodipy appears to be affected 
mainly by the Rh24+ moiety, it is possible that the tethered bodipy fluorophore is 
influencing its biological properties and subcellular localization, which could explain the 
exclusion of Rh2phenbodipy from the nucleus. The influence of a fluorophore on the 
localization of Ru(II) polypyridyl complexes conjugated to D-octaarginine peptides has 
been documented by Barton and coworkers,275 where the intracellular localization of the 
Ru-peptide conjugate changed when fluorescein was covalently attached to the 
conjugate. 
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Figure 4. 29 Confocal fluorescence images of Hoechst 33258 dye (nuclear stain, left), 10 µM Rh2phenbodipy (middle), and  
overlay of images (right) after 24 h of incubation in A549 cells. Field of view = 75 µm × 75 µm. 
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The uptake of Rh2phenbodipy was also measured after 24 h of incubation at 10, 
50 and 100 µM concentrations. The mean fluorescence intensity of Rh2phenbodipy did 
not increase at concentrations greater than 50 µM (Figure 4.30), which could explain 
why the colocalization coefficients with Lysotracker (or Mitotracker) did not increase 
when the concentration was increased ten-fold, as well as the lack of cytotoxicity of 
Rh2phenbodipy.  
 
 
 
 
 
Figure 4. 30 Fluorescence mean intensity of Rh2phenbodipy in A549 cancer cells 
measured after 24 h incubation. The graphs represent means with standard deviation. 
The asterisk (*) indicates significant difference compared to the 10 µM concentration at 
p < 0.05. 
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Conclusions 
 
The compound [Rh2(μ-O2CCH3)2(η1-O2CCH3)(phenbodipy)(H2O)3][O2CCH3] is 
the first example of a M–M bonded fluorescent compound. This dirhodium compound 
actually exists as a 1:1 mixture of two geometric isomers due to the C1 symmetric 
structure of the fluorescent phenbodipy ligand. The compound displays an intense 1ππ* 
bodipy LC transition at 500 nm (5.9 × 104 M-1 cm-1) and exhibits weak green 
fluorescence emission (ΦF = 5%) with maximum at 514 nm in aerated methanol 
solution. This molecule provides the first evidence that Rh–Rh bonded compounds can 
be tagged with fluorescent probes without total quenching of fluorescence and that the 
intracellular localization is dictated at least in part by the dirhodium core since the 
cellular distribution pattern of [Rh2(μ-O2CCH3)2(η1-
O2CCH3)(phenbodipy)(H2O)3][O2CCH3] differs from that of the free phenbodipy ligand.  
The compound targets mainly lysosomes and mitochondria in the 1–100 µM 
range of concentration, with a slight preference for the former organelle (~1.4-fold). In 
contrast to the closely related compound 11 (see molecular structure in Figure 4.9), 
which targets the nucleus and induces DNA damage, [Rh2(μ-O2CCH3)2(η1-
O2CCH3)(phenbodipy)(H2O)3][O2CCH3] does not show nuclear localization in A549 
cells which supports the hypothesis that other cellular organelles can be targeted by 
ligand design around the dimetal unit.  
Further studies are currently underway in the laboratories of Professor Kim R. 
Dunbar to modify the nature and lipophilicity of the fluorophore, to change its position 
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relative to the dirhodium core (equatorial binding or covalently attached to bridging 
carboxylate ligands) and to improve the uptake and cytotoxicity of this new type of 
fluorescent dirhodium compounds, which we expect will provide a deeper understanding 
of the anticancer properties of this interesting class of inorganic compounds.  
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CHAPTER V 
CONCLUSIONS AND FUTURE OUTLOOK 
 
 Medicinal inorganic chemistry offers an opportunity to capitalize on the chemical 
properties of transition metal ions and organic compounds and to simultaneously tailor 
their biological properties as anticancer drugs. The increasing interest in the 
development of metallodrugs based on Ru have led to the discovery of compounds with 
improved anticancer activities, novel mechanisms of action and lower side effects 
compared to Pt drugs. Moreover their study has shifted the paradigm towards the design 
of metal drugs with non-classical targets rather than nuclear DNA. In this dissertation, 
two new families of Ru compounds and a novel fluorescent dirhodium compound are 
reported. The results described herein help to expand the current state-of-the art in 
metal-based anticancer drugs.  
 In Chapter II, four new monocationic Ru(II) complexes of the type 
[Ru(N^N)2(N^O–)]+, with N^N = polypyridyl ligand and N^O– = anionic bidentate 
ligand, were successfully synthesized and characterized. Their cytotoxic properties and 
mitochondrial changes that these compounds induced in human lung adenocarcinoma 
(A549) cells were also examined. The compounds exhibit IC50 values in the low 
micromolar range that are comparable or lower than that of the prototype anticancer drug 
cisplatin and promote cancer cell death via the mitochondrial pathway of apoptosis. 
From this study it is evident that the lipophilicity of the N^O–-donor ligand plays an 
important role in the cytotoxicity of the Ru complexes and provides a new strategy to 
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design anticancer active Ru compounds with [RuN5O]+ pseudo-octahedral coordination 
environment. This work represents a second report that reveals that the exploration of 
the anticancer properties of this type of Ru complexes is highly worth investigating.  
To better understand the correlation between the lipophilicity of the N^O–-donor 
ligand, cellular uptake and anticancer activity of the Ru compounds, it will be necessary 
to determine the Ru content inside A549 cells using ICP-MS. Selective isolation of 
mitochondria, nuclei and cytosol of cancer cells exposed to these Ru compounds, 
followed by determination of metal content in each fraction will be fundamental to 
determine cellular targets and to tailor their anticancer properties. Additionally, the 
synthesis of two new compounds containing 4,7-diphenyl-1,10-phenanthroline (DIP) as 
N^N ligand is proposed (Figure 5.1) since Ru(II) polypyridyl complexes containing DIP 
are usually very cytotoxic. Finally, it was shown that the Ir(III) compound Ir(phpy)(hbtz) 
is cytotoxic against A549 cells which clearly hinds that the synthesis of Ir(III) analogs 
incorporating a variety of N^O– ligands is of interest. Importantly, the intrinsic 
photoluminescent properties of Ir compounds can be exploited to study its mechanism of 
action by using confocal fluorescence microscopy.  
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Figure 5. 1 Molecular structures of monocationic Ru compounds containing the DIP 
ligand. 
 
 
 
 Chapter III describes a study aimed at exploring the cytotoxic properties of 
Ru(II) cyclometallated compounds equipped with a variety of neutral bidentate ligands. 
Such organometallic compounds were studied because of the increasing interest in this 
class of molecules in bioorganometallic chemistry. Moreover, they represent an 
important class of inorganic dyes for solar energy conversion purposes whose properties 
in other totally unrelated areas such as cancer drug research have not been extensively 
studied. Additionally, their light absorption in the visible region render them interesting 
candidates for photochemotherapy. It was found that two cyclometallated compounds 
containing the dppn ligand, [Ru(phpy)(bpy)(dppn)]+ and [Ru(phpy)(pap)(dppn)]+, are the 
most cytotoxic from the series of compounds that were synthesized, displaying greater 
cytotoxic properties than cisplatin in cervical (HeLa) and ovarian (OVCAR-8) cancer 
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cells. Even more exciting is the fact that they are cytotoxic against the multidrug 
resistant NCI/ADR-RES ovarian cancer cell, revealing the great potential of Ru 
cyclometallated dyes for cancer drug research. Additional biological studies to confirm 
the mechanism of cancer cell death promoted by these compounds are currently 
underway, as well as the exploration of their photochemical properties in order to find 
suitable candidates for photochemotherapy applications. 
In Chapter IV, the first example of a fluorescent metal-metal bonded compound, 
[Rh2(μ-O2CCH3)2(η1-O2CCH3)(phenbodipy)(H2O)3][O2CCH3], is reported and its 
fluorescent properties exploited in order to decipher its cellular distribution, subcellular 
localization and cellular uptake in A549 cancer cells. This dirhodium compound targets 
lysosomes and mitochondria, but does not show nuclear localization. These findings 
demonstrate the versatility of dirhodium compounds in cancer drug research because it 
suggests that different cellular organelles can be targeted by fine tuning the ligand 
environment around the dimetal unit. Further studies are currently underway to modify 
the nature and lipophilicity of the fluorophore, to change its position relative to the 
dirhodium core (equatorial binding via a chelating ligand or a bridging carboxylate 
ligand, Figure 5.2) and to improve the uptake and cytotoxicity of this new type of 
compounds, which is expected will provide a deeper understanding of the anticancer 
properties of dirhodium drugs.  
The strategy of appending a fluorophore to a dimetal core will also expand the 
toolbox for studying the biological properties of multicenter inorganic complexes since 
the same approach can be used to label diruthenium and dirhenium anticancer molecules. 
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It is worth pointing out that our findings that Rh–Rh bonded compounds can be tagged 
with light harvesting units, such as bodipy, are expected to positively impact other 
research areas where dirhodium compounds are used in photocatalysis, since attaching a 
moiety with a high molar absorptivity to the dimetal core could improve the efficiency 
of such catalytic systems. 
 
 
 
 
 
Figure 5. 2 Schematic representation of the (a) equatorial and (b) axial positions from 
which a fluorophore can be attached to the dirhodium core. 
 
 
 
Taken together as a body of work, the research described in this dissertation 
provides a new platform for studying anticancer active Ru(II) compounds with 
[RuIIN5O]+ pseudo-octahedral coordination environments and is expected to encourage 
further explorations of this type of molecule and studies of the biological properties of 
analogs containing anionic ligands with other heteroatoms. The findings that Ru 
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cyclometallated dyes display promising cytotoxic properties have diversified the 
architectures of organometallic anticancer drugs and opens up new avenues for the 
development of bifunctional compounds that can be structurally modified to act as either 
anticancer drugs or light harvesting units for solar energy conversion. Finally, the 
cellular studies of a fluorophore-labeled dirhodium compound have increased our 
knowledge of the intracellular distribution and cellular targets of Rh–Rh bonded 
compounds in living cancer cells and will help to guide the design of anticancer 
dirhodium compounds towards a targeted therapy. 
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